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ABSTRACT 
Protection from HCV infection – Identification of mechanisms of resistance to 
HCV infection in exposed uninfected injection drug users. 
By Isaac Thom Shawa 
Hepatitis C virus (HCV) is a leading cause of chronic liver disease.  In the developed 
world, injection drug use (IDU) through sharing of infected needles and other 
paraphernalia remains the principal risk factor for HCV transmission.  Effective but 
expensive treatment is now possible but there remains a pressing need for a vaccine.   
A proportion of people who inject drugs (PWIDs) remain uninfected despite HCV 
exposure from a long history of sharing needles and other paraphernalia.   These cases 
are termed exposed but uninfected (EU) and   test negative for both HCV antibodies and 
RNA and exhibit a phenotype of resistance to HCV infection.  Improved understanding 
of the mechanisms that confer resistance in the EUs has the potential to aid 
development of an effective vaccine and novel therapeutic strategies.  
This thesis reports on the findings from 3 different strategies to identify characteristics 
of HCV resistance. I used urinary metabolomics, serum lipidomics and the study of 
adaptive and innate immune responses.  Each of these methods has demonstrated clear 
differences between EU cases and healthy controls and/or spontaneous resolvers of 
HCV infection.  Urinary metabolomics suggest a potential role of the gut microbiome, 
the serum lipidomics showed marked differences in lipid profiles in EU cases pointing 
towards a perturbed lipid/virus interaction, and the immune studies confirmed previous 
work identifying low level T cell responses in many EU cases but has also identified a 
marked upregulation of interferon alpha production to low dose viral RNA in EU cases 
utilising ELISA assay.     
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In conclusion, this thesis reports data that identifies a number of new findings that 
provide insight into mechanisms of resistance to HCV infection.  My findings suggest 
that the complex interplay between the virus and lipids together with an upregulated 
innate immune response may together help determine the outcome following HCV 
exposure.    
In summary, studies performed in this thesis have demonstrated that there are different 
pathways that define the EU phenotype.  Despite being a heterogenous subgroup of 
PWIDs, the EUs are clearly distinct from a healthy control population.   
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1 CHAPTER ONE 
 
1.1 Introduction. 
1.2 Background. 
This introduction will outline the HCV life cycle highlighting the involvement of HCV-
lipid interactions during the viral lifecycle, and also unravel the innate immunological 
factors that describe the potential putative mechanisms of resistance for HCV infection 
in exposed but uninfected intravenous drug users (IVDU). 
Hepatitis C virus (HCV) is a major cause of liver disease, and is a global public health 
problem that requires worldwide active interventions for effective prevention and 
control of the infection (Gower et al., 2014).  Humans are the only known natural host 
(Pybus et al., 2009) but HCV experimental transmission to chimpanzees can occur.  The 
World Health Organisation (WHO) estimates that 71 million people are persistently 
infected with HCV worldwide.  An estimated 399,000 people die annually from HCV 
associated liver diseases (WHO, 2017).  An HCV global epidemiology report for people 
who inject drugs (PWIDs) in 77 countries indicated  a midpoint prevalence estimate of  
60 – 80% of PWIDs  had HCV detecting antibodies, with over 80% prevalence in  12 
countries (Nelson et al., 2011).   Approximately 10 million PWIDs have HCV detecting 
antibodies worldwide with an estimated 1.6 million in China, 1.5 million in the United 
States of America , and 1.3 million in Russia (Nelson et al., 2011).  
54 – 86% of the acutely infected individuals develop chronic hepatitis annually 
(Hoofnagle, 2002);  while 20% are able to clear the virus spontaneously in the first 6 
months after exposure (Thomas et al., 2009).  However, some studies also reported 
spontaneous resolution of HCV infection after one year (Scott et al., 2006; Mosley et al., 
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2008).  Liver cirrhosis develops in approximately 20 – 30% of chronic patients within 
20 years (Lauer and Walker, 2001); 1 – 4% may progress to liver cancer such as 
hepatocellular carcinoma (HCC) (Fattovich et al., 2004).  Approximately 25% of 
primary HCC cases are due to chronic HCV(CHCV) infection worldwide (Tanaka et al., 
2006).   
In the developed world, injection drug use through sharing of needles and other 
paraphernalia, remains the highest risk factor for HCV transmission, with HCV 
prevalence rates of greater than 90% reported among injection drug users (IDUs) (Tseng 
et al., 2007).   
The outcome of HCV exposure is affected by a complex set of interactions between the 
host and the virus.  Exposure to HCV may be considered to result in one of three 
outcomes;  remain antibody seronegative and aviraemic by sensitive RNA PCR 
(uninfected) (Thurairajah et al., 2008), spontaneous clearance (detectable HCV-
antibodies but HCV-RNA negative), or chronic infection (both HCV antibody and RNA 
positive) (Knapp et al., 2010).  Only chronic HCV infection leads to cirrhosis and HCC, 
although the risk of HCC persists in those with cirrhosis even after successful antiviral 
treatment of HCV (European Association for Study of Liver, 2014). 
Several mechanisms have previously been described in relation to the immune failure 
resulting in persistent HCV infection.  Other researchers described the peripheral and 
intrahepatic virus-specific T cell responses targeting different HCV epitopes in HCV 
clearance (Rehermann, 2009).  Therefore occurrence of mutations in epitopes targeted 
by virus-specific CD8+ T cells in HCV acute infections (Tester et al., 2005) contributes 
to development of HCV infection.   HCV employs strategies in order to escape the host 
immune responses.   The host adaptive immune responses are mediated by both cellular 
and humoral immunity.   Therefore, CD4+ and CD8+ T cells play an essential role in 
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the outcome of HCV infection.   The CD8+ T cells prevent establishment of HCV 
infection by inhibiting viral replication through activation of cellular cytolytic 
mechanisms (Thimme, Binder and Bartenschlager, 2012).   The function of CD8+ T cell 
cytolytic activities is dependent on CD4+ T cells, therefore failure of CD4 T helper cells 
function compromises the function of CD8+ T cells (Penna et al., 2007; Sun, Rajsbaum 
and Yi, 2015).            
There is no effective vaccine developed yet to prevent HCV infection due to a high 
degree of strain variation (Forns, Bukh and Purcell, 2002; Torresi, Johnson and 
Wedemeyer, 2011).  Researchers have studied different targets for design and 
development of a vaccine in animals; but currently HCV vaccine testing has reached 
phase II clinical trial in humans (Halliday, Klenerman and Barnes, 2011; Young et al., 
2015) but extreme diversity of HCV is one of the major challenges for vaccine design.   
Numerous research efforts have been made to understand HCV infectivity and factors 
that could potentially confer resistance in exposed individuals.  In the last decade, HCV 
standard of care has been a combination of pegylated interferon (PEG-IFN) and 
ribavirin (RBV), but these have many side effects as a result of poor tolerability, 
suboptimal sustained viral response rates in difficult-to-treat cases, and reports of 
resistance have emerged (Pawlotsky, 2011).  The licencing of multiple direct acting 
antivirals (DAAs) e.g. Sofosbuvir that could potentially reduce the treatment duration 
and adverse effects has enabled efforts to improve efficacy and tolerability of HCV 
therapy.  
Over the years, our research group and others (reviewed in (Mina et al., 2015)) 
characterized a cohort of IDUs called ‘exposed uninfected’ (EU) who are at risk of 
HCV infection but still remain negative for both HCV antibody and HCV RNA 
(Thurairajah et al., 2008).  The phenotype of repeated exposure to HCV without the 
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development of infection is of considerable interest and suggests these individuals are in 
some way resistant to HCV infection.  In this chapter, I have considered the phenotypic 
definitions of the EU cohort, and the distinct immunological, and genetic features that 
characterise the EU group for insights into possible mechanisms of HCV resistance 
(Shawa, Felmlee, et al., 2017). 
1.3 Hepatitis C virus discovery. 
Before the discovery of HCV in 1989, the common hepatitis viruses were hepatitis A 
virus (HAV) discovered in 1973 (Feinstone et al., 1975) and hepatitis B virus (HBV).  
Viral hepatitis that was caused by neither hepatitis A nor hepatitis B viruses, was 
previously termed ‘Non-A, non-B’ (NANB) hepatitis.  In 1975, Feinstone et al, reported 
that transfusion-associated hepatitis was not due to type A or B hepatitis viruses due to 
absence of serological markers of NANB viruses.  They further reported that nearly 10% 
of transfusions resulted in NANB hepatitis, a condition characterised by persistent liver 
damage in majority of cases (Feinstone et al., 1975), and increased serum transaminases 
(transaminasemia) (Alter and Houghton, 2000).  The existence of the NANB hepatitis 
(NANBH) aetiological agent was demonstrated following intensive investigations and 
development of numerous immunological and serological assays to identify reliable and 
reproducible biomarkers specific for NANB hepatitis.  An experimental chimpanzee 
model was developed using NANBH patient blood which successfully demonstrated the 
presence of an NANBH transmissible agent (Alter et al., 1978; Hollinger et al., 1978; 
Tabor et al., 1978).   Immunoscreening of bacterial complementary deoxyribonucleic 
acid (cDNA) derived from samples from chimpanzees infected with NANBH, led to the 
isolation of a single cDNA clone (5-1-1) which enabled the sequencing and 
identification of the whole viral genome.  Antibodies derived from an NANBH patient 
were used for an immunoscreening for identification of a cDNA clone that encodes non-
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structural (NS) protein 4 epitope.  Further analysis of a larger overlapping ‘clone 81’ 
showed that the clone was bound to a single-stranded ribonucleic acid (ssRNA) 
molecule derived from NANBH infected blood samples (Houghton, 2009).  Following 
years of vigorous experimental and clinical studies, on 21st April 1989, Michael 
Houghton and his colleagues in collaboration with Daniel Bradley using molecular 
approaches, discovered the aetiological agent of NANB hepatitis termed ‘Hepatitis C 
virus’ (Choo et al., 1989).    
1.4 Virology.  
1.4.1 HCV genome organisation. 
The HCV has a positive-sense single-stranded RNA (+ssRNA) genome that is 
approximately 9.6kb that belongs to Flaviviridae family (Houghton, 2009).  The HCV 
genome contains one long open reading frame (ORF) coding for a polyprotein precursor 
of approximately 3000 amino acids (aa) flanked by non-translated regions (NTRs) at 
both ends (Choo et al., 1989).  HCV belongs to the genus Flavivirus.  Other viruses that 
belong to Flavivirus include: yellow fever, west Nile virus, Dengue virus.  Previous 
studies have grouped HCV together with GB virus B (GVB-B) in Hepacivirus genus 
(Simons et al., 1995).  GVB-B was used as a surrogate model for HCV; is 
phylogenetically related to HCV, and they both have common 5' structural protein-3' 
non-structural protein organization (Muerhoff et al., 1995) that is required for 
replication and initiation of translation.  The 5' NTR which is ∼341 nucleotide (nt) in 
length, contains an internal ribosomal entry site (IRES) that is essential in facilitating 
the  translation of viral RNA (Buratti et al., 1998).  HCV encodes 10 different structural 
(Core, envelope 1 (E1), envelope 2 (E2)) and non-structural (NS) viral porin (p7), (NS2, 
NS3, NS4A, NS4B, NS5A and NS5B) proteins (Welbourn and Pause, 2007) (Figure 
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1.1).  The HCV genome has high genetic variability, with high mutation rates in 
different regions (Martell et al., 1992).    
 
Figure 1.1: Hepatitis C virus genome organisation. 
 
Figure 1.1: HCV genome organization.  HCV genome contains a single open reading 
frame (ORF) flanked by 5′ and 3′ non-translated regions (NTRs).  The 5′ and 3′ NTR 
consists of four highly structured domains that contain the internal ribosome entry site 
(IRES); and stable stem-loop structures respectively.  HCV ORF translation is directed 
via 5′ NTR that function as an IRES.  It permits binding of ribosomes to the ORF start 
codon.  The viral polypeptide is cleaved co- and post-transcriptionally by protease 
enzymes encoded by both the virus and the host for production of structural and non-
structural (NS) proteins.   
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1.4.2 Features of structural and non-structural viral proteins. 
1.4.2.1 Structural proteins. 
1.4.2.1.1 Core. 
The HCV core protein released in a 191 aa precursor is an RNA-binding protein that 
forms the viral capsid.  The HCV core contains three distinct hydrophilic domains in the 
first 120 aa: an N-terminal hydrophilic domain (domain D1) that contains 
immunodominant antigenic sites; a C-terminal hydrophobic domain (domain D2) (Penin 
et al., 2004), and the last 20 aa that serve as signal peptides for E1 (Majeau et al., 2004).  
Domain D1 is involved in binding RNA, whereas D2 facilitates the association of the 
core protein with the endoplasmic reticulum (ER) and lipid droplets (LDs) (Ren et al., 
2004; Suzuki et al., 2005).  The HCV core protein was reported to facilitate the 
accumulation of LDs in vitro (Harris et al., 2011) whereby core protein is loaded onto 
LDs.  The junction between core-loaded LDs and the viral replication complex-rich ER 
membranes acts as a site for assembly of progeny virions.  Mechanisms of the HCV 
core protein assembly still remains unclear (Penin et al., 2004).  The structural 
peculiarity of the HCV core describing its domains provides some useful explanations 
for the physiopathological differences between HCV and the other flaviviruses.  The 
structural and functional role for D2 was thoroughly characterized.  Thus, functional 
studies of the relevance of D2 and the interaction of the core protein and lipid droplets 
was understood following development of HCV cell culture (HCVcc) system in a cell 
culture to enable the description of the HCV life cycle.  Further analyses also revealed 
that the D2 domain was responsible for HCV production efficiency (Shavinskaya et al., 
2007). 
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1.4.2.1.2 E1 and E2 glycoproteins and p7. 
The two HCV envelope glycoproteins E1 and E2 assemble as noncovalent heterodimers 
(Op De Beeck, Cocquerel and Dubuisson, 2001) and play important roles in the HCV 
life cycle.  The E1 and E2 transmembrane glycoproteins, with N-terminal ectodomains 
of 160 and 334 aa respectively, are essential in viral attachment to host receptors 
together with entry and fusion with host cell membranes (Deleersnyder et al., 1997; 
Bartosch et al., 2003; Nielsen et al., 2004).  The HCV E2 glycoprotein sequence has 
hypervariable regions (HVR) (Weiner et al., 1991) whose aa sequence differs by 80% 
among HCV genotypes.  The first segment of E2 is HVR1 which forms HCV 
neutralization epitope (Farci et al., 1996).  The second hypervariable region HVR2 was 
described in HCV genotype 1, and together with HVR1 plays a role in host cell 
recognition and attachment (Roccasecca et al., 2003).  The HCV structural and non-
structural proteins are separated by p7 (63aa), a small intrinsic membrane protein that 
belongs to the viroporin family, and is located between the E2 and NS2 region.  p7 was 
reported to mediate membrane ion permeability and also plays a role in the formation of 
progeny viruses, maturation and release (Harada, Tautz and Thiel, 2000; Pavlovic et al., 
2003). 
1.4.2.2 Non-structural proteins.  
1.4.2.2.1 NS2. 
The non-structural proteins are encoded by HCV and form a group of viral enzymes 
(viral replicase) that are involved in host-viral interactions.  The NS2 (250aa) is a 
nonglycosylated integral membrane protein whose function is unclear.  Some studies 
suggest that N2 participates in proteolytic cleavage at the NS2-NS3 junction of the 
polyprotein (Yamaga and Ou, 2002) and interacts with both structural and non-
structural proteins in HCV particle assembly (Popescu et al., 2011).   
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1.4.2.2.2 NS3 – 4A complex. 
The NS3 protease (500aa) is a serine protease located within the ER, and forms a 
complex with NS4A (54aa) (Love et al., 1996).  The NS3 is a multifunctional enzyme 
that interacts with other NS proteins NS4B, NS5A and NS5B within the replication 
complex (Ishido, Fujita and Hotta, 1998).  The NS4A is a cofactor of NS3 protease 
activity that provides its stability, localization at ER membrane and cleavage at other 
NS proteins complex junctions (Bartenschlager et al., 1995).  The NS3 – NS4A 
complex is essential in the life cycle and pathogenesis of HCV infection.  The NS3 – 
NS4A protease is an important viral target for the development of antiviral therapeutic 
agents.  The NS3 – NS4A complex plays a significant role in its interaction with host 
cell pathways and proteins in HCV life cycle.  The NS3 – NS4A protease was reported 
to catalyse HCV polyprotein cleavage at the NS3/NS4A, NS4A/NS4B, NS4B/NS5A 
and NS5A/NS5B junctions (Yan et al., 1998).  
1.4.2.2.3 NS4B. 
The NS4B is a small integral hydrophobic membrane protein located within the ER and 
is essential in recruiting other viral proteins (Hügle et al., 2001).  It plays a role in 
inducing ER morphological changes during the formation of the membranous web that 
harbours the HCV genome, structural and NS proteins (Egger et al., 2002; Gosert et al., 
2003).  Therefore, it is believed that NS4B induces alteration of specific membranes 
that serve as a scaffold for the formation of the viral replication complex (reviewed in 
(Penin et al., 2004)).  
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1.4.2.2.4 NS5A. 
The NS5A is a membrane associated phosphoprotein whose function in the HCV 
replication cycle is still unclear.  The NS5A was reported to be involved in the 
formation of the functional viral replication complex (Bartenschlager, 2002).  The 
NS5A enzymatic activity is observed through interaction with other viral and cellular 
proteins.  The NS5A an enzyme processed by NS3 proteases, exerts a wide range of 
activities on cellular pathways such as induction of innate immune response, host cell 
growth and proliferation (reviewed in (Reed and Rice, 2000)).  The interaction of NS5A 
with multiple host cell and viral proteins suggests its significant role as part of the 
replication complex in mediating viral replication, viral-host interactions, and viral 
pathogenesis.    
1.4.2.2.5 NS5B. 
The NS5B RNA-dependent RNA polymerase belongs to a class of membrane proteins 
commonly known as tail-anchored proteins (Ivashkina et al., 2002).  Non-nucleoside 
inhibitors and the new licenced direct acting antiviral drugs target NS5B to prevent viral 
replication (Biswal et al., 2006).  The NS5B forms an integral part of the membrane 
bound replication complex, and is essential for HCV replication through transcription of 
the viral positive-sense RNA strand.  The resultant negative-sense RNA strand serves as 
a template for the synthesis of viral RNA genome (Lohmann, 2013).  The NS5B 
nucleoside analogues interfere with HCV genome replication by inducing chain 
termination that results in interruption of transcription and translation of viral 
polypeptides (Sofia et al., 2010).  The NS5B catalytic site is highly conserved in 
different HCV genotypes; therefore NS5B RNA-dependent RNA polymerase has 
emerged as a major target for antiviral intervention. 
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1.4.3 HCV life cycle. 
The HCV must attach to and infect hepatocytes in order to carry out its life cycle.  Key 
steps in HCV life cycle occur outside the host’s nucleus, and include attachment of the 
virus to the host cellular receptors, entry, uncoating of viral capsid, translation of viral 
proteins, replication, assembly, maturation and egress of virions via the lipoprotein 
pathways.   
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1.4.3.1 Formation of lipoviral particles (LVPs). 
 
Figure 1.2: Lipoviral particle. 
 
 
Figure 1.2 shows a schematic cartoon of LVP.  The HCV particles circulate in the blood 
in association with lipoproteins in a complex called ‘lipoviral particles’ that are rich in 
cholesterol, triglycerides, and apolipoproteins (apo) B, E and C1.  The LVPs help to 
attach the virus to the host cell via cellular lipoprotein receptors (Shawa, Sheridan, et al., 
2017).    
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An essential stage in the HCV lifecycle is the formation of lipoviral particles (LVPs) 
(Figure 1.2).  These circulating HCV particles are associated with different classes of 
lipoproteins (Dao Thi, Dreux and Cosset, 2011).  HCV binds directly to low density 
lipoprotein (LDL), very low density lipoprotein (VLDL), and chylomicrons (CMs) 
(Diaz et al., 2006) which leads to the viral particle’s heterogeneous buoyant density 
(Felmlee et al., 2010).  LVPs are composed of triglyceride (TG) and cholesterol-rich 
lipoproteins that contain apoA1, apoB, apoE (Diaz et al., 2006; Felmlee et al., 2010), 
apoC1 and viral envelope proteins E1and E2; and nucleocapsids.  LVPs are 
characterised by low buoyant density and larger size inherent from the lipoprotein 
interaction, and LVPs have higher infectivity than non-lipoprotein bound HCV virions 
(Miyanari et al., 2007).    
Evidence suggests that LVPs are formed from viral assembly within the hepatocyte, 
where the machinery for viral replication and assembly is dependent on very low 
density lipoprotein (VLDL) synthesis and export (Bassendine et al., 2013).    A 
subpopulation of LVP may also be formed within the vascular compartment by transfer 
of HCV particles onto native  triglyceride rich lipoproteins (TRL) derived from both the 
liver (VLDL) and intestine (chylomicrons), and thus LVPs have been noted to increase 
after a high fat meal (Felmlee et al., 2010).    
The HCV particles that redistribute to VLDL and chylomicrons in the vascular 
compartment after a high fat meal have a very short half-life (<180 mins), implying that 
very-low density LVP that appear post-prandially are rapidly taken up by the liver 
(Felmlee et al., 2010).  In vitro studies revealed a pan-genotypic capacity for 
extracellular transfer of HCV onto TRL ‘acceptors’, and this transfer enhances 
infectivity of HCVcc (Felmlee et al., 2010).    
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LVPs have inherent increased infectivity in cell culture and in animal models compared 
to non-lipoprotein bound HCV particles (Miyanari et al., 2007).  Silencing of apoE 
disrupts the formation of LVP and inhibits infectivity in vitro (Benga et al., 2010).  
Furthermore, apoE-poor HCV particles are more sensitive to neutralizing antibodies, 
showing that apoE interaction is a viral adaptation to escape immune surveillance 
(Fauvelle et al., 2016).  Evidence from human studies also supports the model that 
LVPs are important in determining the natural history of early acute HCV infection.  A 
study of patients with early acute HCV infection from the Australian Trial In Acute 
Hepatitis (ATAHC) and Hepatitis C Incidence And Transmission in Prisons Study 
(HITs P cohorts) reported low LVP levels were associated with spontaneous resolution 
of early acute HCV (Sheridan et al., 2014).  Previous studies of LVP in chronic HCV 
infection found an association between increased LVP concentrations and insensitivity 
to interferon based antiviral therapy (Bridge et al., 2011; Sheridan et al., 2012).  In 
chronic HCV G1, LVP levels correlated negatively with markers of interferon 
sensitivity, and higher non-LVPs were associated with the interferon lambda 3 (IFNL3) 
CC genotype (Sheridan et al., 2012). 
The close association of virus and lipoprotein in the  LVP masks HCV epitopes from 
antibody mediated neutralisation (Grove et al., 2007).  It is thought that there is an 
inverse relationship between density and infectivity, such that as HCV particles bind to 
immunoglobulin, so the density increases and infectivity diminishes.  Formation of LVP 
could therefore be a mechanism that enables evasion of antibody mediated 
neutralisation (reviewed in (Felmlee et al., 2013)).  Recent evidence indicates that apoE 
association in itself may be sufficient for escape from neutralization (Fauvelle et al., 
2016).  Thus any mechanism that would disrupt the formation of LVP could potentially 
expose viral epitopes that may increase the likelihood of antibody mediated clearance 
and decreased infectivity of HCV.  
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1.4.3.2 HCV attachment and entry. 
The HCV involves lipid metabolism at each step of its life cycle.  The viral entry steps 
involve complex processes involving viral attachment, clathrin-mediated endocytosis, 
and membrane fusion.  Several studies have demonstrated that HCV utilises virally 
encoded envelope glycoproteins, and cellular protein apoE (Jiang et al., 2012) for 
attachment which is the first step of virus–host cell interactions, and thus represents a 
good target for antiviral therapeutic agents.  Figure 1.3 below outlines an HCV life 
cycle model. 
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Figure 1.3: HCV life cycle. 
 
 
 
Figure 1.3 HCV circulates in the blood as lipoviral particles and enters the liver cells via 
the space of disse through fenestrated endothelia.  L-SIGN (CD209L) and DC-SIGN 
(CD209) capture viral particles and transmit them to target cells to interact with receptor 
molecules such as HS-GAG and LDLR with high affinity for apolipoproteins. 2. The 
viral particles then bind to SR-B1, CD81, OCLN and CLDN1 receptors/entry factors. 3. 
The internalization (endocytosis) process is facilitated by the assembly of clathrin 
(ubiquitous route of receptor invagination into cells) and associated proteins on 
intracellular plasma membranes which mature into early endosomes.  4. Low pH in 
endosomes enables fusion of viral particles with endosome. Uncoating of viral capsid 
delivers viral genomic material to cytoplasmic replication site.  EGFR, EphA2, TfR1 
and NPC1L1 are some of the putative entry factors. 5. The successful viral entry 
through lipoprotein channels leads to translation of polypeptides in the endoplasmic 
reticulum. The expression of the viral NS4B protein induces alteration of cellular 
membranes leading to formation of a membranous web. 6. The replication complex 
forms the +ssRNA strands via the –ssRNA intermediates in membranous web which 
shows characteristics of lipid rafts. 7. Assembly and maturation of LVP. 8. Secretion of 
mature virions via VLDL pathway.  Note: The red stars (numbers 1,2,6,7 and 8) 
highlight stages of HCV-lipid interactions. Any defect in such interaction may provide a 
mechanism of resistance.  
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Several putative HCV receptor candidate molecules have been suggested to be involved 
in viral attachment and entry.  The HCV entry is believed to be a highly orchestrated 
system that involves multiple viral and host cell factors, via receptor-mediated 
endocytosis and subsequent fusion of viral and host cellular membranes (Blanchard et 
al., 2006; Meertens, Bertaux and Dragic, 2006).  The circulating HCV particles gain 
access to hepatocytes through liver sinusoidal blood.  The sinusoidal blood percolates to 
hepatocytes through the space of disse in fenestrated endothelium which lacks a 
basement membrane.  The viral particles get trapped by sinusoidal cells mediated by 
specific molecules such as liver/lymph-node-specific intercellular adhesion molecule-3 
grabbing integrin (L-SIGN) commonly known as CD209L, which are expressed by liver 
sinusoidal endothelial cells (LSECs), and dendritic-cell-specific intercellular adhesion 
molecule-3-grabbing non-integrin (DC-SIGN) also known as CD209 which are both 
expressed by liver kupffer cells.  The HCV envelope glycoprotein E2 binds to L-SIGN; 
and DC-SIGN with high affinity; a process that captures and delivers viral particles to 
hepatocytes (Pöhlmann et al., 2003).  Several host receptors have been suggested to be 
involved in viral attachment and entry into hepatocytes, but the exact hierarchy still 
remains elusive.  The HCV entry mechanism is a highly orchestrated multistep process 
that involves viral envelope glycoproteins E1 and E2, and apoA-1, apoB, apoC-1 and 
apoE (Jiang et al., 2012) that attach to host receptors and co-receptors to facilitate viral 
internalization into endosomal compartment.   
The initial attachment of the virus to hepatocytes occurs via low affinity interaction with 
highly sulphated glycosaminoglycans (HS-GAGs) (Barth et al., 2003) via apoE  and the 
low density lipoprotein receptor (LDLR) (Agnello et al., 1999; Molina et al., 2007).  
The docking of viral particles to HS-GAGS helps to concentrate them on the target cell 
surface for further horizontal interaction with other host entry factors (Barth et al., 2003; 
Zeisel et al., 2011) such as Scavenger receptor class B type I (SR-BI) which is highly 
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expressed at the sinusoidal surface of hepatocytes in the liver and other tissues.  SR-BI 
binds to HDL, LDL, oxidized LDL, and viral envelope protein E2 (Scarselli et al., 
2002).  SR-BI physiologically maintains lipid homeostasis by transporting cholesterol 
from HDL to hepatocytes (Rhainds and Brissette, 2004).  In HCV entry, SR-BI binds 
directly to virus-associated lipoproteins (Dreux et al., 2009) such as ApoE, ApoB, 
ApoC1 and ApoA-1 and the HCV envelope glycoprotein E2 (reviewed in Dao (Dao Thi, 
Dreux and Cosset, 2011)).  Furthermore, serum HDL accelerates viral entry into 
hepatocytes (post-binding stage) by transferring apoC-1 from HDL to HCV during SR-
BI mediated lipid transfer.  SR-BI plays a dual role in attachment and post-attachment 
entry process and enhances viral infectivity (reviewed in (Zeisel et al., 2011)).     
The role of apoE in mediating viral attachment through heparan sulphate is well 
described (Jiang et al., 2012).  The formation of HSPG involves covalent interaction of 
HS and the cell membrane core proteins.  The currently identified HSPG core proteins 
are syndecans (SDC), glypicans, perlecans, and agrin.  SDC1 and SDC4 have recently 
been reported as LVP attachment co-factors, and important mediators that facilitate 
VLDL remnant clearance (Lefèvre et al., 2014) (Shi, Jiang and Luo, 2013). 
The LDLR was proposed as another HCV receptor (Agnello et al., 1999; Molina et al., 
2007) but its role still remains controversial.  It is yet to be established whether LDLR is 
a true host cellular receptor or a mediator of LVP attachment to hepatocytes.  Other 
researchers described LDLR as an HCV co-receptor that interacts with apoE; further 
proposing that availability of apoE-containing lipoproteins such as VLDL but not LDL 
facilitates infection through interaction with LDLR (Owen et al., 2009). 
The tetraspanin CD81 is another HCV co-receptor that interacts with HCV E2 
(Nencioni et al., 1990)  as a post-binding entry molecule.  The interaction of CD81 with 
HCV E2, induces conformational changes in the HCV envelope glycoproteins which 
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primes HCV to respond to low pH of the endocytic compartment post entry.  E2 
contains a putative fusion domain which binds to CD81, and SR-BI.  The hypervariable 
region 1 (HVR1) of E2 is essential in preserving the viral ability for replication through 
its interaction with SR-BI (Bartosch et al., 2003).  The crystal structure for highly 
conserved E2 antigenic site 412 to 423 was characterized in complex with the broadly 
neutralizing antibody AP33.  The antibodies to CD81-E2 binding complex neutralize 
HCV infectivity by binding to E2 epitopes (Kong et al., 2012).  The CD81 – E2 
complex facilitates the lateral movement of the virus to bind to other entry molecules 
such as Claudin-1 (CLDN1) (Evans et al., 2007) and Occludin (OCLN) (Ploss et al., 
2009).  
The CLDN1 is principle component of tight junction proteins required for late step viral 
entry into hepatocytes, but there is no clear evidence suggesting a direct interaction 
between HCV and CLDN1 (Evans et al., 2007).  However, CLDN1 was reported to 
form a complex with CD81 that promotes HCV entry (Harris et al., 2008).  Another 
critical component of tight junctions is OCLN which is involved in post-binding viral 
entry that confers HCV permissivity in mouse cell line (Ploss et al., 2009).  The OCLN 
interacts with HCV glycoprotein E2, but it is still unclear how OCLN/E2 interaction 
takes place.  Whether OCLN binds directly to E2, or binds to CD81/CLDN1 complex is 
still elusive (Zhu et al., 2014).  What is known is the fact that OCLN acts as an anchor 
to the tight junction complex by providing cell-cell adhesion (Peng, Lee and Campbell, 
2003).  
The HCV internalization into the cell cytosol (endocytosis) is mediated by clathrin 
(Blanchard et al., 2006) promoted by CD81 in association with CLDN1 (CD81/CLDN1 
co-receptor complex) (Farquhar et al., 2012).  A recently identified entry factor 
transferrin receptor 1 (TfR1) was reported to assist in HCV internalisation after binding 
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CD81 (Martin and Uprichard, 2013).  It was reported by Coller et al. (Coller et al., 2009) 
that HCV endocytosis does not preferentially take place at cell-cell contact junctions as 
observed by imaging studies. 
The final step of HCV cell entry which involves fusion of viral and host cell membranes 
(a process triggered in a pH-dependent fashion), depends on viral particles lipoprotein 
density and envelope protein integrity (Haid, Pietschmann and Pécheur, 2009).  The 
endosome acidic pH, and virus – receptor interactions triggers viral penetration through 
fusion of cell receptors and envelope glycoproteins that contain fusion peptides (Smith, 
2004).  In vitro fusion assays showed that HCVpp/liposome fusion does not only 
depend on acidic pH and temperature but cholesterol as well (Lavillette et al., 2006).  
Apart from the above explained viral entry route, a direct cell-cell viral infection has 
been described which potentially avoids the effects of neutralizing antibodies (Grupp et 
al., 2007). 
Other entry factors include epidermal growth factor receptor (EGFR), ephrin receptor 
A2 (EphA2) (Lupberger et al., 2011) and Niemann-Pick C1-like 1 (NPC1L1) proteins 
(Sainz et al., 2012).  No single entry factor permits HCV entry into a susceptible cell.  
Viral attachment and entry is a complex multistep process, with no clear hierarchical 
order fully elucidated. However, combined expression of four entry factors (CD81, SR-
BI, OCLN, and CLDN1) is essential for HCV to productively infect hepatocytes (Da 
Costa et al., 2012).   
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1.4.3.3 HCV RNA translation and replication.  
The successful viral entry mediated by cathrin leads to translation of polypeptides in the 
endoplasmic reticulum.  The RNA translation is initiated by the involvement of host 
cellular factors (Niepmann, 2013).  The HCV genome contains a single open reading 
frame flanked by 5′ and 3′ non-translated regions (NTRs).  The NTRs contain RNA 
elements that are important for RNA translation and replication (Lohmann, 2013).  The 
5′ NTR contains IRES which initiates HCV RNA translation into polypeptides which 
are later processed into structural and NS proteins by viral and host encoded proteases 
(Welbourn and Pause, 2007).   
After translation, there is formation of a membrane-associated replication complex 
composed of HCV proteins associated with altered host cell membranes derived from 
the ER.  The replication machinery constitutes viral proteins (NS3/4A, NS4B, NS5A, 
and NS5B) and the replicating RNA, which replicate the +RNA genome through a –
RNA intermediate (Lohmann, 2013).  The single +RNA genome template and the 
newly synthesized –RNA strand are base-paired which results in the formation of 
double-stranded (ds) RNA (Quinkert, Bartenschlager and Lohmann, 2005) (Targett-
Adams, Boulant and McLauchlan, 2008).    
The HCV replication takes place on double membrane vesicles known as lipid droplets 
(LD) with co-localization of structural core protein and non-structural NS5A (Masaki et 
al., 2008).  Viral replication induces formation of micro-environment in the host cell 
cytoplasm called ‘membranous web.’  Compartmentalisation of the replication complex 
protects the viral genome from double-stranded RNA (dsRNA) – mediated host 
defences, and exogenously administered nucleases and proteases  (Moradpour et al., 
2002; Miyanari et al., 2003).  The intermediate dsRNA is copied multiple times for 
generation of +RNA progeny virions.  The dsRNA serves as a pathogen-associated 
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molecular pattern (PAMP) and induces host innate immune system as a result of its 
recognition by toll-like receptors (TLR).  One of the important replication factors 
identified is Phosphatidyl-inositol-4-kinase-III (PI4KIII) which interacts with NS5A to 
induce production of phosphatidylinositol-4-phosphate (PI4P) within the membranous 
web.  Disruption in or absence of PI4KIII and NS5A interaction confers conformational 
changes in the membranous web (Reiss et al., 2013).  MicroRNAs (miRNA) are small 
RNAs involved in inhibition of RNA molecules (Hobert, 2008).  The HCV is believed 
to utilise liver-specific miRNA-122, the most abundant miRNA in hepatocytes, for 
replication (Jopling, 2005) through the binding of miRNA-122 to two HCV binding 
sites in the 5' NTR of HCV genome (Machlin, Sarnow and Sagan, 2011).  The HCV 
infection induces expression of lipogenic genes in hepatocytes that facilitate replication 
and assembly of infectious viral particles.    
ApoA-I is also thought to play a role in the HCV replication as evidenced by the 
siRNA-mediated silencing of apoA-I that resulted in reduced concentration of viral 
RNA (Mancone et al., 2011).  However, the exact role of apoA-I in HCV replication is 
poorly understood. 
1.4.3.4  HCV assembly and exit. 
The later stages of the HCV life cycle involve assembly of viral proteins for production 
of progeny virions, and exit.  The core protein forms the viral nucleocapsid of 
assembled virions but also binds to intra-cellular lipid droplets for production of 
infectious virions.  It was observed that the HCV core causes steatosis in HCV genotype 
3 patients by inducing lipid accumulation within hepatocytes; it also inhibits 
microsomal triglyceride transfer protein (MTP) activity (Jhaveri et al., 2008).  Thus, 
steatosis was reported to be more frequent in HCV genotype 3 infected patients than 
those infected with HCV genotype 1.  The mechanisms underlying the significant 
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association between HCV genotype 3 and steatosis are unclear (Asselah et al., 2006).  
The MTP plays a crucial role in VLDL synthesis; therefore its inhibition could 
potentially affect VLDL production and HCV assembly and exit.   
The NS5A mediates the assembly of viral RNA genome in progeny virus by binding to 
apoE (Benga et al., 2010).  The NS5A also binds to HCV RNA and contributes to 
formation of the membranous web.  The emergence of NS5A resistance associated 
variants in relapsing patients treated with DAAs on the interaction with apoE is 
unknown.  Effective HCV particle formation involves packaging of nucleocapsid and 
envelope proteins into progeny virions that bud through the endoplasmic reticulum 
lumen via the VLDL secretory pathway (reviewed in (Felmlee et al., 2013)).  The 
assembly of infectious virions is dependent on an intact VLDL pathway. Co-
dependency of HCV assembly on VLDL secretion is demonstrated by silencing of apoB, 
apoE and MTP, all of which inhibit HCV production in Huh 7 cells (an hepatocyte 
derived cellular carcinoma cell line) (Benga et al., 2010).  MTP plays a crucial role in 
VLDL synthesis; therefore its inhibition could potentially affect VLDL production and 
HCV assembly and exit.  Expression of HCV core protein in transgenic mice was 
reported to inhibit MTP activity which also decreases VLDL secretion (Perlemuter et al., 
2002).   
During HCV assembly, the HCV core protein is located on the cytosolic side of the ER, 
it is therefore believed that assembly occurs in the cytosol, whereas maturation and 
egress occur on the luminal side of ER, to enable mature virions to exit the cell via the 
low density lipid secretory pathways (reviewed in (Jones and McLauchlan, 2010)).  
Endogenous VLDL secretion occurs daily with an estimated 10 particles produced 
every 24 hours; whereas approximately 1012 HCV virions per day are produced from a 
complete HCV life cycle (Neumann et al., 1998; Bassendine et al., 2013).      
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Defects at any stage of the HCV replication and assembly pathway including induction 
of lipid droplets by core to facilitate viral replication, or defects in MTP or apoE or 
other proteins involved in HCV assembly through the VLDL secretory pathway may 
therefore provide resistance to establishing chronic infection in EUs.  
 
1.5 HCV transmission. 
HCV is primarily transmitted via parenteral routes.  Risk for HCV transmission include 
factors with potential percutaneous exposure to unsafe blood or its products such as: 
unprotected sexual intercourse (Terrault et al., 2013), solid organ transplant from an 
infected donor, blood transfusion before 1992 (Schreiber et al., 1996), healthcare 
associated exposures (Grebely, Prins and Hellard, 2012), intravenous drug use (IVDU), 
acupuncture, tattooing (Pérez et al., 2005), intranasal cocaine use and other unknown 
risk factors (Bunchorntavakul et al. 2014).  Multiperson use of contaminated injecting 
needles, syringes and other injection paraphernalia is the common mode of transmission 
among IDUs (Hagan et al., 1995).  5% of children with HCV infection, were infected 
through vertical transmission (Gibb et al., 2000).  Heterosexual intercourse poses a low 
risk to HCV infection than men who have sex with other men (Terrault et al., 2013).  
Cell-to-cell HCV transmission has been reported in some studies, this poses a potential 
evasion of the virus from anti-HCV neutralizing antibodies as well as host immunity 
(Brimacombe et al., 2011).   
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1.6 HCV epidemiology, genotype and geographical distribution. 
Global HCV epidemiology has been reported based on seroprevalence.  HCV is 
distributed worldwide among all races, age groups, gender and regions.  HCV 
prevalence is high in economically less developed countries; with a total anti-HCV 
global prevalence ranging between 1.3 – 2.1 % (Gower et al., 2014).  In the developed 
world, HCV infection is also a problem with a prevalence of (0.9%) in Western Europe 
(United Kingdom 0.6%) (Gower et al., 2014).  Egypt has the highest reported HCV 
prevalence in the world owing to use of non-sterile injecting needles during the 
widespread use of a tartar emetic to treat schistosomiasis (Lehman and Wilson, 2009).  
Since variabilities in HCV geographical distribution have been reported, determination 
of specific HCV genotypes has become a useful method to predict the disease outcome, 
and treatment options.  However, the impact of genotypes on outcome of HCV infection 
seem to be minimal in long term (reviewed in (Bukh, 2016)).   Six major HCV 
genotypes have been reported, each comprising multiple subtypes and subspecies.  The 
recently additional genotypes 7 through 11 have been suggested as variants of genotype 
6 (Gower et al., 2014).  Genotypes 1, 2, and 3 have a worldwide distribution despite 
predominantly prevalent in western countries where in Europe alone, 90% of HCV 
infection are genotypes 1, 2 and 3 (Esteban, Sauleda and Quer, 2008; Messina et al., 
2015).  The HCV genotype 4 seems to be confined in Egypt and the middle-east (Gower 
et al., 2014).  In Egypt genotype 4a is prevalent due to national anti-schistosomiasis 
mass treatment/injection campaigns from 1960s through to the 1980s (Ray et al., 2000; 
Pybus et al., 2003); whereas genotype 5 and 6 are highly prevalent in South Africa and 
Hong Kong respectively (Tokita et al., 1998).       
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1.6.1 HCV epidemiology in injecting drug users. 
In developed countries, injection drug use is the dominant mode of HCV transmission 
(Alter, 2002).  As injection drug use still remains the highest risk factor for HCV 
infection, a long duration of injection usage is associated with high anti-HCV 
prevalence, and decreased HCV incidence rates (Lorvick et al., 2001).  HCV 
seroprevalence among long term IDUs is greater than 90% (Lorvick et al., 2001; Alter, 
2002; Tseng et al., 2007) among IDUs who had an injection history of more than 6 
years (Thomas et al., 1995; Diaz et al., 2001).  Studies have reported a seroprevalence 
of less than 50% in IDUs who had an injection history of less than 5 years; but annual 
HCV incidence rates remain very high (10 – 40%) among uninfected IDUs (Diaz et al., 
2001; Hahn et al., 2001; Miller et al., 2002; Des Jarlais et al., 2003).  The HCV 
transmission is sustained by injecting drug practices such as sharing injecting needles 
and other paraphernalia (Thorpe et al., 2002).  There is a low risk of developing 
persistent HCV viraemia in IDUs who successfully cleared the infection even with 
continued exposure to the virus through injecting drug use (Grebely et al., 2006).  There 
is little data about the prevalence of HCV among IDUs in the developing world.  
 
1.7 HCV natural history. 
Exposure to HCV may be considered to result in one of three outcomes;  remain 
antibody seronegative and aviraemic by sensitive RNA PCR (exposed uninfected) 
(Thurairajah et al., 2008), spontaneous clearance (detectable HCV-antibodies but HCV-
RNA negative), or establishment of chronic infection (both HCV antibody and RNA 
positive) (Knapp et al., 2010) (Figure 1.4).   
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Figure 1.4: HCV Natural History 
 
Figure 1.4: HCV natural history in untreated cases. Untreated HCV infection can lead to 
chronic infection, and liver cirrhosis. The liver-related mortality rates are due to 
decompensated liver cirrhosis or hepatocellular carcinoma. World health organisation 
(WHO) estimates that between 350,000 – 700,000 HCV infected individuals die every 
year.  The estimated percentage for the exposed uninfected population among IDUs is 
yet to be reported globally.  Plymouth city has more than 200,000 recorded cases of 
IDUs. 
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The outcome of acute HCV (AHCV) infection is dependent on host and viral factors 
that include age, sex, clinical presentations, viral co-infections, immune antiviral 
response and immunogenetic polymorphism.  HCV infection is self-limiting within 12 – 
16 weeks after onset of acute infection.  During the first 12 weeks of disease onset, 
spontaneous viral clearance is achieved in a minority of self-limiting patients but 
beyond 24 weeks may suggest viral chronicity (Maasoumy, 2012).  Approximately 80% 
of acutely infected individuals may progress to chronic hepatitis (Shepard, Finelli and 
Alter, 2005; Te and Jensen, 2010)  because they fail to eliminate the virus (Mas 
Marques et al. 2009).  It still remains elusive why some individuals clear the virus while 
others do not.  However, Ball et al. (Ball, Tarr and McKeating, 2014), in their review 
indicated that immune T cell response and rapid induction of cross-reactive neutralizing 
antibody responses was an important factor for viral spontaneous clearance in acute 
infection.  Women are twice likely to clear the virus than men.  The mechanism behind 
such a phenomenon is unclear, though some findings have suggested that high 
oestrogen levels could be associated with sustained viral clearance (Baden et al. 2014). 
 
1.7.1 HCV exposed uninfected. 
There are subsets of individuals who remain uninfected with HCV despite long term 
repeated exposure through injection drug use; the global figures are yet to be reported.  
This naturally resistant unique cohort of IDUs has been referred to as ‘exposed 
uninfected’ (EU) (Thurairajah et al., 2008).  There is clear evidence that there is an 
absence of demonstrable infection in the EU cohort, who might represent a phenotype 
that is resistant to HCV infection.  These individuals are serially negative for anti-HCV 
antibody and HCV RNA on at least 2 occasions more than 6 months apart with 
extremely high risk of HCV exposure, typically through injection drug use and sharing 
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of injection paraphernalia (Mizukoshi et al., 2008; Knapp et al., 2010).  The probability 
of true HCV exposure has been determined on the basis of risk questionnaires and/or by 
the presence of HCV specific immune responses by interferon gamma (IFN-γ) enzyme-
linked immunospot (ELISpot) assay.   
IDUs who share needles with individuals who are known to have HCV infection are at 
high risk of HCV exposure.  High risk of exposure is associated with high incidence of 
HCV infection during the first year of sharing drug injection equipment.  Likewise, 
HCV sero-prevalence increases with a long duration of injection history (Law et al., 
2003; Roy et al., 2007) as probability of actual exposure increases.  The EU group 
needs to be carefully distinguished from unexposed by close scrutiny of the probability 
of actual HCV exposure.   
An example utilising exceptional high-risk behaviours was described by Sugden et al, 
using a composite risk index for HCV exposure based on a time dependent cox-
regression analysis of 14 separate weighted risk factors of risk behaviours and 
demographics (Sugden et al., 2014).  Significantly higher composite risk scores were 
found in those that subsequently became infected rather than uninfected.  However, 
within the uninfected group there were individuals that remained uninfected despite 
high risk behavioural profiles.  Separation of the uninfected group’s risk into tertiles 
(two points that divide data into three equal parts) indicated that those in the highest 
tertile had a pattern of risk actually higher than that observed in subjects who 
subsequently become infected (Sugden et al., 2014).  Thus based on statistical models it 
is highly probable that these subjects had been exposed to HCV but were uninfected.  
Some people were infected with HCV through receiving of blood products before 1992 
(Williams et al., 2005).  The HCV lookback programme described the outcome of HCV 
exposure and  number of HCV infections following blood transfusions (The English 
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National Blood Service HCV Lookback Collation Collaborators, 2002).  The residual 
risk of HCV transmission was reduced by implementation of an HCV RNA testing 
programme for individual blood donations (Legler et al., 2000). 
An alternative definition of HCV exposure in EUs is the presence of HCV specific 
immunological responses (Sugden et al., 2014) in the absence of anti-HCV antibodies 
and HCV RNA.  T cell responses can be measured to an array of HCV peptides from 
viral structural and non-structural proteins, and may thus be used as a marker of 
immunological exposure to actual HCV particles.  Up to 60% of high risk individuals 
have detectable HCV specific T cells responses by ELISpot (Knapp et al., 2010), but 
this definition of EU may exclude others who may have alternative pathways of 
resistance other than immunological.  The ELISpot is a technique employed for 
detection and analysis of individual cells that secrete specific proteins such as cytokines 
in vitro (Czerkinsky et al., 1983).  ELISpot is one of the sensitive cellular assays that 
allows for detection of one cell in 100,000; and is between 20 and 200 times more 
sensitive than the conventional enzyme immunosorbent assay (ELISA) (MABTECH, 
2016).  Cellular IFN-γ production is used as readout of single cell activation (T helper 1 
cells) in the specific immune response.   Generation of an individual spot (cellular 
footprint) represents an individual cytokine secreting cell (reactive cell) (MABTECH, 
2016).       
The detection of an HCV-specific T cell immune response may not conclusively 
suggest the presence of HCV infection, as adaptive immune response can also be 
detected in healthy individuals who show cross-reactivity between HCV NS3 proteins 
and influenza virus neuramidase proteins (Wedemeyer et al., 2001).  Therefore, testing 
against an array of other HCV NS proteins could potentially increase the specificity of 
ELISpot assays as a marker of HCV exposure.   Cross-reactivity to an array of HCV 
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structural and non-structural antigens may be common among IDUs due to exposure to 
different antigens from contaminated injection equipment (Zeremski et al., 2009) and 
may therefore be a more robust marker of HCV exposure.   
HCV resistance may represent a spectrum, with some individuals having high level 
resistance even after exposure to high concentrations of HCV, such as a few cases that 
received known HCV contaminated blood products.  Other EU cases may have a lower 
degree of resistance, potentially  on the same spectrum as those ~20% that 
spontaneously clear HCV by immune mediated pathways (Elliot et al., 2006).  Our 
research group characterised the EU cohort, defined on the basis of high risk behaviours 
but without demonstrable HCV infection (Thurairajah et al., 2008) supports the notion 
of a spectrum of levels of HCV resistance, because HCV specific T-cell immune 
responses are demonstrated in more than 50% , but not all EU cases (Thurairajah et al., 
2008).   
 
1.7.2 HCV spontaneous resolution. 
A number of research groups have investigated the ~ 20% that are able to clear HCV 
spontaneously (spontaneous resolvers) (Thomas et al., 2009).  HCV spontaneous 
resolution has been associated with multi-faceted cellular immune response with 
neutralising antibodies (nAb) playing a vital role.  There is growing evidence suggesting 
that protective natural immune response allows viral clearance without seroconversion.  
In-vitro studies have also demonstrated that genetic polymorphism can confer partial 
resistance to establishment of HCV infection (Liu et al., 2009).  The discovery that 
genetic resistance for Human immunodeficiency virus (HIV) infection was conferred via 
the homozygosity for the truncation mutation of C-C chemokine receptor-5 (CCR5) 
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gene (HIV entry co-receptor also known as CD195) (Olivieri et al., 2007), underpins 
the belief that HCV clearance could be conferred in a similar fashion.   Establishment of 
HCV primary infection is deterred by a characterised combination of genetic and 
environmental factors.  There was a major breakthrough in 2009 regarding identification 
of some host factors that are associated with viral clearance.  
Single nucleotide polymorphisms (SNP) in the interferon lambda (IFN-λ) 3 gene locus 
(IFNL3) linked to interleukin 28B (IL-28B) are the dominant host genetic factors 
associated with HCV spontaneous resolution (Ge et al., 2009; Thomas et al., 2009; 
Rauch et al., 2010) and PEG-IFN treatment induced viral clearance (Sugiyama et al., 
2011).  The interferon lambda genes encode 3 distinct but related proteins denoted IFN-
λ 1, -λ2 and -λ3 also known as interleukin (IL)-29 (IL-29), IL-28A and IL-28B 
respectively which form a group of cytokines called ‘type III IFNs’ (Kelly, Klenerman 
and Barnes, 2011).  These cytokines share a common signalling pathway with type I 
IFNs but exert their actions via a receptor complex that is distinct from type I IFNs 
(Ank et al., 2008).  Therefore IL-28B is a significant marker that could be used to 
distinguish the healthy population, spontaneous resolvers, chronic infection and EUs. 
Spontaneous resolution of acute HCV infection is associated with a sustained HCV-
specific T cell response.  However, such a T cell response is weak, and transient in 
CHCV patients (Mizukoshi et al., 2008).  The crucial change in gene expression that 
occurs during HCV infection is the activation of the type 1 interferon response.  The 
complex cell signalling process inducing the cytokine production during initial steps of 
viral infection allows recruitment of coordinated and effective innate and adaptive 
immune responses.  However, HCV interferes with cytokines at various levels including 
escaping the surveillance of the immune responses by inducing a Th2 cytokine profile.  
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1.7.3 Acute HCV infection. 
Acute hepatitis C virus (AHCV) is usually misdiagnosed because the majority of 
infected individuals are asymptomatic (Deterding et al., 2009).  Only 20 – 30% of the 
clinically asymptomatic infected adults develop clinical symptoms.  Even in 
symptomatic acute hepatitis, the symptoms are very unspecific which last for few 
weeks.  The HCV incubation period ranges from 3 to 12 weeks and varies depending on 
the transmission route.  The longer incubation period is experienced when one is 
infected with low viral load (Mosley et al., 2005).  Therefore, >1 log viraemia 
fluctuation and low titre HCV-RNA are enough to support the AHCV laboratory 
diagnosis.  Notable symptoms include; fever, nausea, anorexia, abdominal discomforts, 
mild jaundice and malaise.  Jaundice is the hallmark for liver disease and is apparent in 
50 – 84% of infected overt patients.  Seroconversion takes 8 – 12 weeks after viraemia.  
HCV RNA can be detected within 1 to 3 weeks after exposure, whereas anti-HCV 
antibodies are negative at this stage, but they could be detected at the onset of clinical 
symptoms in some patients.  Therefore antibody diagnostic assays are unreliable in 
acute infection (Maasoumy, 2012; Bunchorntavakul et al., 2014).  AHCV infection is 
reported to be declining but increased risk factors such as IVDU, sexual activities and 
occupational exposures  are some of the predisposing factors that increase the incidence 
of AHCV infection (Maasoumy, 2012; Baden, Rockstroh and Buti, 2014; 
Bunchorntavakul et al., 2014). 
1.7.4 Chronic HCV infection. 
The chronic hepatitis could be defined as the presence of HCV RNA in the blood for at 
least 24 weeks after infection (Seeff and Hoofnagle, 2002).  The spontaneous resolution 
is rare once chronic hepatitis is established (Maasoumy, 2012).  It is clear that HCV 
employ multiple strategies to persist within the infected host.  The AHCV is often 
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followed by chronic infection in approximately 85% of infected individuals (Seeff, 
2002).  There is strong evidence associating chronic HCV infection (CHCV) to 
development of liver fibrosis, cirrhosis and HCC.  Approximately 500,000 new cases of 
liver cancer are reported annually whereby 22% of such new cases are due to chronic 
HCV infection (Lozano et al., 2012).  Once infection is established, the viral – host 
interactions underpin HCV pathogenesis.  The CHCV is typically acquired during 
adulthood, and disease progression is advanced by greater age, alcoholism, obesity, HIV 
co-infection.  Interferon based therapy is less effective in chronic infection but DAAs 
have improved the sustained viral response (SVR) rate (Dabbouseh and Jensen, 2013).  
Other researchers defined SVR as undetectable serum HCV RNA based on a 
transcription-mediated amplification assay, maintained for 24 weeks after treatment 
(Barnes et al., 2009). 
1.8 HCV laboratory diagnosis. 
HCV diagnostic assays include serological assays that detect HCV antibodies, and 
molecular techniques that detect, quantify and characterize the HCV RNA genome.  
Enzyme immunoassay (EIA) assays are screening methods for detection of anti-HCV 
antibodies in CHCV patients’ serum; whereas recombinant immunoblot assay (RIBA) is 
a supplementary method designed to resolve false positive results generated by 
screening methods.  HCV recombinant proteins and synthetic peptides from core, NS3, 
and NS5 proteins (immunodominant epitopes) were used as antigens that lead to 
successful development of RIBA anti-HCV IgG immunoglobulins detection assays 
(Colin et al., 2001).  Detection of anti-HCV by RIBA is based on immobilisation of 
HCV recombinant antigens into a test strip membrane that appear as individual bands.  
Positive results are detected by reactivity with ≥ 2 proteins, whereas reactivity to 1 
protein indicates indeterminate results (Gerlach et al., 2003).  Anti-HCV antibodies are 
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undetectable in early AHCV infections and severely immunocompromised patients 
(Alter et al., 2003).  Anti-HCV antibody concentrations persist in the circulation in the 
absence of HCV RNA following spontaneous or treatment-induced resolution  
(Chevaliez and Pawlotsky, 2008; Kamili et al., 2012).   
Diagnosis of AHCV or CHCV is dependent on detection of HCV RNA in body fluids 
by sensitive molecular detection techniques (lower detection limit <9.3 HCV RNA 
international units (IU)/ml in plasma) such as polymerase chain reaction (PCR).  
Confirmation of active HCV infection is established by detection of HCV RNA by PCR 
in patients’ samples, as well as monitoring treatment antiviral response to therapy.  
HCV viral load is determined by a sensitive quantitative PCR.  Nucleic acid testing 
(NAT) remains the gold standard for active HCV confirmatory testing, and HCV RNA 
is detectable in plasma as early as 1 week post-exposure (Pawlotsky, 2003).  NAT 
testing in clinical laboratories requires skilled technical personnel,  the reagents and 
consumables are expensive, as well as dedicated procedure areas (Hosseini-Moghaddam 
et al., 2012).  The current NAT testing is based on PCR (relies on in-vitro amplification 
of the target sequence), branched DNA signal amplification (a signal amplification 
technology that does not require amplification of a target sequence), and transcription 
mediated amplification.  NAT testing exhibits approximately 99% specificity across all 
6 major HCV genotypes (Kamili et al., 2012).  Advances in molecular techniques have 
improved that led to the development of prototype nanoparticle-based diagnostic assays 
that detect HCV biomarkers.  Examples of the developed nanoparticles are quantum 
dots (QDs) and gold nanoparticles (Azzazy, Mansour and Kazmierczak, 2006).  HCV 
blood metabolites profiling have recently been successfully quantified by Mass 
Spectrometry (MS) and Nuclear Magnetic Resonance (NMR) techniques (Gowda et al., 
2008).   
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Identification of AHCV infection is seldom possible because the majority of patients 
test positive for anti-HCV antibodies or HCV RNA at diagnosis.  Therefore no anti-
HCV IgM immunoglobulins serve as early markers for HCV infection because HCV 
IgM are variably detected in both AHCV and CHCV infections (Quinti et al., 1995).  
AHCV and CHCV infection are distinguished by monitoring fluctuations of HCV viral 
load (McGovern et al., 2009), variations in anti-HCV titres (Coppola et al., 2009), and 
determination of IgG avidity to HCV (Kanno and Kazuyama, 2002).  The rapid HCV 
serologic assays for detection of anti-HCV antibodies have been introduced for rapid 
screening of HCV infections, but discrimination between active HCV infection and 
resolution requires molecular techniques.   
1.9 HCV treatment and drug resistance. 
The CHCV treatment has significantly been revolutionized recently with the licencing 
of DAAs.  Interferon based standard therapy in combination with RBV has been the 
cornerstone for HCV treatment for the past two decades but has many adverse effects.  
The common adverse effects associated with PEG-IFN/RBV treatment include cough, 
haemolytic anaemia, neuropsychiatry, muscle aches, teratogenicity, poor tolerability and 
significant toxicity which result in premature discontinuation of therapy in 10 – 20% of 
patients (Russo and Fried, 2003).  The HCV treatment with PEG-IFN and RBV is 
relatively ineffective with 50% SVR rate (Niederau et al., 2012).  Because of reduced 
SVR for interferon-based therapy, there has been a motivation for development of 
alternative therapeutic agents with minimal adverse effects, and a convenient drug 
administration route as opposed to the subcutaneous administration of PEG-IFN/RBV 
(Abraham and Spooner, 2014).  The DAAs target HCV specific NS proteins to disrupt 
viral replication and subsequent infection.  The following four classes of DAAs have 
been defined depending on their therapeutic targets and mechanisms of action:  NS3/4A 
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protease inhibitors, NS5A inhibitors, NS5B nucleoside polymerase (NS5B RNA-
dependent RNA polymerase) inhibitors, and NS5B non-nucleoside polymerase 
inhibitors (Table 1.1) (Poordad and Dieterich, 2012).  In 2011, NS3/4A serine protease 
inhibitors (Boceprevir and Telaprevir) were the first DAAs to be approved for HCV 
treatment in conjunction with PEG-IFN and RBV; which improved the SVR to about 75%  
in CHCV genotype 1 treatment naïve patients (Jacobson et al., 2011; Poordad et al., 
2011), but they have to be used in combination with the PEG-IFN and RBV standard of 
care regimen.  SVR is defined by absence of detectable viremia (HCV RNA in blood) 
12 or 24 weeks post HCV treatment (Swain et al., 2010).  The successful SVR is 
associated with reduced risk of HCC development but does not fully offer protection 
against development of HCC (Russo, 2010; Swain et al., 2010).  Sofosbuvir is an oral 
NS5B nucleotide polymerase inhibitor that was licenced in Europe in January 2014 and  
has been reported to have HCV pan- genotypic effect, either as a dual therapy with RBV 
or triple therapy with NS5A inhibitors, and protease inhibitors (reviewed in (Stedman, 
2014)).  Sofosbuvir is administered orally once a day even without food dependence.  It 
achieves its  highest plasma concentration within 0.5 to 3 hours (Abraham and Spooner, 
2014; Mariño et al., 2014).  Sofosbuvir’s virologic efficacy rate varies between 70 – 
90%, has high genetic barrier to resistance, and can easily be eliminated renally 
(Jacobson et al., 2013).   
The USA biotechnology company, Gilead Sciences has developed an experimental 
HCV drug ‘Ledipasvir’ an NS5A inhibitor that has antiviral activities again genotype 1 
subtypes only whereas Sofosbuvir works against genotypes 1 – 4 in combination with 
Ribavirin with or without PEG-IFN (Afdhal et al., 2014).  A 12 week or 24 week 
therapy combination of Ledipasvir and Sofosbuvir with or without Ribavirin has been 
reported to have an increased SVR in genotype 1 treatment naïve patients while the 
previously genotype 1 treated patients equally showed high SVR (between 94% to 99%).  
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Generally, a Ledipasvir and Sofosbuvir combination with or without Ribavirin has 
a >97% SVR regardless of treatment duration and patients’ characteristics.  Therefore, a 
single tablet regimen of Ledipasvir and Sofosbuvir without Ribavirin for 12 weeks is 
effective enough, but the addition of Ribavirin in the regimen has little benefit (Afdhal 
et al., 2014).   
HCV exists in quasispecies (a mixture of closely related but different genomes) in the 
host due to high degree of genetic variations as a result of high mutation rate (Forns, 
Purcell and Bukh, 1999).  This renders the available treatment options less effective 
(Schweitzer and Liang, 2013; Zeng et al., 2013).  Other newly licenced DAAs include 
Simeprevir (an NS3/4A protease inhibitor) approved in May 2014, and Daclatasvir (an 
NS5A inhibitor) approved in September 2014 (The European Association for the Study 
of the Liver, 2014).  Baseline predictors of treatment response include: viral factors 
(viral load, HCV genotype), ethnicity, IL-28B polymorphism, HIV co-infection, degree 
of liver fibrosis and previous HCV treatment (Delwaide et al., 2005; Ramachandran et 
al., 2012).  In the current DAA era, HCV genotype 3 SVR is lower as opposed to 
genotype 2 (Jacobson et al., 2013), making HCV genotype 3 as the more difficult –to-
treat genotype (Goossens and Negro, 2014; Pawlotsky, 2014). 
HCV becomes resistant to the commonly prescribed Interferon and Ribavirin due to 
selective pressure which results in adaptive mutations.  The mutations in viral NS3 and 
NS5B regions are associated with protease and non-nucleotide inhibitors’ resistance 
(Stedman, 2014).  Nucleotide analogue inhibitors have a high barrier to resistance 
because they select viral resistant variants that hardly replicate in the presence of drugs, 
and rarely present at baseline.  The other DAAs have low barrier to resistance because 
they select fit viral resistant variants in the presence or absence of the drugs (Pawlotsky, 
2014). A 90% cure rate was achieved in phase III clinical trials (a single-pill 
64 
 
combination of Sofosbuvir plus Ledipasvir, Sofosbuvir plus Daclatasvir, and a two-pill 
combination of Sofosbuvir plus Simeprevir); however, a subset of CHCV patients (13 
out of 316) had treatment failure (Zeuzem et al., 2015).  The CHCV patients who failed 
to clear the virus experienced post-treatment relapse to DAAs which have low barrier to 
resistance.  There is a growing evidence confirming that patients who fail oral IFN-free 
treatment, contain highly resistant viral strains at the time of relapse (Dvory-Sobol et al., 
2015).  
 
Table 1.1 Newly licenced HCV DAAs. 
 
Classes of 
DAAs 
Name of drugs Mode of 
action 
HCV 
regimen 
Therapeutic 
target 
Targetable 
HCV 
genotype 
NS3/4A 
protease 
inhibitors 
- Telaprevir 
- Boceprevir 
- Simeprevir 
- Paritaprevir 
- Asunaprevir 
- Faldaprevir 
- Elbasvir 
- Grazoprevir 
Arrests 
protein 
synthesis 
Paritaprevir 
+ 
Ombitasvir 
+ RBV 
NS3/4A Genotype 
4 
NS5A 
inhibitors 
- Ledipasvir 
- Ombitasvir 
- Daclatasvir 
- Velpatasvir 
Prevents 
replication 
Lediprevir 
+Sofosbuvir 
+ RBV 
NS5A Genotypes 
1, 4, 5 & 6  
NS5B 
nucleoside 
polymerase 
inhibitors 
- Sofosbuvir 
 
Prevents 
replication 
Sofosbuvir 
+ RBV 
NS5B Genotypes 
2 & 3 
NS5B non-
nucleoside 
polymerase 
inhibitors 
- Dasabuvir  Dasabuvir + 
Paritaprevir 
+ 
Ombitasvir 
± RBV 
NS5B Genotype 
1 
 
Table 1.1: Examples of IFN-free HCV regimens for treatment of CHCV in Europe 
(European Association for the Study of the Liver, 2017). 
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1.10 HCV reinfection following spontaneous resolution and/or treatment. 
After clearance of HCV infection either spontaneously or following treatment, people 
remain at risk of reinfection with HCV.  People who successfully resolve HCV 
infection do not possess protective immunity against reinfection, but available evidence 
suggests that reinfection does occur despite efficient immune responses that result in 
viral clearance (Grady et al., 2012; Grebely et al., 2012).  Blackard defined HCV 
reinfection as a complete resolution of an initial infection prior to a subsequent infection 
either with a different genotype/subtype or the same type (Blackard and Sherman, 2007).  
On the contrary, recurrence of HCV viraemia within 24 weeks after completion of 
treatment is defined as a viral relapse.  Viral coinfection is a simultaneous acquisition of 
more than one viral strain; whereas superinfection occurs in CHCV cases that are re-
exposed to different HCV viral strain(s) (Grady et al., 2013).  Therefore detection of 
viraemia in individuals who previously cleared HCV infection either spontaneously or 
following cessation of therapy, are classified as reinfection cases. 
Studies of HCV reinfection have provided insights into important aspects that offer 
against viral persistence.  It was further reported that reinfection bouts are associated 
with improved control of HCV replication and an increased likelihood of resolving the 
infection as opposed to the primary infection (Bassett et al., 2001; Prince et al., 2005) 
possibly due to induction of HCV-specific T cell responses (Shoukry et al., 2003; 
Abdel-Hakeem et al., 2014).  Cases of HCV reinfection were reported in PWIDs and 
men who have sex with other men (Grady et al., 2012).  The proportion of incidences of 
HCV reinfection after spontaneous resolution versus incidences of primary infection 
should be assessed.  Grebely et al. explained that if most reinfections spontaneously 
cleared, there would be a strong logical argument for some level of protection.  
Determination of the size and length of HCV viraemia during reinfection as compared 
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to the primary infection aid to establish whether protection is generic or immunological.  
A simplification in the degree or duration of viraemia would suggest that acquired 
protective immunity resistance has a role, because fixed genetic factors would not adapt 
and become robust as does the immune response (Grebely et al., 2013). 
Notably, HCV reinfection does not always lead to viral persistence; data suggest that 
spontaneous clearance of reinfection also occurs even when infected with a different 
genotype from that of the primary infection (Page et al., 2009).  Therefore reinfection 
rates among IDUs are still low, but despite such low incidences, there is a need to 
provide awareness and sensitisation education to PWIDs regarding the possibility of 
HCV reinfection even after resolution of the initial infection. 
1.10.1 Models for the study of HCV infection. 
1.10.2 In vivo models. 
The HCV clinical research and investigation is inherently hampered by the 
heterogeneity of human host, tissue tropism and its restricted access, and lack of a 
suitable small animal model.  Numerous experimental tools have been developed to 
describe the HCV interaction with its human host.  Efforts to identify a small animal 
model to study HCV life cycle are on-going.  Chimpanzees (Pan Troglodytes) are well-
studied, established wild animal species with a 98% genetic identity to humans that are 
susceptible to HCV infection.  The chimpanzees have played a pivotal role in the 
discovery of HCV (reviewed in (Houghton, 2009)) and remains the gold standard for 
other small and large animal models.  The HCV has a narrow host range (humans and 
chimpanzees only), therefore studying HCV in large animal models (great apes) is 
restricted by cost implications, ethical issues, and limited availability (Bukh et al., 
2001), which led to some countries banning the use of large apes as experimental 
models in research.  The host immune response to HCV infection was described by 
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successful experimental infection of Chimpanzees which helped assessment of potential 
drug and vaccine candidates (reviewed in (Bukh, 2004; Houghton, 2011).   
Various animal species have been challenged with HCV to identify alternative animal 
models.  The simians and their orthologs of HCV attachment and entry factors were 
reported to share sequence similarities with humans and Chimpanzees (Flint et al., 
2006).  The HCV replication in Simian hepatocytes is antagonised by different kinetics, 
and monkey cells’ magnitudes of antiviral defences (Billerbeck et al., 2013).  Despite 
genetic similarities between the large primates and humans, establishment of infection 
in Chimpanzee models does not directly translate to human infection. 
The tree shrew (Tupaia belangeri) – a wild small squirrel-like mammal related to 
primates, is a reported putative candidate for small animal models for HCV infection, 
which has shown to be susceptible to HCV infection.  Establishment of HCV infection 
in tree shrew animal models is difficult due to transient viremia and need for 
immunosuppression.  Tupaia belangeri orthologs of HCV entry factors have been 
reported to facilitate viral uptake  (Tian et al., 2009; Tong et al., 2011).  Intermittent and 
transient viremia was reported in Tupaia belangeri challenged with serum mixture of 
HCV genotypes (Xie et al., 1998).  Immunosuppression of Tupaia by X-ray irradiation 
increased infection frequency of 50%.  However, Tupaia challenged with patient or cell 
culture derived HCV resulted in increased frequency of infection rates to more than 80% 
without the need for immunosuppression (Amako et al., 2010).  Despite the long-
standing track of mice in biomedical research, they are not susceptible to HCV infection.  
Different transgenic mice strains have been studied to model HCV infection, but 
transgenic models have different pathways and strictures that limit their utility.  
Numerous approaches toward the development of small animal models for HCV 
infection such as xenotransplantation, non-primate hepacivirus, continue to be pursued.  
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1.10.3 Small animal model for the study of HCV. 
Researchers previously observed that the CD81 and occludin were the human entry 
factors required to render mouse cells permissive to HCV entry in vitro (Ploss et al., 
2009).  It was further reported that transgenic mice capable of expressing human CD81 
and occludin factors support HCV entry into hepatocytes, but the establishment of HCV 
infection in vivo was restricted by the host innate and adaptive immune responses 
(Dorner et al., 2013).  The genetically humanized mouse models may offer new avenues 
for studying HCV infection in vivo.  The transient expression of human CD81 and 
occludin entry factors by adenoviral delivery efficiently supported HCVcc entry into the 
mouse hepatocytes (Dorner et al., 2011).  The transgenic mice with four human entry 
factors but deficient in innate immune signaling pathways was reported to allow HCVcc 
entry into the hepatocytes, low level replication was also observed, and infectious viral 
particles were recovered in mouse serum (Dorner et al., 2013).    
1.10.4 The newly discovered hepaciviruses. 
Until 2011, the only known HCV homolog was GB virus B (GBV-B) named after a 
surgeon (initials GB) suffering from an acute hepatitis in 1967 whose serum caused 
transmissible acute hepatitis in tamarins in 1995 (Stapleton et al., 2011).  Both the 
GBV-B and HCV belong to the hepacivirus that also include the recently accepted 
genus Pegivirus  (Stapleton et al., 2011), but GBV-B rarely establish persistent infection 
(Takikawa et al., 2010).  The HCV-related hepaci- and pegiviruses were discovered in 
animals such as horses, non-human primates, bats, dogs, and rodents (Scheel, 
Simmonds and Kapoor, 2015).  Based on phylogenetic relationships and the genome 
organization, Pegivirus contains GBV-A, GBV-C, and GBV-D viruses  (Stapleton et al., 
2011).   The GBV-A was not shown to cause hepatitis in tamarins whereas GBV-B was 
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associated with the development of acute, self-limiting hepatitis infection in tamarins 
(Schlauder et al., 1995).   
A well-studied hepacivirus that belongs to the hepaciviridae family is non-primate 
hepacivirus (NPHV) also identified in dogs, bats, horses and wild rodents (El-Attar et 
al., 2015).  The NPHV are phylogenetically related to HCV (Burbelo et al., 2012).  
Another hepacivirus to be characterized and reported to infect a wild non-human 
primate (Colobus guereza) was guereza hepacivirus (GHV) that share some common 
features with the GBV-B.  A novel equine Pegivirus (EPgV) has also been discovered 
recently that infects horses (Chandriani et al., 2013).  These new discoveries explain the 
host range and evolution of hepaciviruses. 
 
1.10.5 In vitro models. 
The lack of reliable cell culture systems in the past hampered the initiation of productive 
HCV infection in biomedical research.  Molecular techniques enabled the development 
of efficient in vitro culture systems for study of HCV infection.  Primary cells from 
humans and Chimpanzees were used in initial attempt to establish the in vitro HCV 
infection; but due to contamination problems observed in primary hepatocytes, 
researchers tried to develop immortalized human hepatoma cell lines (Castet et al., 
2002).  Human liver cancer cell lines (Huh 7 cells and its derivatives), were proposed as 
an ideal in vitro human hepatic cell model for recapitulation of the HCV life cycle.  The 
development of in vitro hepatocyte culture platforms has enables the elucidation of a 
detailed analysis of essential aspects of HCV pathogenesis.  The in vitro models do not 
directly represent the clinical host responses and disease development in vivo.  
Hepatoma cell line 7721 (Song et al., 2001) and human hepatocyte cell line PH5CH 
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(that is immortalised with simian virus 40 large antigen) were susceptible to HCV 
infection but with less efficiency (Kato et al., 1996) suggesting that overexpression of 
viral oncogenes could be enough to support the in vitro growth of arrest of adult 
hepatocytes.  However, human adult hepatocytes have limited proliferation capacity and 
do not undergo cell growth in vitro.  
1.10.5.1 HCV sub-genomic replicon. 
Woerz et al. defined a replicon as a nucleic acid (either DNA or RNA) that is capable of 
autonomous replication, but in this context, a replicon refers to RNA molecules capable 
only of intracellular self-replication i.e. unable to support the production of infectious 
viral particles (Woerz, Lohmann and Bartenschlager, 2009).  The HCV replicon system 
facilitates the replication of a modified HCV genome in human hepatoma (Huh 7) cells.  
The HCV replicons contain either NS proteins for RNA replication (sub-genomic) only 
or the entire HCV genome (genomic) in length.  Both replicon systems contain the 
neomycin phosphotransferase resistance gene for selection with G418 (geneticin).  A bi-
cistronic replicon was created with the inclusion of sub-genomic clones of HCV 
genotype 1b in combination with a heterogenous encephalomyocarditis virus (EMCV) 
IRES sequence for synthesis of HCV NS proteins (Lohmann, 1999).   All genes were 
driven by the T7 promoter.   Following transcription by T7 RNA polymerase, the sub-
genomic replicon RNA was transfected into Huh-7 cell lines, to observe the intracellular 
replication of viral genome.  RNA replication facilitates cell growth and colony 
formation in the presence of G418 antibiotic.  Poor replication efficiency and reduced 
reproducibility of the replicon system were observed.  However, to enhance replication 
levels, HCV genotype 1b clone adaptive mutations were developed in NS region.  Some 
RNA replicons replaced the neomycin phosphotransferase gene with the luciferase gene 
in transient assays to identify adaptive mutations.  The adaptive mutations observed in 
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the replicons were acquired through mechanisms that are unclear.  Detection of adaptive 
mutations in HCV NS proteins NS3, NS5A and NS5B were observed (Blight, 2000) 
(Lohmann et al., 2003).   It was reported that IFN resistance was associated with NS5A 
adaptive mutations.  Adaptive mutations increased viral genome replication 
(Bartenschlager, 2002).  Characterization of cells harbouring replicons showed that they 
were able to sustain RNA autonomous replication for over one year, but effective clone 
replication decreased over time (Pietschmann et al., 2001).  The study of sub-genomic 
replicons systems has allowed elucidation of viral replication, and screening of 
chemicals for development of novel therapeutic agents with antiviral actions against 
HCV.  Despite great strides made in studying in vitro HCV models, the production of 
intact viral particles for elucidation of a complete HCV life cycle is yet to be achieved.  
 
1.10.5.2 HCV producing pseudo particle (HCVpp) and infectious HCV cell culture 
systems (HCVcc). 
Infectious cell culture systems have been developed for in-vitro study of HCV 
replication.  The development of full length replicon (Japanese fulminant hepatitis 
isolate 1 – JFH-1) for HCV genotype 2a that was derived from a Japanese patient with 
fulminant hepatitis represent a major breakthrough.  This full length genomic replicon 
efficiently replicates in Huh-7 and other cell lines without requiring adaptive mutations 
(Kato et al., 2003).  Wakita and his colleagues developed a replicon system that 
efficiently propagates and secretes viral particles in Huh-7 cells using a full length JFH-
1 sequence (genomic replicon).  Transfection of JFH-1 genomic replicon supports the 
propagation of HCV in cell culture (HCVcc) that produces culture-derived HCV 
infectious particles (the HCVcc particles) as authentic virions (Wakita et al., 2005; 
Zhong et al., 2005; Lindenbach et al., 2006).    
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Further improvements were made to the Huh-7 cell lines, to derive Huh-7.5.1 cell lines 
that are highly permissive to JFH-1 infection and increase viral titre to between 104 – 
105 infectious units per ml of culture supernatant (Zhong et al., 2005).  The current 
models of HCV replication cycle are based on studies of JFH-1 infectious viral particles.  
Attempts for explanation of the early stages of HCV life cycle were provided by 
studying HCV pseudotype particles (HCVpp).   Transfection of three vectors in human 
embryo kidney cells (293T) led to production of HCVpp (Da Costa et al., 2012).  The 
HCVcc system covers the complete viral replication cycle, but has its strong impact in 
dealing with late steps of the replication cycle (assembly and egress); whereas the 
HCVpp system is superior at providing an explanation for early stages of HCV life 
cycle (attachment, entry, and uncoating) (Baumert et al., 1998; Blanchard et al., 2002).  
The efficient production of viral particles in HCVcc is only restricted to JFH-1 isolates 
which is a major limitation.  Other infectious viral particles were produced in H77 
genotype 1a isolates, but the produced particles have low infectivity (Yi et al., 2006).   
Generally, the HCV replicon systems attain a high genetic flexibility and cover a 
broader range of isolates and genotypes that offers avenues for the development of 
antiviral agents.  
1.11 Lipid metabolism. 
The host factors are important in viral infectivity, therefore this section will describe the 
host factors that play a role in HCV infection.  HCV is associated with lipoproteins and 
their associated apolipoprotein components in the viral life cycle as already described in 
this Chapter from Section 1.4.3 above.  Available evidence indicates the close 
connection between HCV and lipid metabolism through the formation of LVPs (Shawa, 
Sheridan, et al., 2017). 
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1.11.1 Post-prandial lipid metabolism. 
1.11.1.1 Exogenous lipid pathway. 
This is the process that produces lipids from the diet in the intestines and are transported 
to the liver.  The digestion of dietary fat starts in the stomach that involves mechanical 
emulsification, lipolytic action by lipase enzymes and bile salts action.  Lipolysis 
describes the enzymatic breakdown of complex lipids that releases free fatty acids 
(FFA).  The lipolysis of the emulsified fat is catalysed by pancreatic lipase (an enzyme 
that mainly acts on dietary triglycerides – TG).  Dietary fats containing TGs as the 
principal lipid components in the diet, are emulsified in the small intestines, and 
absorbed in enterocytes (Ramasamy, 2014).  The newly re-esterified TGs together with 
cholesterol esters associate with apolipoproteins and phospholipids and are packaged 
into CMs.   
Nearly 90% of TGs in the intestine is absorbed that later forms the lipid content of CMs; 
whereas only 40% of dietary free cholesterol is absorbed (Griffin, 2013) through the 
NPC1L1 to be incorporated into the CMs.  The FFAs generated through hydrolysis of 
TGs are taken up by enterocytes via fatty acid binding protein and are resynthesized into 
TG before being incorporated into CMs.  The digested dietary lipids are efficiently 
assembled into CMs by the apoB-48, a truncated isoform of apoB exclusively found in 
the small intestines (Davidson and Shelness, 2000).  The ApoB-48 is synthesized in the 
rough ER of the enterocytes and later transported to the smooth ER to combine with 
LDs.  ApoB-48 is 48% of the size of apoB-100 (synthesized in the liver).  ApoA-I, 
apoA-IV, and apoB-48 are the only apolipoproteins synthesized in the enterocytes.  The 
combination of apoB-48, apoA-I and apoA-IV occurs in the Golgi apparatus within the 
enterocytes (Griffin, 2013). 
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Before their delivery into the lymphatic system, the TG-rich CMs acquire exchangeable 
apolipoproteins (apoA-I and apoA-IV) leave the enterocytes by exocytosis and travel 
via the thoracic duct to enter the vascular compartment.  While in the circulation, the 
CMs mature through acquisition of apoC (I – III) and apoE from HDL (Ramasamy, 
2014) that consequently activate lipoprotein lipase (LPL) to hydrolyse the TGs in order 
to release FFAs for storage in adipose tissue.  TG hydrolysis results in shrinkage of the 
CMs, decrease in size and transfer of apoC (II & III) and cholesterol back to HDL. The 
ApoE remains/stays on the CM surface.  The TG-depleted chylomicron remnants are 
cleared from the circulation via the liver (Ramasamy, 2014), mediated by interaction of 
apoE and cellular HSPG receptors since apoB-48 on the CMs lacks the binding domain 
for cellular receptors such as LDLR (Davidson and Shelness, 2000).  Therefore apoA, 
apoC, and apoE are commonly known as exchangeable apolipoproteins that are able to 
dissociate from one lipoprotein and reassociate with another in the circulation 
(Sundaram and Yao, 2012).   
1.11.1.2 Endogenous lipid pathway. 
The liver is responsible for regulating the ingested lipids, non-esterified FFAs from 
adipocytes and de novo synthesis of lipids.   As described in Section 1.11.1.1 above, 
CMs mediate the delivery of dietary lipids to the liver, whereas hepatocytes synthesize 
and secrete VLDL (another class of TG produced dependent on availability of lipid 
substrates for TG synthesis) that deliver endogenously synthesized TG to peripheral 
tissues (Ramasamy, 2014).   
Similar to CM production, VLDL synthesis occurs in two main stages that eventually 
fuses nascent VLDL with LDs.  Initial stages of VLDL synthesis involves lipidation of 
apoB-100 in the ER by MTP where they acquire TGs, cholesterol and other 
apolipoproteins (i.e. apoC and apoE) before being released into the systemic circulation, 
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while in the circulation there is sequential lipolysis of TGs by LPL to produce FFAs, 
VLDL remnants, and IDL.  During the process of lipolysis, the IDL lose both apoC-II 
and apoE to eventually become LDL that are rich in apoB-100 and contain high 
cholesterol (Aizawa et al., 2015).   
The VLDL remnants, half of IDL (Aizawa et al., 2015), and LDL are cleared from the 
circulation by binding to LDL receptor through recognition of apoE (exclusively in 
VLDL remnants, and IDL), and apoB-100 (present in LDL).  The metabolic fate of 
VLDL is largely dependent on its size and lipid composition; but is eventually removed 
as VLDL remnants or by following the sequential VLDL-IDL-LDL pathway.  The later 
pathway favours the removal of smaller VLDL (often referred to as pre-VLDL) (Griffin, 
2013).  
Table 1.2 Properties of lipoproteins in blood circulation. 
 
Lipoprotein Size (nm) Density Apolipoprotein 
CM Largest (80 – 1200) and most TG-
rich lipoproteins  
Lowest  B-48, A-1, C-II, 
E 
VLDL 30 – 52  Very low B-100, C-II, E 
IDL 24 – 30  Intermediate  B-100, C-II, E 
LDL 18 – 24  Low B-100, C-II 
HDL 8 – 15 (smallest) Highest A-I, A-II, E 
 
Table 1.2 shows the properties of lipoproteins in blood circulation.  Distinct families of 
lipoproteins have been described, each of which play different roles in lipid metabolism 
and transport.  The lipoprotein classes contain characteristic apolipoproteins.  Each 
lipoprotein class varies in size, density, and the lipid composition.  The CMs are the 
VLDL are the largest lipoproteins but have lowest density, whereas the HDL are the 
smallest but have the highest density.  CM, chylomicron; VLDL, very low density 
lipoprotein; IDL, intermediate density lipoprotein; HDL, High density lipoprotein 
(Griffin, 2013). 
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1.11.1.3 Reverse cholesterol transport: HDL. 
The bulk of free cholesterol that is absorbed from the stomach is re-esterified in the 
enterocytes through the action of acyl-CoA-cholesterol acyltransferase (ACAT).  HDL 
transports cholesterol from the peripheral tissues to the liver (hence reverse transport) 
for excretion.  This is the only route that eliminates cholesterol from the body.  The 
cholesterol is an important constituent of cell membranes.  The HDL is primarily 
synthesized in the gut and liver.  The plasma HDL is highly heterogeneous (different 
size, density and composition) as a result of acquisition of cholesterol from peripheral 
tissues, and from VLDL and CM following LPL-mediated lipolysis of TGs (Kontush et 
al., 2015).  The initial steps for HDL biosynthesis begin with the interaction of apoA-I 
(forms 70% of HDL protein) and adenosine triphosphate binding cassette transporter A1 
(ABCA1) proteins that facilitate cholesterol efflux to apoA-I to generate immature 
discoidal HDL (Wang and Smith, 2014).  The re-esterification of free cholesterol by the 
lecithin cholesterol acyltransferase (LCAT) and the migration of cholesterol esters into 
immature discoidal HDL to generate mature spherical HDL3.  The acquired cholesterol 
esters are transported back to the liver directly as HDL or indirectly via a shuttle protein 
called cholesterol ester transfer protein.  Thus, HDL2 provides cholesterol influx into 
hepatocytes by transporting cellular cholesterol to the liver for excretion through SR-BI 
receptor (Ramasamy, 2014).    
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1.11.2 Lipid storage. 
Lipids are mainly stored as TGs in adipose tissue but perform biological functions as 
phospholipids in cell membranes.  TGs are synthesized exogenously in the intestines, 
and endogenously produced in the liver where they are transported in macromolecular 
complex with lipoproteins to tissues for oxidation or storage.  Lipoprotein transport is 
described in relation to production and removal of cholesterol and TG from the vascular 
compartment.  Forward transport refers to the influx of cholesterol from the gut and 
liver to the blood circulation and back to the liver again, whereas reverse transport 
describes the cholesterol efflux from peripheral tissues via HDL pathway to the liver 
(Sehayek and Hazen, 2008) that offer protection from development of atherosclerosis.  
Two types of adipose tissues exist in relation to the function and location namely: 
visceral and subcutaneous where visceral adipose tissue is located in close proximity 
with internal organs. 
1.11.3 HCV modulates lipid metabolism. 
The CHCV infection is characterised by abnormal accumulation of fat in the liver, a 
condition known as steatosis.  The HCV genotype 3 is considered the most difficult to 
treat genotype in patients with advanced liver disease.  The HCV genotype 3 is 
associated with hepatic steatosis, rapid progression to cirrhosis, reduced apoB-
containing lipoproteins, and low LDL cholesterol as opposed to genotype 1 (Negro and 
Sanyal, 2009; Sheridan, Neely and Bassendine, 2013).  This is due to the apparent viral 
inhibition of MTP transfer (Mirandola et al., 2010).  It is clear that different HCV 
genotypes utilise different pathways for HCV infectivity that consequently deregulate 
lipoprotein concentrations.  
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The HCV modulates lipid metabolism by reducing lipid oxidation and at the same time 
increasing lipid synthesis leading to increased accumulation of cellular fats.  As 
described previously, apoE plays an essential role in HCV infectivity, and probably acts 
as a potential ligand for infectious LVPs through interaction with HSPG cellular 
receptor (Baumert et al., 2014).  Previous studies have reported the positive correlation 
of increased concentrations of apoB-containing lipoproteins (VLDL and LDL) and 
treatment outcome in CHCV patients receiving IFN-based therapy (Sheridan et al., 
2009).    
Furthermore, other researchers suggested that apoE mediates the interaction between 
IFN-sensitivity, lipoprotein metabolism, and infectious viral particles in CHCV.  
Therefore apoE is associated with IFN-response (Sheridan et al., 2012).  The above 
information presents the important roles of apolipoproteins in modulating lipoprotein 
metabolism and as critical regulators of HCV life cycle involving lipid metabolism. 
 
1.12 Innate and adaptive immunity. 
Moving from host lipid interactions, this section describes the host immune responses 
that are crucial in determining the outcome of HCV exposure. 
The innate immune system constitutes the non-specific defence mechanisms, and plays 
a crucial role in recognition and triggering pro-inflammatory response to pathogenic 
microorganisms (Medzhitov and Janeway Jr., 2000).   The innate immune system 
recognises evolutionary highly conserved molecular structures of pathogens, termed 
pathogen-associated molecular patterns (PAMPs) (e.g. ssRNA).  The PAMPs are 
invariant structures unique to microbes and distinguishable from host’s ‘self’ (Schenten 
and Medzhitov, 2011).  The recognition of PAMPs by innate immune system is 
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primarily mediated by the host’s pattern recognition receptors (PRRs) that fall into 
several families such as Toll-like receptors (TLRs), cytoplasmic retinoic acid-Inducible 
Gene 1 (RIG-I)-like receptors (RLRs),  nucleotide-binding oligomerisation domain 
(NOD)-like receptors (NLRs) (Mogensen, 2009), and C-type lectin receptors (CLRs) 
that recognise fungal pathogens (Vautier, MacCallum and Brown, 2012).  The RIG-I 
and melanoma differentiation-associated protein 5 (MDA-5) are important innate 
immune receptors that detect dsRNA in the cytosol (Kato et al., 2006; Pichlmair et al., 
2006). 
The classification of PRRs depends largely on specificity, function, and localisation of 
their ligands.  Since PAMPs are perceived as molecular signatures of infection, their 
recognition by cellular transmembrane proteins such as TLRs leads to the induction of a 
cascade of downstream mechanisms that result in inactivation of invading pathogens, 
modification of innate immune response, and subsequent activation of adaptive immune 
response.  These coordinated systems manage to either clear the pathogens or restrict 
their replication  (Fejér et al., 2005; Kumar, Kawai and Akira, 2011; Schenten and 
Medzhitov, 2011).  PRRs are capable to distinguish self from non-self by binding 
PAMPs present in pathogens but typically absent on host molecules.   
Likewise, the adaptive or acquired immune system comprises highly specialised cells 
that provide specific response to particular pathogens that induced the immune response.  
Adaptive immunity is characterised by elimination of invading pathogens, and 
generation of immunological memory (Bonilla and Oettgen, 2010).  Unlike the innate 
immunity, adaptive immune system is highly specific and provides long-lasting 
protection through destruction of pathogens and their secreted toxins.  Lymphocytes are 
the main type of leucocytes that are involved in adaptive immunity.  The B cells and T 
80 
 
cells are the major lymphocytes involved in ‘humoral’ and ‘cell-mediated’ immune 
responses respectively (Schenten and Medzhitov, 2011).    
1.12.1 Humoral immune response. 
The B cells mature in the bone marrow and spleen and remain in peripheral tissues until 
activated by presence of a foreign antigen.  The B cell activation requires two distinct 
signals, achieved by firstly, binding of antigen to B cells’ membrane-bound receptors 
(BCRs) whose binding moiety contain membrane-bound antibodies; and secondly, by T 
helper (Th) cell stimulation (Baumert et al., 2014).  Upon binding to B cell receptors, 
the receptor mediated endocytosis takes place that internalises the detected antigen, 
where it gets broken down and complexed to Major Histocompatibility Complex II 
(MHC-II) present on the surface of the B cells (immediately acting as antigen 
presenting cells – APCs).  The B cell activation signal occurs via the interaction of B 
cells and Th cells; where antigen/MHC-II complex on the B cell surface is presented to 
Th cells through the T cell receptors (TCRs) present on Th cells.  Binding of 
antigen/MHC-II complex to TCRs, results in T cell activation that consequently enables 
a second activation of the B cells achieved by presence of different peptides (Holgate, 
2012).  The activated B cells differentiate to produce memory cells, or plasma (effector) 
cells that secrete antibodies.    
  
1.12.2 Cell-mediated immune response. 
Contrary to the humoral immunity, cell-mediated response does not involve antibodies.  
T cells develop in the thymus, and enter the circulation.  Upon reaching the peripheral 
lymphoid organs, they exit the blood stream and migrate through the lymphoid tissue 
and return again to the blood stream until they get activated by specific antigens.  Naïve 
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T cells are the recirculating mature T cells before they encounter their specific antigens.  
The naïve T cells are induced by specific antigens in order to proliferate and 
differentiate into effector T cells (activated naïve T cells) that participate in adaptive 
immune response.  The T cells are divided into Th cells that contain CD4 proteins on 
their cell surface; and killer T cells or cytotoxic T cells (Tc) that contain CD8 proteins 
on their cell surface (Bonilla and Oettgen, 2010).    
The naïve T cells are activated by either exogenous or endogenous antigens that drive 
the activation of Th cells and Tc cells respectively.  The T helper CD4 receptor binds to 
the MHC-II in order to regulate both innate and adaptive immune responses, whereas Tc 
CD8 receptors are attracted to the MHC-I in order to directly kill the infected cells (by 
releasing cytotoxins and granulysin (a protease) to infected cells to undergo apoptosis) 
(Bonilla and Oettgen, 2010).  The activation of T cells is basically achieved by 
recognition of antigen/MHC-I or -II complex along with costimulatory signals from 
APCs.   
Dendritic cells (DCs), macrophages, and B cells are specialised cells often known as 
professional APCs.   The MHC-II carries peptide antigens from extracellular pathogens 
and activates Th CD4 cells that eventually differentiate into two types of effector T cells 
(i.e. Th1 and Th2 cells – CD4+), whereas MHC-I presents peptide antigens from 
intracellular pathogen that multiply in host cell cytoplasm to CD8 T cells that 
differentiate to Tc cells (CD8+) (Park and Rehermann, 2014).  The Th1 CD4 T cells 
(inflammatory) are the main activators of cellular immunity that activate macrophages 
to kill cells, whereas Th2 CD4 T cells play a crucial role in humoral immunity that 
activate B cells for antibody production. 
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1.12.3 Innate immune receptors: Toll-like receptors. 
Upon PAMPs recognition, the TLRs flag them (PAMPs) as biological markers of 
infection that activates intracellular signalling pathways, and trigger antimicrobial 
effector and pro-inflammatory responses (Janeway and Medzhitov, 2002).  The TLRs 
first identified in 1997, are well studied examples of germ-line encoded PRRs; deriving 
their name from Drosophila melanogaster Toll protein (Mercurio et al., 1997).  Ten 
different TLRs were identified in humans and each recognises distinct PAMPs from 
different microorganisms either through direct interaction or via an intermediate PAMP-
binding molecule (Figure 1.5).  TLRs are expressed in APCs including sentinel cells 
such as macrophages and DCs (Akira, Uematsu and Takeuchi, 2006).   
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Figure 1.5: TLRs and the recognised PAMPs. 
 
 
 
 
Figure 1.5: Toll pathway.  Structurally, TLRs are cellular integral glycoproteins that 
have extracellular or luminal ligand-binding domains that recognise PAMPs.  Human 
TLRs were divided into subfamilies TLR1, TLR2, TLR4, and TLR6 that recognise 
lipids; whereas TLR3, TLR7, TLR8, and TLR9 recognise microbial genomes such as 
DNA or RNA.  Key: PGN = Peptidoglycans   LPS = Lipopolysaccharide   CpG = 
‘C..phosphate..G’ (DNA regions with higher G+C content). 
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The recognition of PAMPs by innate immune system is primarily mediated by 
phagocytic cells and APCs such as dendritic cells, macrophages, and granulocytes.  The 
activation of TLRs amplifies the initiation of adaptive immune responses (Janeway and 
Medzhitov, 2002).   The formation of TLRs heterodimers between TLR2 and either 
TLR1 or TLR6 further distinguishes several bacterial PAMPs.  The TLRs 1, -2, -4, -5, -
6, and -10 are expressed at the surface of sentinel cells, whereas TLRs 3, -7, -8, and -9 
are located in intracellular compartments such as endosomes and lysosomes (Ozinsky et 
al., 2000; Iwasaki and Medzhitov, 2004).  Triggering TLRs on these cells induces the 
activation of naïve T cells specific for antigenic peptides expressed on APCs in complex 
with either MHC-I or -II molecules. 
1.12.4 Cytoplasmic pathogen recognition receptors. 
The expression of TLRs in sentinel cell surface or endo-lysosomal membranes hinders 
their recognition of intracellular cytosolic microbes and their derivatives (e.g. nucleic 
acids).  A group of cytosolic PRRs were identified that induced an immune response 
independent of TLR – PAMP recognition.  There are three types of cytoplasmic PRRs 
in humans that sense viral replication; these are RIG-I, Melanoma differentiation-
associated gene 5 (MDA-5), and laboratory of genetics and physiology 2 (LGP2).  The 
cytosolic PRRs were subdivided into RIG-I-like receptors (RLRs) (Yoneyama et al., 
2004), and nucleotide-binding oligomerisation domain (NOD)-like receptors (NLRs) 
(Kanneganti, Lamkanfi and N????ez, 2007).  The MDA-5 is a member of RIG-I-like 
receptors family that are cytosolic PRRs that recognise intracellular viruses (especially 
dsRNA).   Both the RIG-I and MDA-5 are IFN-inducible RNA helicases that recognise 
cytoplasmic RNA suggesting a similar mechanism of action for both PRRs (Yoneyama 
et al., 2004).   Studies have reported different roles played by both helicases; evidence 
suggested that RIG-I activates immune response to paramyxoviruses, HCV, and 
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influenza virus; whereas the MDA-5 induces an immune response to picornavirus, and 
norovirus (Kato et al., 2006).   
The RIG-I recognises 5′-phosphorylated short (<300bp) dsRNA ligands that have blunt 
ends; whereas MDA-5 internally recognises long kilobase-scale (>1000bp) genomic 
dsRNA with no end specificity (Kato et al., 2006) (Pichlmair et al., 2006).  The RIG-I 
associates with interferon-β promoter stimulator 1 (IPS-1), upon sensing viral RNA 
nucleotides.  IPS-1 overexpression induces interferon and interferon-inducible genes, 
via activation of transcriptional factors (Zeng et al., 2010).  The RIG-I and MDA-5 
contain N-terminal caspase recruitment domains (CARDs) that induce a cellular 
response upon recognition of viral dsRNA containing 5′ triphosphate (5′-ppp-dsRNA) 
(Schlee et al., 2009) via IPS-1 (Zeng et al., 2010); whereas LGP2 lacks  a CARD 
domain and does not induce a signalling response independently, but was reported to 
mediate positive regulation of RIG-I/MDA-5 antiviral response in a mechanism that is 
still unclear.    
When the viral dsRNA nucleic acids are absent in the cytosol, the RIG-I stays in a 
closed inactive conformation but undergoes conformational rearrangement upon sensing 
the viral dsRNA ligands (Jiang et al., 2011; Kowalinski et al., 2011).  RIG-I binding of 
the RNA through the helicase and C-terminal domain (CTD) (Jiang et al., 2011) enables 
release of the CARDs and subsequently recruits and activates mitochondrial antiviral-
signalling protein (MAVS) such as IPS-1that is highly associated with RIG-I (Zeng et 
al., 2010). 
Unlike RIG-I, the MDA-5 does not sequester CARDs in the absence of RNA ligands, 
but cooperatively forms dimers and ATP-sensitive filaments upon binding to the 
dsRNA.  MDA-5 CTD is not used for RNA binding but rather for cooperative filament 
assembly (Berke and Modis, 2012). 
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1.13 Immune response to viral infections. 
Virus-mediated PRR activation results in either successful clearance or establishment of 
infection.  Viral immunostimulatory nucleotides produced during replication or 
possessed within the virus are detected by the host’s nucleotide sensors such as TLRs.  
The TLR2 and TLR4 were also reported to sense viral glycoproteins apart from 
bacterial lipids (Mogensen, 2009).  Formation of PRR–viral-PAMP complex induces 
signalling cascades that activate nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF- κB) and interferon regulatory factor 3 (IRF3) (both are transcription 
factors), that trigger activation of interferon-regulated genes and inflammatory 
responses through the MAVS (Dreux et al., 2012).   
Two subsets of mononuclear phagocytes namely plasmacytoid dendritic cells (pDCs) 
and CD14dim CD16+ monocytes were identified to produce predominantly antiviral 
responses; such as secretion of type I interferons by pDCs, and pro-inflammatory 
cytokines by CD14dim CD16+ monocytes  (Barchet, Cella and Colonna, 2005; Cros et al., 
2010).  In like manner, TLR9 induces type 1 IFN response when sensing DNA region 
with high G+C content (CpG DNA) in pDCs (Fejer et al., 2008).  Apart from pDCs, 
other cells also possess TLR-independent receptors that are capable of inducing an 
antiviral response during infection (Mogensen et al., 2003).  The activation of viral-
infected cellular receptors releases signalling proteins such as type I and III IFNs that 
induce neighbouring cells to heighten the defence against viral infection.  The inhibition 
of viral replication is done by the secreted cytokines (IFNs and tumour necrosis factor -
TNF) that indirectly arrest the viral replication through activation of other antiviral 
immune cells and mechanisms (Kumar, Kawai and Akira, 2011).  When mammalian 
cells are infected with viruses, the MHC-I display viral peptides on APCs to signal 
cytotoxic T cells to release toxic mediators that kill the infected cells.  Cytotoxic T cells 
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possess T cell receptors (TCRs) on their surfaces that recognise virally-infected cells to 
initiate apoptosis.  However, some viruses prevent MHC-I from displaying viral 
peptides, and consequently preventing apoptosis.   NK cells have a special property of 
recognising and killing host cells with reduced number of MHC-I molecules.  Cytotoxic 
cells also release IFN-γ and TNF-α, when augmented with the innate immune system, 
enhancing the killing of invading pathogens.   
 
1.13.1 Specific immune response to HCV.  
The HCV has evolved several immune evasion mechanisms to establish human 
infection.  During acute viral infection, regulatory T (Treg) cells suppress the T cell 
immunity by inhibiting both CD4+ and CD8+ cell proliferation and their cytokine 
production.  In HCV infection, dendritic cells are functionally impaired, which hinders 
stimulation of CD4+ and CD8+ T cells.  Upregulation of programmed death-1 (PD-1) 
and increased secretion of IL-10 was reported to impair T-cell function that enables 
HCV immune evasion (Park et al., 2015).  The outcome of HCV infection is determined 
by a complex set of interactions between the host and the virus.  HCV infection clears 
spontaneously in 20% of infected individuals, attributed to the innate and adaptive 
immune responses, whereas the majority (80%) progress to chronic infection (Thomas 
et al., 2009).  Interferons α and β secretion increases during the AHCV infection 
followed by the high production of antiviral interferon stimulated genes (e.g. viperin) 
which disrupt viral replication via interaction with NS5A (Helbig et al., 2011).  Early 
proliferation of activated CD4+ and CD8+ cells in response to HCV infection (Chang et 
al., 2001), high expression of interferon stimulated genes in the liver (Su et al., 2002) 
and activation of natural killer (NK) cells (Golden-Mason et al. 2007) were reported as 
high predictors of HCV spontaneous resolution.  In vitro models of HCV infection 
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suggested that cellular immune responses promote liver injury but mechanisms of tissue 
injury are unclear.  However, understanding of the liver disease indicates that 
hepatocellular injury is not caused by direct cytolysis, because HCV does not possess 
cytopathic factors.  Viral interaction with cellular proteins induces a T cell immune 
response that activates hepatic stellate cells, which leads to liver inflammation and 
fibrosis, subsequently affecting liver hepatocyte survival (Benhamou et al., 1999).  
Investigation of the effect of host immune response in CHCV progressive liver disease 
is difficult due to slow chronicity progression in humans and a lack of fibrosis 
development in chimpanzee models.   
1.13.2 Innate immune response to HCV infection. 
Available evidence shows that HCV induces an innate immune response that sometimes 
arrests virus replication.  Conversely, the HCV sometimes evades the immune responses 
that results in establishment of chronic infection.  The HCV encodes PAMPs that are 
recognised by the host PRRs such as TLRs and RLRs resulting in the activation of 
downstream signalling pathways that activate secretion of pro-inflammatory cytokines, 
and chemokines such as types I and III IFNs (Thomson, Smith and Klenerman, 2011).  
The IFNs elicit their antiviral activity through induction and upregulation of IFN-
stimulated genes (ISGs).  The HCV PAMPs bind the RIG-I through the 5′- terminal 
triphosphate on the viral RNA that induces production of type-I IFNs and antiviral ISGs 
(Kowalinski et al., 2011).  The type I and III IFNs are produced by host cells infected 
with HCV and by sentinel cells of the innate immune system as well such as the DCs, 
and macrophages.  The DCs and macrophages regularly secrete IFNs even in the 
absence of interactions with viruses.  Although both type-I IFNs and type-III IFNs 
(IFN-λ) are produced upon innate recognition of HCV, they can also trigger 
downstream signalling cascades through phosphorylation of signal transducers and 
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activators of transcription 1 (STAT1) and STAT2 suggesting induction of the same 
group of ISGs (Heim, 2013).  The STAT1 function was also reported to be inhibited by 
HCV (Sun, Rajsbaum and Yi, 2015).   
The HCV NS3/4A protease was also reported to inhibit the RIG-I response (Gale and 
Foy, 2005) as well as the TLR3 signalling by cleaving to IPS-1 (Meylan et al., 2005) 
and TRIF (Gale and Foy, 2005) respectively.   Other researchers reported that HCV 
NS5A also induces IL-8 production that inhibits the IFN-α secretion.  Again, HCV NS3, 
NS5A and E2 proteins inhibit IFN-α induction through blocking expression and 
transcription of IFN-α/β induced genes (Polyak et al., 2001).     
Despite several mechanisms employed by HCV to inhibit the host response, the 
induction of the innate response by HCV is achieved prior to accumulation of sufficient 
HCV particles.  When HCV infects some hepatocytes, the uninfected hepatocytes 
heighten their type-I IFN response as evidenced by upregulated nuclear factor kappa B 
(NF-ĸB) in uninfected cells and downregulation in infected cells in response to HCV 
infection (Joyce and Tyrrell, 2010; Sun, Rajsbaum and Yi, 2015).  
Overall, HCV recognition is achieved by TLRs 3, 7, and RIG-I through the adaptor 
molecule TIR (toll/interleukin receptor) domain-containing adaptor protein inducing 
IFN-β (TRIF), IPS-1, and Myeloid differentiation factor 88 (MyD88).  This signalling 
process leads to phosphorylation of the transcription factors interferon regulatory factor 
(IRF)-3, IRF-7 and NF-ĸB that induces secretion of type-I IFNs (Joyce and Tyrrell, 
2010). 
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1.13.2.1 Dendritic cells.  
The DCs are a special type of APCs of the innate immune system known as professional 
APCs.  Two subsets of the DCs exist namely: the plasmacytoid dendritic cells (pDCs) 
also known as CD123+, and myeloid DCs (mDCs) also called CD11c+ that sense 
pathogens through recognition of TLRs.  The mDCs express several TLRs such as 
TLR3 and TLR7/8 that recognised dsRNA, and ssRNA viruses respectively.  Likewise 
pDCs express  several TLRs including TLR7 that enables recognition of ssRNA virus 
(Hespel and Moser, 2012).  The DCs have a high phagocytic capacity but upon 
recognition of HCV PAMPs through TLRs, the DCs become activated into mature 
immunologically competent DCs and express high levels of MHC and co-stimulatory 
molecules.  The activation and maturation of DCs induces multiple signalling pathways 
that prime naïve T cells (Hespel and Moser, 2012).  The DCs process viral antigens and 
present them to immune cells in complex with MHC-II or MHC-I molecules leading to 
production of different types of cytokines such as IFN-α, IL-10, IL-12, and TNF- α that 
regulate the response of neighbouring cells. 
The DCs also play a key role in adaptive immune response adequate enough to enable 
viral clearance.  The DCs are the only cells known to have the capacity for initiation of 
immune response in inactive T lymphocyte.  The DCs function by capturing viral 
particles/antigens which they process and present on their cell surface, thus activating 
the T cell response to initiate an antiviral cell-mediated immune response.  Immature 
DCs are specialised for antigen capture, whereas the mature DCs serve as the APCs by 
activation of an antigen-specific naïve CD8+ T cells.  Therefore, the DCs main 
functions are antigen presentation, T cell stimulation, and secretion of cytokines.  The 
DCs are found in tissues that have contact with the outside environment but immature 
forms of DCs are circulated in blood stream.  The mature DCs exit the liver following 
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viral epitope collection and enter the lymphatic system for activation of T cells (Bauvois 
et al., 2009).   
In HCV infection the DCs are functionally impaired, which hinders stimulation of CD4+ 
and CD8+ T cells that resulting in chronic viral persistence (Torresi, Johnson and 
Wedemeyer, 2011).  In vitro studies demonstrated that HCV replicates in DCs, therefore 
HCV infection of dendritic cells can impair their function that leads to chronicity.  The 
DCs function in concert with HCV proteins such as Core and NS3 leading to changes in 
cytokine secretion that consequently results in increased production of IL-10 and TNF-α 
(Pachiadakis et al., 2005). 
1.13.2.2 Natural killer cells. 
Following HCV exposure, a primary cell defence mechanism includes the activation of 
natural killer (NK) and natural killer T (NKT) cells (Yokota, Okabayashi and Fujii, 
2010).   Since infected hepatocytes release type-I IFNs, they in turn activate NK cells.  
The NK cells are a subset of lymphocytes that interact directly with virus-infected cells, 
hence they are considered the principal innate immune effector cells.  The activated NK 
cells kill infected cells either directly via the release of cytotoxic factors (e.g. perforins, 
granulysin and granzymes) (both stored in granules) or via secretion of cytokines such 
as IFN-γ.  The activated NK cells also exert their antiviral activity indirectly by 
triggering the activation and/or trafficking of other key immune cell populations, 
including T cells to promote adaptive immune responses (Shawa, Felmlee, et al., 2017).  
Despite being a subset of lymphocytes, NK cells are more highly enriched in the liver 
than in the vascular compartment (Doherty et al., 1999).  
The NK cell activation is regulated through a complex balance between activating and 
inhibitory receptors.  The inhibitory NK receptors (NKRs) signalling dominate over 
92 
 
activating receptors to safeguard from NK cell reactivity towards normal, healthy cells 
(Shawa, Felmlee, et al., 2017).  The NK cells express regulatory cell surface proteins 
called killer-cell immunoglobulin-like receptor (KIR) that recognize MHC-I to inhibit 
the NK cell activity  (Middleton, Williams and Halfpenny, 2005).  The main classes of 
NKRs are the predominantly inhibitory KIR, the natural killer group 2 (NKG2) family 
of inhibitory (NKG2A) and activatory (NKG2C/D) isoforms, and the activating natural 
cytotoxicity receptors (NCRs) NKp30, NKp44 and NKp46 (Shawa, Felmlee, et al., 
2017).  Previous genetic studies of the NK cell KIR receptors identified homozygosity 
for KIR human leucocyte antigen class 1(KIR2DL3:HLA-C1), which is linked to a 
readily activated NK cell phenotype (Khakoo et al., 2004), to be associated with the 
resistance to HCV infection seen in EU cases (Knapp et al., 2011).  Functional and 
phenotypic differences in NK cells was described among PWIDs where increased 
KIR2DL3+NKG2A− NK cells levels were observed in seronegative and aviraemic 
PWIDs as opposed to those who developed CHCV infection or who cleared HCV 
infection spontaneously.  Such NK cells were not susceptible to HLA-E-mediated 
inhibition (Thoens et al., 2014).  Other researchers reported a sustained NK cell 
activation as a contributing factor for protection against HCV infection.  In the same 
study the highly exposed uninfected cohort showed high numbers of both activated and 
cytotoxic cells, coupled by increased frequencies of IFN-γ secreting NK cells (Sugden 
et al., 2013).   
The NK and NKT cells were reported to secrete sufficient amount of IFN-γ and TNF-α 
that are responsible to inhibiting viral replication (Rehermann, 2013).  The DCs secrete 
IL-12 that activates NK cells, therefore NK cells also play a role in inducing DC partial 
or total maturation (Marcenaro et al., 2005).  The HCV also blocks NK cells function 
through interaction of HCV E2 and the NK cell CD81 molecule (Brimacombe et al., 
2014).   
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1.13.3 Adaptive immune response to HCV infection.  
1.13.3.1 T-cell mediated response. 
The activation of both humoral and cytotoxic T cell-mediated adaptive responses is 
dependent on the help from CD4 T cells that play a crucial role is activating arms of 
adaptive immune responses.  The CD4+ T cells secrete Th1 cytokines including IFN-γ 
that recruit leucocytes involved in providing inflammatory response.  CD4+ T cells also 
secrete Th2 cytokines such as IL-4 and IL-10 that restrict the Th1 cytokine-mediated 
response and favour initiation of the humoral response (Larrubia et al., 2014).  
Although the HCV is capable of interfering with a wide range of the host physiological 
and pathophysiological processes, the recruitment of an effective adaptive response 
takes several weeks (Chang et al., 2001).  Such a swift immune response has the 
potential to resolve the viral infection, but it is ineffective in 50% of cases leading to the 
progression of chronic infection.  The CHCV infection is characterised by decreased  
activities of CD4+ T helper and CD8+ cytotoxic T cells (Gremion et al., 2002; Thimme 
et al., 2002) with reduced type 1 IFN cytokine production.   
Despite the host’s robust coordinated antiviral activity, HCV develops genetic 
mutations that evade immune surveillance resulting in persistent viraemia in the absence 
of memory T cell help (Grakoui, 2003).  The HCV persistence is associated with 
increased frequency of CD4+ regulatory T cells (Treg) that suppress the activity of 
HCV-specific CD8+ cytotoxic T cells (Sugimoto et al., 2003).   In brief, virus specific 
CD8+ T cell response fails due to two important mechanisms.  Firstly, mutational 
escape of MHC-I epitopes that prevent viral recognition, and secondly, functional 
exhaustion of the virus specific CD8+ T cells due to persistent antigen stimulation 
(Wieland and Thimme, 2016). 
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Previous studies have reported the role of T cell response, and early multispecific T cell 
responses that target multiple viral epitopes  in spontaneous clearance of HCV infection  
(Gremion et al., 2002; Thimme et al., 2002).  Following successful resolution of HCV 
infection, partial protective immunity develops with lower rates of reinfection (Midgard 
et al., 2016) than would be expected in a matched uninfected cohort of PWIDs (Grebely 
et al., 2006).  Up to 60% (Thurairajah et al., 2008) of the EU population have 
demonstrable weaker T cell responses to multiple viral antigens as compared to 
spontaneous resolvers (Mizukoshi et al., 2008; Zeremski et al., 2009; Knapp et al., 
2010).  The cytokines secreted by the T cells also play a crucial role in regulation of the 
humoral immune response. 
1.13.3.2 Humoral response. 
Anti-HCV neutralizing antibodies (nAbs) have been reported to support viral clearance 
in acute infection (Osburn et al., 2014) as well as spontaneous resolution after 
establishment of CHCV infection (Raghuraman et al., 2012) (de Jong et al., 2014).  
Since the mechanisms that offer protection for the EU population from HCV infection 
still remain a mystery, we previously speculated that the effect of robust nAb responses 
hardly detectable by conventional serological assays may contribute to the existence of 
the EU phenotype (Shawa, Felmlee, et al., 2017).  Following establishment of CHCV 
infection, broad HCV nAb responses appear in the circulation but HCV continuously 
escapes from nAbs (von Hahn et al., 2007).  Several mechanisms may be involved in 
the viral evasion of humoral immune response that include epitope masking by 
interfering antibodies, the shield provided by lipoproteins (Cashman, Marsden and 
Dustin, 2014), and genetic mutations (von Hahn et al., 2007) amongst others.  Other 
researchers have also described the cell-to-cell viral transmission as another nAb escape 
strategy employed by HCV (Mothes et al., 2010). 
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There is evidence supporting the theory that HCV nAbs have a limited influence on the 
outcome of HCV infection since there is a delayed antibody development and the 
antibody titre wanes rapidly.  Other reports indicated viral clearance in the absence of 
detectable anti-HCV antibodies (Thimme et al., 2001; Post et al., 2004).  On the 
contrary, more evidence supports the role of nAbs in spontaneous resolution of HCV 
infection (de Jong et al., 2014). 
1.14 Summary of cytokines and chemokines secretion in HCV infection. 
Cytokines are soluble proteins secreted by immune cells that provide intercellular 
communication by binding to specific cellular receptors in order to induce or inhibit 
cytokine regulated genes.  Different cytokines that play several roles have been reported 
and are classified into subgroups in accordance with their functions as follows:  
a) Pro-inflammatory cytokines (e.g. IL-1, IL-6, TNF- α) (Bowen and Walker, 
2005). 
b) Th1 type cytokines (e.g. IFN- γ, IL-12, IL-18) (Bowen and Walker, 2005). 
c) Th2 type cytokines (e.g. IL-4, IL-5, IL-10, IL-13, IL-14, IL-15) that 
downregulate the Th1 responses (Marcenaro et al., 2005).  However, IFN-λ has 
been shown to favour production of Th1 responses activity by decreasing 
secretion of Th2-type cytokines (Jordan et al., 2007; Srinivas et al., 2008).   
d) Th17 type cytokines (e.g. IL17, IL-21, IL-23) that induce differentiation of Th17 
lymphocytes (Rowan et al., 2008).   
On the other hand, chemokines are known as chemotactic cytokines that belong to 
multifunctional family of cytokines that recruit leucocytes to migrate to the site of 
infection.  The chemokines are described as homeostatic or pro-inflammatory 
depending on their functions (Yokota, Okabayashi and Fujii, 2010).  The chemokines 
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are structurally related cell signalling proteins containing four invariant cysteine 
residues that result in four subfamilies as follows:  alpha (CXC), beta (CC), gamma (C), 
and delta (CX3C) that function by activation of their specific receptors namely CXCR, 
CCR, CR, and CX3CR respectively (Heydtmann and Adams, 2009) (Zeremski, Petrovic 
and Talal, 2007).  Chemokines and pro-inflammatory cytokines are some of the proteins 
released by macrophages and dendritic cells as a result of activation of receptors (Fejer 
et al., 2008; Lauterbach et al., 2010; Yokota, Okabayashi and Fujii, 2010).   
One important cytokine family essential in the control of HCV infection is IFN-λ.  
Discovered in 2003 (Kotenko et al., 2003; Sheppard et al., 2003), the IFN-λ family 
enabled understanding of potential genetic and immunologic resistance mechanisms 
conferred by HCV infection.  There are three IFN-λ genes that encode IFN-λ1, -λ2, and 
-λ3 proteins also designated IL-29, IL-28A, and IL-28B, respectively (Kelly, Klenerman 
and Barnes, 2011).  They all belong to type III IFN subsets.  The type-I and type-II IFN 
subsets have different signal transduction receptor complexes to type-III IFN, but they 
activate similar intracellular signalling pathway that induce antiviral and 
immunomodulatory immune responses (Kelly, Klenerman and Barnes, 2011).  The 
expression of IFN-α and IFN-λ genes are inducible as a result of cellular recognition of 
different viruses.  The IFN-α receptors are expressed on leucocytes and all nucleated 
cells whereas IFN-λ receptors are expressed on fewer cell types of epithelial origin 
(Pagliaccetti and Robek, 2010).   
The complex cell signalling process inducing the cytokine production during initial 
steps of viral infection allows recruitment of coordinated and effective innate and 
adaptive immune responses.  However, HCV interferes with cytokines at various levels 
including escaping the surveillance of the immune responses by inducing a Th2 
cytokine profile.  
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1.15 Potential mechanisms of resistance for HCV infection. 
Given the importance of host lipid, and immune responses in HCV infection these 
factors may be considered as putative mechanisms of resistance.  This section describes 
some potential mechanisms that confer resistance to HCV infection. 
1.15.1 Genetic: IL-28B gene polymorphism. 
Genetic polymorphism is one of the suggested factors that confer resistance to 
establishment of HCV infection (Rauch et al., 2009).  Different sub-groups of 
individuals respond differently to microbial exposures due to genetic variations among 
human populations that determine resistance or susceptibility to establishment of 
infection. 
Several studies have documented the role of host genetic factors such as SNPs in IL-
28B IFNL3 that may be relevant in EU phenotypes that was reported to be associated 
with spontaneous viral clearance (Rauch et al., 2009; Thompson et al., 2010; 
Prokunina-Olsson et al., 2013).  The IL-28B genotype is used to predict HCV treatment 
response to PEG-IFN/RBV (Suppiah et al., 2011).  The IL-28B SNP rs8099917 ‘‘G’’ 
was associated with absence of treatment-induced resolution and absence of 
spontaneous resolution (Suppiah et al., 2011).  Genome-wide association studies 
(GWAS) reported SNPs in IL-28B gene that allowed prediction of ≤64% for failure to 
clear virus during therapy in cross-sectional cohorts (Suppiah et al., 2009, 2011).  
Knapp et al, investigated the presence or absence of IL-28B protective genotype 
rs12979860-CC in EUs, and reported that the EUs had a significantly lower frequency 
of IL-28B genotype rs12979860-CC as opposed to spontaneous resolvers, but a similar 
frequency to CHCV patients (Knapp et al., 2011).   
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Our previous work demonstrated that a small proportion of HCV exposed uninfected 
individuals carried a protective C allele of the IL-12B gene (Hegazy et al., 2008).  The 
IL-12B is a heterodimeric cytokine composed of 35-KDa (p35) and 40-kDa (p40) 
subunits that promote anti-viral Th1 responses.  The IL-12B gene encodes the IL-12 
p40 subunit, and the production of this subunit was reported to be facilitated by variant 
C allele of the 1188A/C polymorphism (Seegers et al., 2002).  We reviewed detailed 
potential mechanisms that offer protection for HCV infection (appendix D). 
 
1.15.2 HCV-lipid interaction. 
The HCV utilises lipid and lipoprotein metabolism at all stages of its lifecycle from 
attachment, entry, replication, assembly and transport with lipoproteins in the 
circulation. HCV has evolved strategies to escape immunological selection pressures to 
establish chronic HCV infection in the majority of those exposed (Knapp et al., 2010).  
Since HCV circulates as an infectious LVP  in the vascular compartment bound to 
plasma lipoproteins, it is suggested that maximum levels of HCV LVPs are associated 
with early and persistent infection (Sheridan et al., 2016).  
The close association of HCV with lipids and lipoproteins contributes to the virus’ 
ability to evade the host’s immune surveillance.  Given this co-dependency on host lipid 
pathways, it is plausible that any mechanism that would disrupt the LVP formation 
would potentially reduce the viral infectivity and influence outcome following HCV 
exposure (Shawa, Felmlee, et al., 2017).  Thus defective HCV-host lipid interactions 
may represent alternative pathways of HCV resistance that warrant further investigation. 
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1.15.3 Suppression of HCV T cell response by sub-infectious HCV dose.  
Several lines of evidence indicate that the host’s cellular immune response to multiple 
HCV epitopes is also vital in controlling early HCV infection, with successful early 
immune responses leading to spontaneous resolution.  Conversely, an ineffective early 
cell-mediated response may lead to the development of chronic HCV infection (Bowen 
and Walker, 2005).  The EU population exhibits HCV-specific T cell mediated 
responses that suggests recognition of viral peptides such as NS proteins by the immune 
system (Mizukoshi et al., 2008; Thurairajah et al., 2008).  Repeated exposure to sub-
infectious HCV particles can induce HCV specific T cell response in nonhuman 
primates, but failed to offer protection against subsequent acute infection (Park et al., 
2013).  Similar T cell immune responses were also described in aviremic and 
seronegative family members of HCV infected individuals (Scognamiglio et al., 1999; 
Al-Sherbiny et al., 2005).  Furthermore, several studies have proposed that repeated 
sub-infectious exposure primes and maintains HCV specific T cells that confer 
protective immunity (Scognamiglio et al., 1999; Al-Sherbiny et al., 2005; Park et al., 
2013).  An early HCV specific T cell response was induced in healthcare workers 
following needle stick occupational exposures to HCV; but they did not exhibit 
detectable HCV antibodies and HCV RNA (Heller et al., 2013).  Thus, sub-infectious 
HCV exposures suppress T cell responses against subsequent acute infection (Park et al., 
2013).  These data imply that the frequency and dose of exposure may influence the 
result degree of protection.  T cell immune response increases in CHCV infection 
(Rivière et al., 2012).  Thus the presence of HCV specific T cell responses in EUs 
supports the evidence that they have indeed been exposed to HCV antigens, but does 
not fully explain why they do not exhibit detectable HCV RNA and HCV antibodies.      
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Repeated exposure to HCV without development of infection among PWIDs suggests 
the presence of a resistant phenotype to HCV infection.  Exposure to HCV was 
determined by history of risk behaviours that include current sharing of needles and 
other injecting equipment as described in chapter 2.  Probability of HCV sero-
prevalence increases with duration of injection history (Law et al., 2003; Roy et al., 
2007).   
1.15.4 Epigenetic. 
Epigenetics is a term that refers to all stable heritable changes that are not due to any 
alteration in the DNA sequence itself (Horsthemke, 2017).  DNA methylation, post-
translational modifications of histone proteins, chromatin remodelling, and noncoding 
RNAs are the four main arms of epigenetic mechanisms (Rongrui et al., 2014).  The 
epigenetic silencing of IFN-stimulated genes was reported to be responsible for the 
acquisition of a partially IFN-resistant phenotype of HCV replicon-harbouring cells 
(Naka et al., 2006).  Some studies have shown that HCV viral proteins may actively 
participate in epigenetic regulation of hepatic cancer stem cell phenotypes, that result in 
epigenetic alterations associated with HCC (Herceg and Paliwal, 2011; Rongrui et al., 
2014).  Host genes that may be epigenetically regulated in exposed uninfected sub-
population are unknown.   
This thesis has however described the immunological (innate) and lipidomic factors that 
could potentially offer protection for HCV infection.  The sequential patterns in which 
these mechanisms work affecting the HCV resistance phenotype remain speculative.  It 
is more likely that there is a combination of different factors that are involved in the 
existence of the EU phenotype, whose mechanisms are still unknown.  
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1.15.5 HCV vaccine development. 
It is important to understand the mechanism for HCV resistance to inform vaccine 
design strategies.  Vaccination has been the most successful strategy for prevention of 
other viral infections such as hepatitis B virus (Zanetti, Van Damme and Shouval, 2008) 
that induce nAbs that could counter highly antigenically diverse viruses (Burton et al., 
2012).  Currently, there is no licenced HCV vaccine available; however, research into 
HCV vaccine development is ongoing.  An important explanation for lack of efficacy of 
vaccine candidates to protect from HCV may relate to the dynamic and complex 
interactions of HCV with host lipid metabolism (Shawa, Sheridan, et al., 2017).  Over 
the years, efforts to develop HCV vaccine have been affected by different factors such 
as: hypervariability of HCV proteins (Sabet et al., 2014), genetic diversity (Dahari, 
Feinstone and Major, 2010), different viral genotypes and quasispecies, since 30% – 50% 
viral sequence diversity exist (Shi and Ploss, 2013).  The meta-analysis of HCV vaccine 
trials conducted in chimpanzees has shown good efficacy, and was reported to contain 
part or all of the HCV structural envelope protein that induced sufficient neutralising 
response (Meunier et al., 2011).  The HCV prophylactic recombinant E1E2 vaccine 
development derived from HCV genotype 1a has reached phase II clinical trial in 
humans (Young et al., 2015).  The recombinant E1E2 vaccine successfully elicited 
broad cross-genotype nAb and cellular responses (Law et al., 2013).   
Although the DAAs have shown significant advancement in HCV therapy, they have 
fewer efficacies against hepatic cirrhosis and HCC cases.  Therefore there is a need for 
continued efforts to develop prophylactic as well as therapeutic vaccine to prevent 
persistent HCV infection (Walker and Grakoui, 2015).  A vaccine that can be used as an 
adjunct to DAAs treatment that could reduce viral persistence or reinfection is the 
desirable target (Swadling et al., 2016).  Previous approaches for vaccine development 
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based on induction of virus-specific CD8+ T cell by therapeutic vaccination did not 
succeed to significantly suppress viraemia, but HCV-specific T cell response was 
partially primed.  It is still unclear why vaccine-induced T cells failed to control 
viraemia (Wieland and Thimme, 2016). 
Likewise, another study on chimpanzees that were repeatedly infected with HCV 
resolved the infection following DAAs treatment; and had demonstrable CD8+ T cell 
responses that were incapable of preventing persistent infection when re-challenged 
with HCV (Tarr, Urbanowicz and Ball, 2012).  Thus, an HCV vaccine will be essential 
to both health individuals as well as those who cleared the infection either 
spontaneously or following therapy.  Therefore, there is an urgent need for a 
prophylactic vaccine that could prevent development of CHCV infection following 
exposure to all HCV genotypes.  Since HCV is genetically diverse, the broadly effective 
prophylactic vaccine candidates must target conserved B cell and T cell epitopes of the 
virus.    
Other researchers previously developed a T cell vaccine for HCV by utilising a 
recombinant chimpanzee-derived adenovirus 3 (ChAd3) and a human adenovirus 6 
(Ad6) in a prime boost regimen (ChAd3-NSmut/Ad6-NSmut regimen), but this 
regimen had some limitations such as poor induction of HCV-specific T cells in a 
healthy control group (Barnes et al., 2012).  The limitations of a heterologous ChAd3-
NSmut/Ad6-NSmut regimen were overcome by utilisation of a ChAd3-NSmut prime 
and a MVA-NSmut boost vaccination.  The ChAd3 and a modified vaccinia Ankara 
(MVA) that encodes the HCV non-structural proteins (NSmut) in a heterologous prime/boost 
regimen previously optimised in healthy individuals  (Swadling et al., 2014) was able 
to induce HCV-specific T cell responses in HCV infected patients (Swadling et al., 2016).  
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The HCV displays a narrow species tropism with humans and chimpanzees as the only 
hosts susceptible to infection; which affects progress in understanding the mechanistic 
analysis of viral pathogenesis and vaccine development.  Significant progress has 
recently been made in relation to HCV treatment following the licencing of DAAs, 
however factors such as high cost, risk of reinfection, heterogeneity of the virus, narrow 
host tropism and lack of an immunocompetent small animal models all hamper vaccine 
development. 
1.16 Metabolic profiling. 
There are different approaches to investigate HCV mechanisms of resistance; either 
following a hypothesis or generating one through a non-hypothesis driven approach.  
Metabolomics is one of the non-hypothesis driven approaches, used in analytical 
chemistry for identification and quantification of smaller molecules (cellular 
metabolites) less than 1 KD in a sample by use of sophisticated and sensitive analytical 
technology coupled by biostatistics and multivariate applications for data acquisition 
and processing (Dettmer, Aronov and Hammock, 2007).  Metabolic profiling refers to 
the global metabolic responses to physiological, genetic or environmental stimuli 
(Nicholson and Lindon, 2008).  Four main approaches applied in metabolomics are: 
target analysis, metabolite profiling, metabolomics, and metabolic fingerprinting (Fiehn, 
2002).  Target analysis involves identification and quantification of specific known 
metabolites using a method suitable for that particular target.  Metabolite profiling 
analyses a large set of compounds present in a mixture to identify known or unknown 
metabolites.  In general, metabolomics approaches employ ‘complementary analytical 
methodologies’ such as MS and NMR for determination and quantification of known or 
unknown compounds.  Metabolic fingerprinting is the fourth conceptual approach that 
involves generation of metabolic signatures (mass profiles) of a sample in comparison 
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to a large data to identify the specific differences between samples (Roessner and 
Bowne, 2009).  The utilisation of metabolomics tools is essential in understanding an 
organism’s response to environmental changes, genetic alterations, and immunological 
stimuli by observation of perturbations to specific metabolic signatures in biofluids such 
as urine (Williams et al., 2009), intact tissues (Yang et al., 2007), and serum (Chen et 
al., 2013).    Furthermore, dietary and geographical differences may be highly 
discriminatory, above that of gender and ethnicity which do affect the metabolic profiles 
(Slupsky et al., 2007; Holmes et al., 2008).    
1.16.1 Mass spectrometry (MS). 
Liquid or gas chromatography mass spectrometry (LC-MS, GS-MS) provide full mass 
spectral analysis in conjunction with biostatistics analysis software (Fitian et al., 2014).  
Since 1970, MS has been utilised to identify metabolic profiles (Pauling et al., 1971).  
Characterisation of metabolites is achieved by molecular weight and ionic charge.  
Serum lipidomic profiling requires chromatographic separation for reduction of ion 
suppression, capillary electrophoresis (CE) is carried out prior to sample analysis in MS.  
LC-MS and/or GC-MS are the common separation methods employed before mass 
spectrometric analysis; whereas Ultra Performance LC (UPLC) utilises separation 
columns that permit small size particles (1.4 – 1.7μm) (Boisen, 2009).  The application 
of other techniques such as GC-MS analysis is usually limited to thermally stable 
compounds; and enough vapour pressure is required for volatilization during sample 
injections. The serum lipidome profiling studies in HCV exposed uninfected 
intravenous drug users have not yet been conducted.  Therefore, determination of 
metabolic alterations associated with HCV resistance may provide a considerable 
amount of useful information that could explain factors that confer resistance for HCV 
infection.  
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1.16.2 Proton nuclear magnetic resonance (1H NMR) spectroscopy. 
Proton nuclear magnetic resonance (1H NMR) spectroscopy detects the magnetic 
properties of atomic nuclei to identify a wide range of hydrogen-containing compounds 
in a mixture.  The number of nuclei measured in a mixture determines the intensity of 
NMR signal (peak) (Lindon, Nicholson and Everett, 1999).  The 1H NMR spectroscopy 
is preferred because hydrogen is the most abundant atom present in living organisms, so 
can identify peaks of small molecules.  Resonances of unknown compounds present in a 
mixture are observed by the position and splitting patterns of signals in NMR spectra.   
The NMR deals with atoms that possess the property of ‘spin’; such as 1H, 13C, 15N and 
31P, with 1H NMR spectroscopy as a preferred NMR method in profiling of biofluids 
such as urine.  The 1H NMR spectroscopy is the common method because of the 
abundance of hydrogen in organic molecules (reviewed in (Patel et al., 2012)).  
Metabolomics investigations in biofluids have been conducted in a variety of diseases 
including liver disease, but have not been investigated in exposed uninfected PWIDs.   
1.16.3 NMR studies in HCV.  
The urinary NMR profiling was performed by Godoy and colleagues to compare the 
urinary metabolomics profiles between healthy individuals without prior history of 
HCV exposure and  chronic HCV patients (Godoy et al., 2010).  Their findings 
indicated that HCV infected patients were correctly identified by urinary metabolomics; 
with a sensitivity of 94% and specificity of 97% (Godoy et al., 2010).  Shariff and 
colleagues also characterised the urinary metabolomics biomarkers of hepatocellular 
carcinoma in two etiologically and ethnically distinct populations (a Nigerian 
population infected with hepatitis B virus; and an Egyptian population infected with 
hepatitis C virus) (Shariff et al., 2010, 2011).  In a Nigerian population study, 
metabolomics analysis distinguished hepatocellular carcinoma patients from healthy 
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controls, and from the cirrhosis cohort.  Creatinine, creatine, and acetone were some of 
the metabolites that contributed to the differences in multivariate models (Shariff et al., 
2010).  A validation study was conducted in hepatitis C virus infected Egyptian patients 
with hepatocellular carcinoma.  Multivariate statistical analysis identified  glycine, 
trimethylamine N-oxide (TMAO), hippurate, citrate, creatinine, and carnitine as the 
discriminatory metabolites that distinguished hepatocellular carcinoma cases from 
cirrhotic patients and healthy controls (Shariff et al., 2011).  This shows that 
multivariate analysis can offer distinction of urinary NMR metabolites among different 
study populations.   
1.16.4 Comparison of MS and NMR. 
The generation of human metabolic profiles in biofluids such as serum and urine are 
performed by two commonly used platforms (NMR and MS) in metabolomic 
investigations.  There are some differences that exist between these two robust 
technologies (Table 1.3). 
MS has higher sensitivity levels than NMR in metabolite detection (MS picomolar 
versus NMR nanomolar concentrations; some GS-MS can reach femtomolar levels) and 
sample degradation during run as opposed to 1H NMR  (Want, Cravatt and Siuzdak, 
2005; Want et al., 2007).  Validation of identified unknown metabolites on MS is used 
by tandem MS as well as accurate mass (time of flight) methods.  Alternatively, Fourier 
transform (FT) MS is used, it has a greater resolution and mass accuracy better than 1 
ppm (Brown, Kruppa and Dasseux, 2005).  The MS requires sample pre-separation and 
purification and then run into liquid or gas chromatography.   The sample preparation 
procedure for the MS is laborious and time consuming.  After sample run and 
processing, the sample is used and unavailable if needed for further investigations using 
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different techniques.  Therefore the MS is considered destructive when it comes to 
sample processing and data acquisition.   
Statistical heterospectroscopy is an approach that has recently been developed by 
Crockford and colleagues (Crockford et al., 2006) that combines the MS and NMR data 
processing.  This approach provides a unique and useful tool to researchers who require 
a combination of both platforms for identification and comparison of metabolic profiles.   
In contrast, NMR sample processing is non-invasive, and has an advantage over MS due 
its non-destructive nature (Dunn and Ellis, 2005).  Therefore the same samples can be 
used for separate different experiments when necessary.  The NMR has a high 
throughput, and requires minimal sample preparation protocols (Chen et al., 2006).  The 
NMR is known to have limited a metabolite coverage which could result in same set of 
metabolites being reported in a variety of different pathological conditions.  Such a 
limitation in NMR can be overcome by MS technology.  Comparison of the NMR data 
processed at separate external laboratories for external quality assurance shows that 
NMR technique has a high degree of inter-laboratory reproducibility of results.  
Recently, the sensitivity of NMR has been improved by use of higher magnetic field 
strengths and cryogenic probe technology (Keun et al., 2002).   
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Table 1.3 LC-MS/GS-LC versus Proton NMR. 
 
Category LC/MS, GS/MS 1H NMR 
Sensitivity Higher than NMR (picomolar). Some 
forms of GS-MS reach femtomolar 
levels.  
 
Lower than MS 
(nanomolar at high fields 
using new cryoprobes) – 
with limits of detection on 
the order of 10μM.  
Sample 
preparation 
Requires separation and purification 
before directing samples into mass 
analyser, which makes sample analysis 
time consuming. 
Suitable for samples in 
different conditions. 
Sample 
degradation 
Degrades. Does not degrade. 
Metabolite 
identification 
Labour intensive and not fully 
categorised. 
Less laborious and well 
categorised. 
Reproducibility Moderate. Highly quantitative and 
reproducible. 
Throughput Approximately 60 samples per day. High (500 samples per day 
with the assistance of 
flow-injection probes and 
automated liquid handlers) 
(Pan and Raftery, 2007).  
 
LC-MS, GS-MS and 1H NMR technologies complement each other, however there are 
obvious differences as summarised in Table 1.3.  Profiling and analysis of the entire 
metabolome using a single technology is difficult due to diversity of compounds and 
differences in their chemical structures.    
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1.17 Rationale of the study.  
Increasing evidence suggests that the EU population is distinct from those who become 
infected but spontaneously clear HCV, and is a true but rare population highly pertinent 
in the study of mechanisms of resistance to HCV infection to facilitate rational 
development of vaccine and alternative therapeutic avenues.  The HCV lifecycle is 
dependent on host lipid pathways for production of infectious virions.  A hallmark of 
HCV infection is altered lipid and lipoprotein metabolism. Differences in lipidomics 
profiles may indicate unique protective mechanisms against infection by HCV.  There’s 
growing evidence suggesting that HCV utilizes lipid and lipoprotein metabolism at all 
stages of its lifecycle. Therefore, an ‘omics’ approach was employed to assess if there 
are any unique lipidomic signatures that can separate the EUs from other comparator 
groups.  
The main aim was to determine metabolic alterations associated with HCV resistance to 
gain mechanistic insight into HCV protection.  In this study, serum lipidomics analysis 
was performed to characterise the lipidomic profiles of EU cases compared to HCV 
susceptible cases.  I sought to use UPLC-MS to identify distinguishing factors in serum 
lipidomics of the EU cohort.  Differences in lipidomics profiles may indicate unique 
protective mechanisms against infection by HCV. 
I also employed the urinary NMR-based metabolic phenotyping to identify metabolic 
unique fingerprints that could emerge to distinguish the exposed uninfected cohort from 
the comparator groups.  Cellular metabolic products perform different important 
functions that maintain physiological state of an organism.  Any genetic or 
environmental perturbations in metabolites will change their functional properties which 
will determine how an organism responds to different stimuli.  Analysis of both serum 
lipidomics and/or urine metabolomics provides useful insights for resistance to HCV. 
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The innate immune response plays a crucial role in providing the first line of defence 
against the establishment of HCV infection, and subsequently coordinates the HCV-
specific adaptive immune responses.  Understanding the peculiar interplay of HCV with 
host innate immunity could reveal mechanistic insights into the outcomes following 
HCV exposure.  The activation of host immune signalling pathways leads to the 
induction of highly orchestrated responses that are designed to prevent establishment of 
HCV infection.  The contributions and interactions of these factors in protection from 
HCV are unknown.  Protection from viral infection can arise as a consequence of an 
adaptive immune response able to prevent an infection becoming established, or it may 
be innate in that an individual has genetically determined resistance and is not 
susceptible to infection.  The available evidence suggests the involvement of both innate 
and adaptive responses in spontaneous clearance of acute HCV infection however, 
evasion of the innate immune response in early stages of HCV infection results in HCV 
persistence and potential progression to CHCV disease.  The HCV is also capable of 
disrupting cellular immune signalling pathways and subsequently blocks expression of 
interferon-stimulated genes to partly or completely limit their antiviral activities.  
Therefore this work attempted to investigate the host immune responses following 
repeated exposure to HCV through injecting and sharing of needles and other 
equipment in PWIDs.     
It is now accepted that there is a subset of PWIDs who remain uninfected despite 
repeated long-term exposure through sharing of contaminated needles and other 
paraphernalia.  Detection of true exposure to HCV and determination of infective dose 
is difficult to estimate; but there is a relatively high risk of exposure when sharing 
contaminated injecting equipment.  This thesis will address fundamental key questions 
in order to establish the existence of the EU phenotype among PWIDs.  Such important 
questions expounded included: 
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a) Does the exposed uninfected phenotype exist? 
b) If yes, what are the potential mechanisms of resistance? 
c) Why are some people susceptible to HCV infection than others? 
d) Why do some individuals clear HCV infection more efficiently than others? 
e) Do the EUs have unique lipidomics features that could potentially protect them 
from HCV infection? 
f) Do the EUs exhibit potent multi-faceted immune responses that possibly work in 
concert with the HCV-lipid interactions?  
 
1.18 Hypothesis. 
The hypothesis is that there are host metabolic determinants involved in interrupting the 
HCV life cycle or  that are involved in innate immunological response that confer 
resistance to the HCV exposed uninfected cohort.    
 
1.19 Overall aim. 
The overall aim of the project is to identify aberrations in lipid profiles or metabolic 
pathways that point to the protection from HCV infection; and to analyze the 
involvement of innate factors responsible for conferring resistance to intravenous drug 
users who are exposed to HCV but remain seronegative and aviraemic.  
 
 
112 
 
2 CHAPTER TWO 
 
2.1 Methodology. 
2.2 Study population: exposed uninfected intravenous drug users. 
Individuals with a history of high risk parenteral exposure to HCV who have no 
evidence of infection, testing negative for both HCV antibody and HCV RNA by 
sensitive assays, were studied. 
2.2.1 Ethical approval. 
The study was approved by the National Research Ethics Service (NRES) Committee 
South West - Cornwall & Plymouth; through the health research authority (HRA) (REC 
number 1703; Grant reference number PUPSMD-0004R1) for collection of blood and 
urine samples from exposed uninfected IDUs.   The study was carried out by adhering 
to ethically acceptable standards.  
2.2.2 Case identification and recruitment procedure. 
After obtaining ethical approval, I set off for case identification and recruitment.  Fliers 
(appendix A) were distributed in various pharmacies and drug and alcohol rehabilitation 
centres; and posters (appendix A) were placed in selected centres in Plymouth.  The 
study information sheet was included in the drug injection pack given to clients on their 
routine visits to inform potential study participants.   
Interested study participants were booked via telephone, and were given adequate time 
to consider their decisions for participation without coercing them.  The blood-borne 
virus Nurse (Ms Lynsey Opara) and my colleague (Dr Paraskevi Mandalou) also offered 
their help in blood sample collection.  The intravenous drug users studied for this thesis 
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were identified and recruited amongst over 2000 clients attending drug services at the 
Harbour Drug and Alcohol Service in Plymouth, United Kingdom (UK).  HCV exposed 
uninfected (EU) cases were selected based on the high probability of HCV exposure as 
determined from their injection history. The degree of exposure was assessed using a 
standard questionnaire detailing duration of drug use.  EU study participants fulfilled 
the following criteria: substantial long (more than 6 months) and repeated history of 
injection drug use, currently sharing of needles and other injection paraphernalia, 
Caucasian adults who gave a written informed consent, and those who were screened to 
be negative for their last HCV test.  A structured questionnaire was used to collect drug 
injection history, and assess the risks of HCV exposure (refer to the questionnaire in 
appendix A 9.1.2).  The questionnaire covered the following aspects: frequency of drug 
injection; sharing of needles and other paraphernalia with friends, and history of 
imprisonment amongst others.  Other HCV transmission risk factors such as blood 
transfusion, tattooing, and sexual contact with an HCV positive individual were also 
assessed using the questionnaire to ascertain the extent of viral exposure from other 
sources other than drug injection.  Serum blood samples were sent to Microbiology 
laboratory at Derriford hospital for HCV antibodies and RNA testing.  Seronegative 
aviremic cases were defined by serial negative testing for anti HCV antibody and HCV 
RNA by conventional assays (Biorad monolisa HCV Ag/ab test; and Roche Ampliprep 
HCV PCR viral load - COBAS® TaqMan® HCV Test v2.0).   No subjects recruited 
tested positive for Human immunodeficiency virus (HIV), and/or Hepatitis B virus 
(HBV) surface antigen (HBsAg) prior to and/or after recruitment.  Blood samples (both 
stored and freshly collected) from chronic HCV infected patients, and those who cleared 
the virus spontaneously, served as comparators.  Stored blood samples from healthy 
volunteers who had no history of HCV infection were used as controls.    
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2.2.3 Comparison cohorts. 
Four cohorts were studied in this project.  The exposed uninfected cohort was compared 
to three distinct groups as follows: (1) IDUs who were categorized as HCV spontaneous 
resolvers (HCV antibody positive but HCV RNA negative), (2) Chronic HCV cases 
(individuals who tested positive for both HCV RNA and antibodies),  and (3) healthy 
volunteers who had no history of drug injection or any risk factors for HCV 
transmission.  For the lipidomic work additional samples were obtained from the HCV 
Research UK (HCVRUK) biobank (Glasgow) from  150 CHCV patients, HCV RNA 
negative patients who cleared the virus following treatment (sustained viral response 
(SVR – 100)), and spontaneous resolvers (20).  
Exposed uninfected cases were recruited as described in Section 2.2.2; whereas stored 
serum samples for healthy individuals were used as comparator group in lipidomics 
investigations.  Additional healthy volunteers were recruited among researchers and 
postgraduate students in John Bull building research laboratories in Derriford.  To 
maintain confidentiality, all recruited cases were anonymised by assigning a unique 
study number (South West number – SW) and data protection protocols were observed.  
No personally identifiable information (such as names) was kept in the study 
documentation.   All hard copies were stored in a safe-locked filing cabinet, and soft 
copies were stored in encrypted external hard drives.   
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2.2.4 Sample collection procedure. 
2.2.4.1 Serum. 
Serum is the fluid part of the blood without fibrinogen and other clotting components.  
Blood was collected in a 5mL serum separating tubes (BD vacutainer gold-topped) (BD 
Diagnostics,UK) containing silica to activate blood clotting; but no anticoagulant; and 
incubated in an upright position at room temperature (to allow clotting) for two hours.  
Samples were transported under ambient conditions to John Bull research laboratories.  
The blood was centrifuged at 2000g (Labofuge 400R centrifuge (Thermo Scientific) for 
10 minutes to allow the separation of serum. Brakes were not used to stop the centrifuge.  
Under a level II biosafety cabinet, the serum was carefully aspirated using clean pipette 
tips; and aliquoted into cryovials (SARSTEDT, Germany).  The labelled aliquots were 
stored at – 20oC.   
2.2.4.2 Plasma. 
Plasma is the liquid component of blood (usually yellowish in colour) where blood cells 
are suspended.  Blood was collected in a 3mL Ethylenediaminetetraacetic acid (EDTA) 
BD vacutainer plastic tubes (BD Diagnostics,UK).  Tubes were inverted 8 – 10 times to 
mix the blood with the anticoagulant. Samples were stored at room temperature  for up 
to 4 hours until centrifugation. Samples were transported under ambient conditions to 
Peninsula School of Medicine, John Bull research laboratories.  Samples were 
centrifuged at 2000g for 10 minutes, with no brakes activated.  The plasma was 
carefully aspirated into clean labelled cryovials (SARSTEDT, Germany), and stored at 
– 20oC.   
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2.2.4.3 Urine. 
Mid-stream urine samples were collected from each participant in a 20 mL screw-
capped container (Sterilin, UK) between 14:00 and 16:00 hrs.  Early urine samples were 
shown to exhibit greater inter-individual variations as opposed to random urine samples 
collected after first-void urine samples (Lenz et al., 2003; Walsh et al., 2006).  Samples 
were transported under ambient conditions to Peninsula School of Medicine, John Bull 
research laboratories.  Samples were centrifuged at 2500 rpm for 20 minutes to remove 
any precipitates, following an adopted protocol from Williams (Williams et al., 2009).  
The samples for cases collected on early stages of recruitment were transferred to a 
clean 15 mL container (Greiner Bio-One, Germany) and stored at –20oC; the rest were 
stored in siliconized microcentrifuge polypropylene vials (Sigma-Aldrich Corporation, 
UK) at –20oC in preparation for metabolomics studies.  No preservatives were used in 
stored urine. 
2.3 Reagents and materials for peripheral blood mononuclear isolation. 
2.3.1 Reagents:  
a) RPMI-1640 (Lonza Verviers, Belgium). 
b) Phosphate Buffered Saline (PBS) (Lonza Verviers, Belgium). 
c) Foetal Bovine serum (FBS) (Sigma-Aldrich Corporation, UK). 
d) Histopaque-1077 (Sigma-Aldrich Corporation, UK). 
e) HEPES 1M (Lonza Verviers, Belgium). 
f) Cell Culture Freezing Medium, dimethyl sulfoxide (DMSO) (Sigma-
Aldrich Corporation, UK). 
g) Mr. Frosty (cell freezing apparatus). 
h) Freezing medium (absolute isopropyl alcohol).  
i) Pen-Strep 10,000 U ( Lonza Verviers, Belgium). 
j) L-Glutamine ( Lonza Verviers, Belgium). 
k) Penicillin-Streptomycin (Pen/Strep) ( Lonza Verviers, Belgium). 
l) 0.4% Trypan Blue (Sigma-Aldrich Corporation, UK). 
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2.3.2 Peripheral blood mononuclear cell extraction. 
Heparinized (Sodium heparin) whole blood collected in a 9 mL vacutainer tubes 
(Greiner Bio-One, Austria), was diluted in equal volumes with 1X Phosphate Buffer 
Saline (PBS) without calcium and magnesium.  The peripheral blood mononuclear cells 
(PBMCs) were isolated using Histopaque-1077 that helps to aggregate red cells by 
polysucrose.  The histopaque separates the blood into layers during centrifugation; 
where lymphocytes and monocytes lie under a layer of plasma (at a plasma/histopaque 
interface) in a separate buffy coat.  The blood mononuclear cells were separated through 
density gradient centrifugation at 2100g for 10 minutes with brake activated to provide 
rapid rotor deceleration.  The isolated PBMCs were washed three times with Roswell 
Park Memorial Institute medium (RPMI)-1640, supplemented with 1M HEPES buffer, 
10,000 U/mL Penicillin-Streptomycin (Pen/Strep), 200mM L-Glutamine and 10%FBS.  
The cells were prepared for counting as described in Section 2.3.3. 
2.3.3 Cell counting and apoptosis assay (cell viability).  
Following cell centrifugation as described in Section 2.3.2, the pellet was re-suspended 
in 1 mL of supplemented RPMI (sRPMI) and counted using the haemocytometer 
(Superior, Marienfield, Germany).  The cells were diluted 1:20 using trypan blue dye 
exclusion method i.e. 0.4% trypan blue (0.4 g of trypan blue into 80mL of PBS).  The 1 
mL of 0.4% trypan blue was added to 4mls of RPMI to prepare counting solution.  The 
haemocytometer was assembled by affixing the micro cover slip (22 x 22mm) ensuring 
absence of Newton’s rings to achieve desirable optical conditions allowing visualisation 
of cells.  The 10µL of diluted cells were carefully loaded into the haemocytomer and 
counted using a low power phase contrast microscope objective (x10).  Four outer 
squares of the counting chamber were counted and the average was obtained, and then 
multiplied by the dilution factor using the following formula:  
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Cell count/ml = Average x dilution factor x 104   
Since dead cells do not exclude trypan blue, they stain blue but viable cells do not allow 
trypan blue in the cellular cytosol.  Cell viability percentage was calculated by counting 
the number of viable cells divided by the total number of cells (both viable and non-
viable) multiplied by 100.  
𝑉𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠 
𝑁𝑜𝑛 − 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠
 𝑥 100 = 𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦  
 
2.3.4 Cryopreservation of PBMCs. 
The isolated counted PBMCs were re-suspended in 10% dimethyl sulfoxide (DMSO) 
(Sigma-Aldrich Corporation, UK) in foetal bovine serum (FBS) (product of Brazil, 
SIGMA, Dorset UK); and stored in 1 mL aliquots of between 2 x106 – 7 x106 cells per 
mL.  Cryoprotectant such as DMSO was used to reduce the amount of ice that forms 
during freezing. Since DMSO is a hypertonic compound and can cause osmotic injury 
to the cells, DMSO was added gently dropwise.  The cryopreservation of cells was done 
by placing the cryovials (Sarstedt, Germany) in a freezing container (1oC/min Mr Frosty) 
with isopropyl alcohol and kept at – 80oC overnight; before being transferred to liquid 
nitrogen tanks for longer storage. 
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2.4 Laboratory testing of collected samples. 
2.4.1 Serum lipid profiling. 
Stored non-fasting serum samples from chronic HCV patients, spontaneous resolvers, 
healthy volunteers, and exposed uninfected cases were analysed for apolipoproteins A1 
(apoA1), apoB, and apo E using automated rate nephelometric methods (Siemens Dade 
Behring, BNII Nephlometer, Germany) in collaboration with University of Newcastle 
(Newcastle Upon Tyne Biochemistry department).  The samples were sent shipped to 
Newcastle on dry ice for apolipoprotein profiling, which was done by their biochemistry 
department and results were analysed by this student researcher. 
A total of 61 stored serum samples from three different study groups were analysed to 
determine their apolipoprotein levels.   Out of the 61 samples, 22 (36.1%) were HCV 
exposed uninfected, 8 (13.1%) cleared the infection spontaneously, whereas the other 31 
(50.1%) were health volunteers previously recruited from research staffs and 
postgraduate students.  The Plymouth samples were compared with 124 CHCV samples 
generated in Newcastle Upon Tyne.    
2.4.2 Serum apolipoprotein E.  
The apolipoprotein E (apoE) testing only was performed at Peninsula School of 
Medicine, John Bull research laboratories using sandwich ELISA; on ABCAM 
ab108813 –apoE human in vitro ELISA kit that recognizes apoE-2, apoE-3, and apoE-4 
isoforms.   The specific apoE antibodies were pre-coated onto a 96-well plate, and 
blocked by the manufacturer.  The serum samples were diluted 1:400 with diluent 
supplied together with the kit.  The standards were serially diluted from an initial 
2μg/mL apoE standard concentration.  50μL of diluted duplicate samples and standards 
were added to appropriate wells and incubated at room temperature for 2 hours.  
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Following steps of washes, 50 μL of biotinylated detection antibody was added and 
incubated at room temperature for an hour.  After further washing, 50μL of streptavidin-
peroxidase (SP) conjugate complex was added and incubated for 30 minutes.  A 
chromogen substrate tetramethylbenzidine (TMB) was added to visualize SP enzymatic 
reaction, and incubated for 15 minutes.  Once the optimal blue colour was formed, the 
reaction was stopped by adding 50μL of stop solution.  The plate was read at 450nm 
wavelength using GENios; Firmware: V 4.62 - 07/01, XFLUOR4 Version: V 4.51 
reader.  
2.5 PBMC stimulation for innate immune response.  
Cryopreserved PBMCs were thawed in ice as described in Section 2.6.1, cultivated and 
stimulated by pattern recognition receptor ligands modelling viral infection (such as the 
RIG-I, TLR3 and TLR7/8 ligands, Polyinosinic-polycytidylic acid (PolyIC),  and R848) 
or infected with Influenza A virus to determine the up-regulation and production of 
specific cytokines in response to viral stimulation.  A total of 200 x 103 cells were 
seeded in each well for 18 hours.  The cells were co-cultured (stimulated) with PolyIC 
(2.5μg/mL), PolyIC:Lyovec complex (2μg/mL), R848 (4μg/mL), and different doses of 
Influenza A virus (Perth strain, subtype H3N2) in 200µL medium; cultured in a 96-well 
plate (Greiner-Bio-One, Germany), and incubated overnight at 37oC in a 5% IR Sensor 
CO2 incubator (SANYO Model MCO-17A, Japan).  The changes in concentrations of 
IFN-α and multiplex panel were analysed using sandwich ELISA and Luminex.  
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2.5.1 Ligands for stimulation of immune cells (optimisation). 
The ELISA optimisation protocols were performed to ensure reliability of the test 
results.  ELISAs were performed on triplicate wells to reduce inter-assay variation and 
possibly increase the sensitivity.  The innate immune response to single or a 
combination of TLR ligands as a model for viral PAMP as well as Influenza A virus, 
was determined by ELISA analysis. Type 1 interferons were discovered to have an 
antiviral activity against Influenza virus (Lindenmann, 1982).  
The following ligands were used: 
a) Single PRR ligands as a model for relevant antiviral signalling pathways: 
- Single stranded viral nucleic acid sensor ligands such as gardiquimod (TLR7) – 
R848 (TLR8) – TL8-506; supplied by Invitrogen, San Diego, USA. 
- Viral replication intermediate nucleic acid sensors such as PolyIC (TLR3 ligand). 
b) PolyIC/ Lyovec complex that serves as RIG-I/MDA-5 ligand.   
c) Influenza A virus subtype H3N2 (A/Human/μ/16/09 strain) supplied by Public 
Health England as a representative of RNA viruses.  This stimulus triggers 
TLR3, TLR7/8 and RIG-I in infected cells. 
The seeded cells were co-cultured overnight with varying volumes of stimulants.  
PolyIC/Lyovec complex, R848, and PolyIC (InvivoGen, San Diego, USA), were used at 
a final concentration of 2μg/mL, 4μg/mL, and 2.5μg/mL respectively.  Different 
concentrations of 20μg/mL, 50μg/mL, and 100μg/mL were used for TLR8-506 in 
optimisation experiments.  The Influenza A virus stimulants had 9.68x106 PFU/mL 
stock; therefore different Influenza A virus doses were prepared as follows: 9.68x103 
PFU, 19.36 x103 PFU, and 29.04 x103 PFU; and were added to the seeded cells for the 
intracellular activation of cytokine production and secretion.   
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PFU is defined as a measure of infectious virus particles; whereas multiplicity of 
infection (MOI) is the average number of virus particles infecting a single cell.  The 
following formula was applied: MOI =  
PFU used to infect the cells
Number of cells
 
200,000 cells were infected by 1µL of Influenza A virus with a titre of 9.68 x 106  
PFU/mL, the MOI was calculated as follows: MOI =  
 0.001∗ 9.68 x 10^6
2 x 10^5
= 0.048  (i.e 
approximately 1 virus particle in 20 cells). 
Unstimulated PBMCs and medium only from seeded cells were used as negative 
controls.  The EU samples were finally stimulated with Poly:IC/Lyovec complex 
(2μg/mL), R848 (4μg/mL), and the lower doses (9.68x103PFU and 9.68x103PFU) of 
Influenza virus. 
2.6 Detection of interferons type-I using ELISA. 
2.6.1 Cell thawing. 
The cryopreserved PBMCs were transferred from the liquid nitrogen tank on ice to a 
37oC water bath until a small piece of ice remained.  The cells were transferred into a 15 
mL Falcon tube, and 1 mL of warm medium (containing 20% FBS) was added gently 
dropwise to fully liquefy the frozen solution.  2 mL of medium was added again after 
shaking, then the last 6 mL of medium.  The tube was shaken and placed in water bath 
at 37oC for 20 minutes.  The cells were centrifuged at 2000g for 10 minutes with break 
activated.  The cells were then resuspended with 1 mL of sRMPI containing 10% FBS.  
Cell count and viability was assessed by trypan blue stain as described in Section 2.3.3.   
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2.6.2 Interferon-α ELISA.   
Following an overnight (18 hour incubation) cell culturing as described in Section 2.5,  
the PBMC cell culture supernatants were harvested and either stored at –20oC or used 
immediately to run ELISA assay for the detection of interferon-α.   
The IFN-α capture antibodies (Mabtech, Sweden) were added to a high-membrane 
binding 96-well ELISA plate in a final concentration of 4μg/mL, and incubated 
overnight at 4 – 8oC.  After overnight incubation, the plate was washed twice with PBS 
and blocked by 0.1% concentration of bovine serum albumin (BSA) containing 0.05% 
Tween20, and incubated for 1 hour at room temperature.  The 50μL of samples, and 
human IFN-α standard (serially diluted from stock solution of 1µg/mL) were added to 
appropriate wells and incubated overnight at 4 – 8oC. The highest IFN-α standard 
concentration was 1000pg/mL.  Following all necessary washing steps, 100µL of 
biotinylated detection antibodies for IFN-α in concentration of 1μg/mL was added to 
each well and incubated for 1 hour.  Horseradish peroxidase (HRP) conjugated 
streptavidin diluted in 1% BSA (1:1000) was added and incubated for 1 hour.  No 
sodium azide was added to the washing buffer to avoid inhibiting HRP activity.  To 
enhance detection of HRP activity, chromogenic substrate (Super Aqua Blue) 
(eBioscience California) was added and allowed to incubate for 45 minutes.  The 
ELISA data acquisition was performed on triplicate wells.  The innate immune response 
to single or a combination of TLR ligands as a model for viral PAMP; as well as 
Influenza A virus, was determined by ELISA analysis (VersaMax PLUS ELISA 
microplate Reader ROM v1.23; Molecular Devices, USA).    
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2.6.3 Principle of sandwich ELISA technique. 
The technique developed in 1977 (Kato et al., 1977) is designed for detection and 
quantification of an analyte of interest (e.g. antigen) between two layers of antibodies 
(capture and detection antibody).  The capture antibody is coated on a polystyrene 
microtiter plate through the antibody Fc region.  The microtiter plates must have a 
minimum protein binding capacity of 400ng/cm2.  All unbound antibodies are washed 
using appropriate washing buffer.  A blocking buffer is added that passively adsorbs to 
the remaining binding sites of the microtiter plate to reduce the nonspecific binding and 
eliminate background.  A sample containing antigens is added and the specific antigen 
is immobilised by binding to the coated antibody.   The plate is incubated and washed to 
remove unbound antigens.  A detection antibody tagged with an enzyme specific to the 
antigen is added, and incubated.  Following a washing step, all unbound antibodies are 
washed.  A secondary enzyme-linked antibody (coupled to substrate-modifying enzyme) 
is added that binds to the detection antibody.  After incubation and washing, the 
substrate is added, and is converted by the enzyme to produce a chromogenic signal 
which is detected by a spectrophotometer.  The colour production reveals an enzyme 
activity, whereas lack of colouration indicates lack of enzyme activity or negative result 
(Aydin, 2015).  The colour intensity is directly proportional to the levels of the 
measured analyte.  The analyte is quantified by measuring the amount of light absorbed 
or transmitted (depends on the analyser) through the coloured liquid in the wells.    
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2.7 Luminex magnetic bead-based multiplex Assay.   
In magnetic multiplex bead-based assay, beads of discrete fluorescence intensities and 
wavelengths detect multiple analytes in a single sample.  This detection method is based 
on flow cytometry and allows repeatability.   The measurements were performed on a 
Luminex system comprising the Luminex LX100/LX200 analyzer, Luminex XYP plate 
handler, Luminex SD sheath fluid delivery system, and Luminex xPONENT software.  
Data analysis was performed on Microsoft Excel 2010, and GraphPad Prism version 
5.01 (GraphPad software Inc. USA).   
 
2.7.1 Cell preparation and assay protocol. 
The samples were prepared following the manufacturer’s instructions.  In brief, frozen 
cell culture supernatants (stimulated with stimulants described in Section 2.5.1) were 
thawed at room temperature.  In this protocol, culture supernatants that were stimulated 
with lower dose of Influenza A virus (9.68x103 PFU) were used in a 6-plex assay.  The 
reagents for the immunoassay were prepared according to the manufacturer’s 
instructions.  The 200µL of the assay buffer was added into each well of the plate; and 
left on a plate shaker at room temperature for 10 minutes.  The buffer was removed by 
tapping onto absorbent towel.  The 25µL of neat samples, prepared controls and 
standard were added to appropriate wells in triplicate.  The wells for controls and 
standard were added with 25µL of assay buffer whereas samples wells were added with 
cell culture media (sRPMI plus 20% FBS).  25µL of premixed fluorescent-coded 
magnetic beads were added to each well (beads were mixed intermittently to avoid 
settling).  The plate was sealed, wrapped with aluminium foil, and incubated with 
agitation on a shaker for 18 hours at 4oC in the dark.  Following overnight incubation, 
the beads were washed twice and 25µL of biotinylated detection antibody was added 
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into each well and incubated on a plate shaker sealed with foil for 1 hour at room 
temperature.  After washing, 25µL of detection conjugate (streptavidin-phycoerythrin) 
was incubated with the beads for 30 minutes at room temperature in a sealed plate 
covered with foil.  The beads were washed again, and the wells were filled with 150µL 
of sheath fluid (pre-filtered, pH balanced PBS concentrated solution for transporting 
samples in a flow cytometer).  The beads were resuspended on a plate shaker for 5 
minutes.  The levels of fluorescence from the cytokines tested in a single bead were 
determined with the Luminex LX100/LX200 analyzer (software version: xPONENT for 
LX100/LX200 3.1.971.0 USA) and expressed as median fluorescence intensity (MFI) 
using a 5-parameter logistic method to determine concentrations of cytokines in samples.   
 
2.7.2 Principle of luminex magnetic bead assay. 
The fluorescent colour-coded beads (microspheres) are pre-coated with cytokine-
specific capture antibody.  When samples are added, the cytokines of interest are 
captured by the analyte-specific antibodies on the beads.  Biotinylated detection 
antibodies specific to the cytokines of interest are introduced to each well and an 
antibody-antigen complex (sandwich) is formed.  The reaction mixture is then incubated 
with Phycoerythrin (PE)-conjugated streptavidin.  The colour-coded beads are read by a 
dual-laser flow-based detection Luminex analyser which excites the internal dyes 
marking the beads and a second laser excites PE, the fluorescent dye on the reporter 
molecule. The Luminex flow-cytometry-based instruments integrate detection 
components (lasers, optics, fluidics, and digital signal processors).  The quantification 
of each microsphere bioassay is based on fluorescent reporter signals. 
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Figure 2.1: Principle of Luminex multiplex assay. 
 
 
 
 
Figure 2.1 shows a diagrammatic representation of the principle of Luminex magnetic 
assay.  The magnetic beads (coloured) contain fluorescent dyes.  The beads are coated 
with capture antibody. The antigens present are captured by the primary antibody.  The 
detection antibody is introduced that binds to the antigen to form an antigen-antibody 
complex. The secondary antibody is tagged with phycoerythrin (PE)-conjugated 
streptavidin (a reporter molecule that completes the reaction on the surface of 
microspheres) allowing detection of the cytokines by the Luminex analyser.   
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2.8 Interferon-gamma (IFN-γ) Enzyme-Linked Immunospot (ELISpot) assay. 
The HCV-specific T cell responses were studied using frozen PBMCs.  The T cell 
reactivity to a range of recombinant HCV proteins and peptides encompassing both 
structural and non-structural regions were characterised by detection of IFN-γ in co-
cultured cells.  The IFN-γ releasing cells were enumerated by ELISpot assay using an 
AID ELISpot Reader version 4.0 (AID GmbH, Strassberg, Germany).  
 
2.8.1 Sample preparation for ELISpot assay. 
The frozen PBMC samples were thawed and counted following protocol described in 
2.5.2.  The cell culture media (RPMI) was supplemented with 50 mL of off-the-clot 
human AB serum (Gemini, UK supplied by Seralab).  The counted cells were adjusted 
to 2.0 x 106 cells/mL by addition of sRPMI/10% AB Serum so that 100µL should have 
200 x 103 cells.  Each well in a 96-well plate contained 200 x 103 cells in 200µL. 
 
2.8.2 Cell culture with recombinant HCV peptides. 
The following antigens were used to stimulate the PMBCs: Lectins such as 
phytohaemagglutinin (PHA) from phaseolus vulgaris (Red kidney bean) (Sigma-
Aldrich Corporation, UK) are potent polyclonal T cell activators that were used as 
positive control in a final concentration of 1µg/ml.  The PHA was used as a non-specific 
T cell mitogen to confirm cell viability in each assay.  An antigen-specific T cell 
stimulation was measured in response to overlapping peptide pools spanning the entire 
HCV genome and  ‘CEFT’ – (JPT Peptide Technologies, Berlin, Germany) consisting 
of immunodominant peptides from Cytomegalovirus, Epstein Barr virus, Influenza virus, 
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and Tetanus toxin.  The CEFT peptide pool was used as a positive control (recall 
antigen response) and consists of 14 viral peptides which stimulates  T cells to produce  
IFN-γ responses in approximately 90% of all Caucasians (MABTECH, 2016).  The 
majority of Caucasians would have been immunised in childhood against different 
viruses, therefore it was expected that the positive controls would induce a T cell 
response.  The CEFT was used in a final concentration of 3µg/mL per well in a cell 
culture plate.  Positive controls were used to assess cell viability as well as functionality 
of the immunoassay.  The wells with unstimulated PBMCs with sRPMI/10% AB serum 
only were used a negative control.  The HCV overlapping peptides were from HCV 
genotype 3 (the dominant genotype PWIDs in Plymouth) and were obtained from 
BEI Resources, USA.  The lyophilised HCV peptides were reconstituted in 50µL 
DMSO to make a stock concentration of 20mg/mL.  Each HCV peptide was pooled by 
pipetting 10µL from each vial into a clean tube, aliquoted and stored at -20oC.  HCV 
genotype 3 peptides used in a final concentration of 3µg/mL per well, were: Core 
(spanning aa 1 – 29 in a single pool), NS3 (aa 1 – 98 single pool), NS5A (aa 1 – 71 
single pool), and NS5B (aa 1 – 91 single pool) all from BEI Resources, USA.  A 
total of 200 x 103 cells/well were co-cultured in triplicate with the peptides in a flat-
bottom 96-well plate (Greiner-Bio-One, Germany) at a final concentration of 1µg/mL 
(Lectin) and 3µg/mL (CEFT, HCV peptides) and incubated for 20 hours at 37oC in a 5% 
IR Sensor CO2 incubator (SANYO Model MCO-17A, Japan).  Our previous 
optimisation experiments determined that a cell density of 200 x 103 cells/well was 
adequate to enhance probability of cell contact between stimulation cells and 
responding cells.  Therefore to achieve an optimal T cell stimulation, 200 x 103 
cells/well were co-cultured overnight with cell stimulants.    
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2.8.3 Interferon-γ ELISpot procedure. 
A high-membrane-binding 96-well ELISpot plate (MAIPS4510; Millipore, Ireland) was 
coated with 100µL of 5µg/mL primary/capture IFN-γ antibody (human IFN-γ, BD 
Bioscience UK) in sterile PBS; and incubated at 4oC for 16 hours.  After overnight 
incubation, the ELISpot plate was washed once with sRPMI/10% AB Serum.  200µL of 
the same medium (sRPMI/10% AB Serum) was added into each ELISpot well to block 
the membrane (in order to reduce cross reactivity), and left at room temperature for 2 
hours.  After 2 hour incubation the blocking solution was discarded from the plate, and 
blotted gently.  The activated PBMCs were transferred from the culture plate to the 
ELISpot plate in respective triplicate wells; and incubated for 24 hours at 37oC in a 5% 
IR Sensor CO2 incubator (SANYO Model MCO-17A, Japan).  
After a 24 hour incubation, the ELISpot plate was washed several times using 1 x 
PBS+0.05% Tween 20 as the main washing solution; allowing soaking for 1 – 2 
minutes between washes.  After cell incubation on the ELISpot plate the stimulated 
cells become sticky, therefore 0.05% Tween 20 was used to ensure complete removal of 
the cells and secondary antibodies during washing.  2µg/mL of secondary biotinylated 
(detection) antibody in PBS + 10% FBS was added to the wells to ensure maximum 
degree of labelling; and incubated at room temperature for 2 hours.   
Following washing, a streptavidin protein that was covalently conjugated to horseradish 
peroxidase (HRP) enzyme (Avidin-HRP) was diluted 1:100 and used as a conjugate in 
this protocol.  The 100µL of the Avidin-HRP conjugate (prepared 45 minutes before use) 
was added to the wells and incubated at room temperature for 1 hour.  The streptavidin 
binds to biotin in secondary antibody, and the enzymatic activity is provided by the 
conjugated HRP.  The ELISpot plates were developed using an HRP substrate 3'-amino-
9-ethylcarbazole (AEC) (BD Bioscience, USA) for 15 minutes for detection of IFN-γ 
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secreting cells.  The AEC dilution was 1 drop of AEC chromogen in 1 mL of substrate; 
prepared not more than 15 minutes before use; to ensure that it forms intense red colour 
spots.   The reaction was stopped by immersion of plates in tap water.  The plates were 
rinsed thoroughly with running water ensuring that each well was filled and emptied at 
least five times.  The plates were left to dry inverted for more than 3 hours, or overnight 
before reading on ELISpot reader.  
 
2.8.4 ELISpot parameters and plate reading. 
Spot forming units (SFU) were counted using an AID ELISpot plate Reader version 4.0 
(AID GmbH, Strassberg, Germany).  The spot definition settings were as follows: 
Thresholds – Intensity (minimum 20, maximum 255), Size (minimum 20, maximum 
5000), gradient (minimum 1, maximum 90); Basic algorithm settings: Emphasis (Small), 
Algorithm C, Invert recognition was left blank, well saturation was set at 60%.   Stage 
calibration was performed before reading each plate.  SFU counts were transferred from 
the reader to excel spread sheet.  A positive IFN-γ response to HCV peptides was 
determined if  the calculated mean number of spot-forming cells in stimulated wells was 
greater that the calculated mean number of spot-forming cells plus 2 standard deviations 
(SD) (Thurairajah et al., 2008).   
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Figure 2.2: ELISpot 96-well plate layout. 
 
 
 
Figure 2.2 shows a schematic diagram of a 96-well ELISpot plate showing the layout of 
cell stimulants.  The 100µL of cell stimulants were added to another 100µL of PBMCs 
(2 x 105 cells).  The total volume in each well was 200µL in a final antigen 
concentration of 1µg/mL (Lectin), and 3µg/mL the rest of the antigens.  Negative 
control wells (PMBCs + media only) were added with 200uL of cells and media only 
without stimulants.  The lectin/PHA and CEFT were used as positive control, with 
CEFT preferentially as a recall antigen.  
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2.8.5 Principle of ELISpot technique. 
ELISpot is a method used for quantification of frequency of cytokine-secreting T cells 
at a single cell level.  PBMCs are cultured overnight in the presence of antigen-specific 
stimuli.  The stimulated cells are then transferred to an ELISpot plate coated with 
cytokine-specific monoclonal capture antibodies immobilised on a polyvinylidene 
difluoride (PVDF) or nitrocellulose membrane; and then incubated appropriately to 
allow cytokine secretion.  Secreted cytokines by stimulated cells are captured by the 
specific antibodies on the surface of the 96-well plate.  The cells are removed through 
washing with appropriate solution, and secreted cytokines are detected by addition of 
biotinylated cytokine-specific detection antibodies.  Spot formation on the membrane is 
enabled by streptavidin-HRP conjugate.  The cytokine secreting cells are detected by 
addition of precipitating substrate (AEC); and the cells appear as visible red spots.  Each 
spot corresponds to the ‘foot-print of an individual cytokine secreting cell.   The colour 
intensity and size of the spots depends on the levels of secreted cytokines.  Artificial 
spots form as a result of incomplete removal of cells from the plates during washing or 
due to aggregation of antibodies in the process of coating and detection (MABTECH, 
2016).   
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Figure 2.3: Schematic diagram of ELISpot principle. 
 
Figure 2.3 shows a schematic illustration of the principle of ELISpot protocol (Hickling, 
1998).    
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2.8.6 A positive IFN-γ response definition criteria for ELISpot assay. 
Positive IFN-γ responses were determined based on the mean + 2SD of the healthy 
volunteers.  A positive IFN-γ response in other studies was determined by subtracting 
the average number of spot-forming T cells in negative control triplicate wells from that 
in antigen-stimulated triplicate wells and expressed as spot forming unit (SFU) per 
million cells (Tang et al., 2005).  Others determined an IFN-γ response by observing the 
probability of a spot appearing in the stimulated well if it was significantly different 
from the probability of a spot appearing in the negative control well (Barnes et al., 
2009).  There is no consensus on criteria for defining ELISpot positive or negative 
responses (Moodie et al., 2010), therefore lack of such agreement may affect the 
number of positive responses.  Reference/precise research laboratories established 
individual in-house criterion; therefore usage of a consensus average in assessing the 
accuracy is appropriate in dealing with the inter-assay variability.  A cut-off of 5 SFU in 
unstimulated control wells were acceptable in this assay (Alexander et al., 2013).  The 
cut-off values were defined with reference to criteria commonly known as empirical 
methods based on responses in known ELISpot negative population (Moodie et al., 
2010).    
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2.9 Metabolomics. 
2.9.1 Shipment of samples. 
All serum and urine samples were collected as described in Section 2.2.4 and shipped 
on dry ice from Plymouth to London where they were stored at – 80oC at Imperial 
College London, and Institute of Hepatology, London until required for preparation and 
analysis.     
 
2.9.2 Mass spectrometry lipidomics profiling. 
I performed serum lipidomics using MS at Imperial College London South Kensington 
London in Prof. Simon Taylor-Robinson and Prof. Elaine Holmes research groups with 
the help of Dr. Maria Gomez-Romero and Dr. Alexandros Pechlivanis.  The lipidome of 
386 serum samples were analysed comprising 60 EU, 36 SR, 100 SVR, 159 CHCV 
patients and 31 healthy controls, utilising EU / SR cases collected locally and additional 
CHCV samples from the HCV Research UK biobank.  An ACQUITY UPLC/MS 
system (Waters) in both positive and negative electrospray ionisation modes (ESI+ and 
ESI-) was used following established protocols.  A composite QC sample defined the 
system suitability, analytical stability, and sample repeatability.   
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2.9.2.1 UPLC-MS mobile phases. 
Chromatographic separation of lipid profile in serum samples using UPLC utilises 
mobile phases/solvents A and B; using Acquity CSH18 column.  The mobile phases 
were prepared with LC-MS grade solvents, formic acid, and ammonium formate 
(NH4HCO2) (Sigma-Aldrich Corporation (Dorset, UK).  The mobile phase A consisted 
of high purity water, 10mM NH4HCO2, and 0.1% formic acid (CH2O2) mixed in that 
order.  Acetonitrile (C2H3N) was added slowly while mixing until the solution was clear.  
The mobile phase B consisted of isopropanol (C3H8O), C2H3N, CH2O2, and NH4HCO2 
all mixed at the same time and sonicated until complete dissolution of ammonium 
formate.   Refer to Table 2.1 for details of solvents preparation.   
Table 2.1 Mobile phase solvents preparation. 
 
 
 
 
 
 
Solvent A (1 litre) 
Chemicals Amount  Rationale 
Acetonitrile 
(C2H3N) 
600mL (60 x A) / 100,  
mL 
Ultra-pure 
Water 
400mL (40 x A) / 100,  
mL 
Formic acid 
(CH2O2) 
1mL (0.1 x A) / 100,  
mL 
Ammonium 
formate 
(NH4HCO2) 
0.6306g A ml x 10e-3 
L/mL  x 
10mmol/mmo, g 
 
Solvent B (1 litre) 
Isopropanol 
( C3H8O ) 
900mL (90 x B) / 100,  
mL 
Acetonitrile 
( C2H3N ) 
100mL (10 x B) / 100,  
mL 
Formic acid 
( CH2O2 ) 
1mL (0.1 x B) / 100, 
mL 
Ammonium 
formate 
(NH4HCO2) 
0.6306g B mL x 10e-3 
L/mL x 
10mmol/mmol, g 
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2.9.2.2 Sample preparation for UPLC-MS: protein precipitation and lipid 
extraction. 
All the samples were thawed at 4oC, and transferred to 2ml safe-lock eppendorf tubes 
(Eppendorf AG, Hamburg, Germany), and prepared for UPLC-MS analysis by 
isopropanol protein precipitation (Sarafian et al., 2014).  In order to precipitate the 
proteins and extract the lipids (Pfaender et al., 2015), 150µL of cold isopropanol was 
added to each 50µL serum sample (ratio 3:1).  Composite (QC) sample was generated 
by pooling 10µL of each sample into a single 2mL safe-lock Eppendorf tube to create a 
single QC.  All the samples and composite QC were homogenised by vortexing for 30 
seconds, and incubated at 4oC for 2 hours.  The virally inactivated serum samples (by 
cold isopropanol) (Pfaender et al., 2015) were centrifuged at 4oC for 15 minutes at 
13,000 rpm.  The 100µL of supernatant was transferred into a glass insert with poly 
spring, in a glass vial.  The prepared samples were kept in the fridge at 4°C or 
transferred to the auto-sampler where they were kept at 8 °C throughout the analysis.    
2.9.2.3 UPLC-MS conditions. 
The serum lipid UPLC-MS profiling was performed using an ACQUITY UPLC system 
(Waters Ltd., Elstree, UK) coupled to a Q-ToF Premier mass spectrometer  (Waters MS 
Technologies Ltd, Manchester, UK) using an electrospray ion source operated in both 
positive and negative modes.  
The LC conditions have been previously described (Shockcor et al., 2011).  Separation 
was done in a Waters Acquity UPLC HSS CSH column (1.7 μm, 2.1 × 100 mm) 
maintained at 55⁰C. The mobile phases consisted of ACN/H20 (60:40) (A) and 
isopropanol/acetonitrile (IPA/CAN) (90:10) (B), both containing 10 mM ammonium 
formate and 0.1% (v/v) formic acid.  The flow rate was set at 0.4 mL/min.  Injection 
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volume was 5µL and 15 µL for positive (ESI +ve) and negative (ESI –ve) modes, 
respectively.  
The ESI conditions were as follows: capillary voltage for ESI- 2500V, for ESI +ve 
3000V, cone voltage 25V for ESI -ve and 30V for ESI +ve, source temperature 120⁰C, 
desolvation temperature 400⁰C, cone gas flow 25L/h, and desolvation gas 800L/h.  The 
MS data were collected in centroid mode.  For mass accuracy, leucine enkephalin 
(555.2692 Da calculated monoisotopic molecular weight) was used as a lock mass.  The 
lockmass scans were collected every 30 seconds and averaged over 3 scans to perform 
mass correction.  Instrument calibration was performed using sodium formate prior to 
each ESI mode. 
To equilibrate the system, ten conditioning QC samples were performed at the start of 
acquisition.  The QC samples were run periodically after 10 sample injections to 
monitor instrument performance.  Data-dependent acquisition (DDA) and MSE analysis 
of the QC sample was performed to obtain MS/MS information for metabolite 
annotation.  
Refer to Table 2.2 for mobile solvents gradient conditions.  High organic wash step 
duration was adjusted for elution completion of lipids, preventing their accumulation on 
the column.  Three cycles of weak solvents (H2O/ C3H8O, 90:10) and strong C3H8O 
solvent were performed in tandem with sample analysis to reduce the injection carry-
overs.   
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Table 2.2 LC conditions. 
 
Variable Conditions 
Column Acquity CSH C18 (2.1 x 100 mm, 1.7 μm) 
Column 
temperature 
55oC 
Sample 
temperature 
8oC 
Flow rate 0.4 mL/min 
Mobile 
phase A 
Acetonitrile/water (60:40 with ammonium formate and 0.1% formic 
acid) 
Mobile 
phase B 
Acetonitrile 90:10 with 10mM ammonium formate and 0.1% formic 
acid 
Injection 
volume 
5 μL (full loop) 
Run time 20 minutes 
 
 
 
 
Gradient 
Time (min) % A % B Curve 
Initial 60 40 Initial 
2.0 57 43 6 
2.1 50 50 1 
12.0 46 54 6 
12.1 30 70 1 
18.0 1 99 6 
18.1 60 40 6 
20.0 60 40 1 
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2.9.2.4 MS data pre-processing. 
The data set was separated into subgroups according to their outcomes following 
exposure to HCV.  The UPLC-MS raw data was acquired using MassLynx software 
version 4.1 (Waters, Manchester, UK) and converted in NetCDF files using Databridge; 
a module within MassLynx software 4.1.  The CDF files were pre-processed using 
XCMS package within the R statistical software version (Rx64 3.2.5), and in-house 
developed scripts.  
2.9.2.5 Multivariate statistical analysis. 
The data was subjected to multivariate statistical analysis using SIMCA-P (version 14.1, 
Umetrics, Umeå, Sweden).  Principal component analysis (PCA) and orthogonal 
projections to latent structures discriminant analysis (OPLS-DA) were performed on all 
data after pareto scaling and log transformation for detection of patterns, trends and 
outliers; and construction of discriminant models for classification and the discovery of 
potential biomarkers respectively. 
2.9.2.6 Filtration and peak identification. 
The generic ‘findpeaks’ function in XCMS was used to find peaks and processed them 
in batch mode, stored, aligned and grouped them for further analysis.  Table 2.3 below 
provides a summary of different parameters used for peak picking in centroid mode to 
enable sensitive detection of low intensity peaks.  Filtering of peak intensity for 
different lipids allowed exclusion of unnecessary signals (drifts and noise) derived from 
the data.  
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Table 2.3 Data pre-processing, and adjustment of parameters. 
Parameter Abbreviati
on used 
Description  Values set 
(ESI +) 
Values set 
(ESI -) 
CentWave centWave Peak detection algorithm in centroid mode.  It detects 
features based on their intensity and wavelet. Detects 
overlapping peaks and close-by-peaks as well  
Default  Default 
Noise noise centroids with intensity < noise are omitted from regions 
of interest (ROI) detection 
50 5 
Parts per 
million 
ppm The maximal tolerated error or m/z deviation between 
actual mass and measured mass in consecutive scans 
35 50 
Prefilter =c c(k,l) Mass traces are only retained if they contain at least x 
scans with intensity y 
(8, 100) (5, 30) 
Signal/Noi
se ratio 
snthresh Signal/Noise ratio: ([maximum peak intensity] - 
[estimated baseline value]) / standard deviation of local 
chromatographic noise 
10 10 
Peakwidth
=c (min, 
max) 
peakwidth Minimum and maximum chromatographic peak width 
detectable (seconds) 
4, 20 4, 25 
Integrate  integrate Integration type (1=on bounds decided by waves, 2=on 
raw data) 
2 2 
nSlaves nS Number of computer core processors 3 3 
minfrac minfrac Minimum fraction of samples necessary in at least one 
sample group for it to be a valid group 
0.2 0.2 
minsamp minsamp Minimum number of samples necessary in at least one of 
the sample groups for it to be a valid group 
0 0 
Bandwidth bw Bandwidth (standard deviation or half width at half 
maximum) of gaussian smoothing kernel to apply to the 
peak density chromatogram 
2 6 
mzwid mzwid Width of overlapping m/z slices to use for creating peak 
density chromatograms and grouping peaks across 
samples 
0.01 0.01 
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The identified peaks were matched and grouped using a default ‘density-based approach’ 
algorithm in XCMS.  This density algorithm groups is capable of grouping peaks in all 
samples using m/z bins, calculates smoothed peak distributions in chromatographic time.  
Some of the parameters that were adjusted included: minfrac, minsamp, bw, and mzwid 
as presented in Table 2.3.  The XCMS software has the ability to identify well behaved 
peaks and differentiate them from missing peaks, and improperly grouped multiple 
peaks from a large fraction of samples, in order to calculate the median retention time, 
and a deviation from that median.  ‘Rector’ generic method and ‘loess’default algorithm 
within XCMS was applied on smoothed deviations for correction/alignment of retention 
time.  Furthermore, normalisation technique helps to remove sources of systematic 
variations between samples as a result of factors that are not related to the biological 
processes.  Finally XCMS generated files in .csv format which was transposed on 
SIMCA-P for multivariate analysis.   
2.9.2.7 MS/MS metabolite annotation. 
The candidate metabolites were annotated using accurate m/z values, fragmentation 
patterns, retention times, and the METLIN database (https://metlin.scripps.edu/).  The 
database contains information related to the rt and m/z value of the precursor ion.  The 
lipidomics moieties annotation procedure involved selection of a valid OPLS-DA model 
in pareto scaling.    
The lipidomics features of chromatographic peaks were extracted in order to further 
identify the lipid compounds that distinguished the EUs from the comparator groups.  
Following OPLS-DA analysis, the results of S- and Variable Importance for the 
Projection (VIP)-plots were assessed and the database provided for retention time (rt), 
m/z (mass over charge ratio), and MS/MS data and was verified by the raw data.  
Significant lipid features were generated from the VIP plots using a VIP cut-off of 1.5 
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that showed confidence intervals for the VIP values at the 95% level.  The VIP plot 
summarizes the importance of the variables both to explain X and to correlate to Y.  
VIP-values larger than 1 indicated “important” X-variables, and values lower than 0.5 
indicated “unimportant” X-variables.  The VIP plot was sorted from high to low, and 
showed confidence intervals for the VIP values, normally at the 95% level.  In this 
study VIP features from 1.5 and above indicated important variables.  All unsorted VIP 
values were copied to an Excel spread sheet ensuring that the VIP values were greater 
than VIP (cvSE), and data ranked according to VIP values.  The data was filtered and 
sorted according to the retention time.  Using the raw chromatogram data organised in 
peak intensity of lipids eluted at the same retention time, the MS/MS data was derived 
by mining the peak intensity.  The MS/MS fragmentation pattern was observed using 
the data dependent analysis (DDA), SURVEY, and MSE.  Peak detection was based on 
their intensity and wavelet.  The peak height and area were defined following conditions 
described in Table 2.3.  
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2.9.2.8 Principle of LC-MS. 
Figure 2.4: Schematic diagram of the principle of ESI LC-MS. 
 
 
 
 
 
 
 
 
Figure 2.4 shows a schematic representation of the basic components of a mass 
spectrometer.  
 
An ESI LC-MS is used for production of ions in a sample by using electrospray and is 
composed of three basic components namely: Ion source, mass analyser, and a detector.  
The ion source is kept at atmospheric pressure, and uses a pressure gradient and voltage 
gradient to help pump out ions from the source to the detector.  When the sample is 
injected in the instrument, and high electric voltage is applied, the molecules are 
bombarded with a beam of energetic electrons from the ion source.  The ESI accelerates 
the movement of ions from the liquid solution to gaseous phase ions (electron 
ionisation).  Ionisation requires solvent evaporation; therefore two different mobile 
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phase solvents are prepared by addition of water, acetic acid to decrease the droplet size 
and increase conductivity, as well as providing protons to facilitate the ionisation 
process.  The ions are separated according to their mass-to-charge ratio (m/z) 
by the mass analyser via ion optics that help the ion  beam stream to 
maintain a stable flight (trajectory) of the ions.  The ESI enables molecular ions 
to undergo fragmentation.  The electrical/magnetic field is created that accelerates the 
ions through the flight tube toward the detector systems to measure their concentrations.   
The magnetic field subjects samples of same masses to deflect with the same magnitude 
according to their m/z; big ions travel slowly whereas light ions arrive at the detector 
first.  Since ions are very reactive and have short life, ion optics for MS are kept in high 
vacuum achieved by use of oil diffusion pumps or turbomolecular pumps.  The sample 
flow rate is enhanced by usage of nitrogen gas (nebulising gas).  Due to evaporation of 
mobile phases, the charged droplets in a mist reduce their size, that result in reduction in 
their radius, and increased surface charge density (Konermann et al., 2013).  The 
charged particles are detected by the instrument systems detector that converts the ions 
into electrical signal.  The signals are processed and transmitted to the computer that 
acquires and compares the spectra data to reference library.  The results are displayed as 
a mass chromatographic spectrum.  Mass spectrum is a graphical plot of signals of ions 
in relation to their m/z, which is used to determine the mass of metabolites in a sample, 
and helps to predict the structural arrangement of the molecules.  Each ion’s ratio of 
mass to charge (m/z) determines the molecular mass of the ion.   
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2.9.3 Nuclear Magnetic Resonance metabolomics. 
The urine samples were collected in Plymouth as described in Section 2.2.4.3, and was 
transported on dry ice to the Institute of Hepatology in London. 
2.9.3.1 NMR data acquisition. 
The NMR sample preparation was performed by Dr Antonio Riva of the Institute of 
Hepatology according to the literature (Dona et al., 2014).  The NMR sample 
processing was performed in the department of Chemistry at University College London 
(UCL).  All data acquisition and analysis was performed by this student researcher. 
2.9.3.2 Proton NMR spectral acquisition.  
The samples were prepared into 5mm NMR tubes for NMR study based on previously 
published standard methodology (Beckonert et al., 2007; Dona et al., 2014).  The urine 
samples were analysed in a random order at the Department of Chemistry, University 
College London.  The NMR spectra were recorded on a Bruker Avance III 600 NMR 
spectrometer operating at proton NMR frequency of 600.13 MHz equipped with a 5 mm 
DCH cryoprobe.  The samples were placed in a sample queue at 21 °C on the auto 
sampler and some samples may have remained in the queue for up to 6 h before NMR 
analysis. 
The data acquisition and processing were performed using standard TopSpin (version 
3.2) software.  The NMR spectra were recorded at 300 K using a standard pulse 
sequence noesygppr1d with water presaturation during relaxation delay (Dona et al., 
2014).  Four dummy scans were used for equilibration followed by 64 scans collected 
into 144K points with a total repetition time of 8.0s at each scan (acquisition time = 4.0 
s; relaxation delay = 4.0s).  The NMR spectra were processed using the Bruker AMIX 
148 
 
data processing package and the KnowItAll Informatics System v9.0 (Bio-Rad, 
Philadelphia, PA).  The Free Induction Decays were zero-filled and an exponential 0.3 
Hz line-broadening function was applied before Fourier transformation.   
All the NMR spectra were automatically phased and a baseline correction was applied.  
The trimethylsilyl propanoic acid (TSP) peak was assigned to be at δ 0.00 ppm for an 
internal chemical shift reference.  The NMR peaks in the range δ 0.50-9.50 ppm were 
analysed, although the region δ 4.50-6.40 ppm was excluded to remove the residual 
water signal and also the signal from urea.  The urinary NMR peaks were assigned to 
metabolites on the basis of chemical shifts and coupling patterns and with reference to 
the published literature (Wishart et al., 2007, 2013, Shariff et al., 2010, 2011; 
Heinzmann et al., 2012; Bouatra et al., 2013; Ladep et al., 2014).  
2.9.3.3 Multivariate data analysis. 
The resonances in the urinary NMR spectra were assigned using online databases (for 
example the Human Metabolome Data Base (HMDB) http://hmdb.ca/) (Wishart et al., 
2007) and according to published literature (Holmes et al., 1997; Lindon, Nicholson and 
Everett, 1999; Trygg, Holmes and Lundstedt, 2007).  The multivariate analysis was 
performed by BioRad KnowItAll® Informatics System version 17.0.  The water and 
urea region (δ 4.50 to 6.40 ppm) was excluded from the analysis as this region was 
distorted by the water suppression technique.  The complex urinary NMR spectra were 
sub-divided into ‘Buckets/Bins’ (smaller regions) using ‘intelligent bucketing’ 
algorithm.  The following regions were specifically identified prior to principal 
component analysis (PCA):  7.80 – 7.88 ppm (hippurate), 7.60 – 7.67 ppm (hippurate), 
7.53 – 7.58 ppm (hippurate), 4.04 – 4.05 ppm (creatinine), 3.04 – 3.05 ppm (creatinine), 
3.97 – 4.01 ppm (hippurate), 2.65 – 2.73 ppm (dimethylamine (DMA)), and 2.51 – 2.55 
ppm (citrate).  The PCA was used to identify outliers and group clustering.   
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2.9.3.4 Statistical comparison of discriminating metabolites.  
The comparison between creatinine, hippurate and trimethylamine N-oxide (TMAO) for 
study groups was assessed by performing One-way analysis of variance (ANOVA) to 
analyse the differences of urinary metabolites among EU, SR, CHCV and HC groups.  
Bonferroni's Multiple Comparison Test was performed using GraphPad Prism-5, and 
statistical significance was accepted at p <0.05.           
2.9.3.5 Principle of NMR technique. 
Figure 2.5: Basic principle of H NMR spectroscopy. 
 
Figure 2.5 shows the basic illustration of an NMR instrument.  The conducting magnet 
generates an external magnetic field rotating around the sample. The probe subjects the 
urine sample to RF frequencies generated externally by the RF generator.  The 
continuous excitation and relaxation of the sample creates NMR signals that are 
forwarded to the computer that processes the data and presents NMR spectrum. 
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The NMR spectroscopy is an analytical chemistry technique used for determining the 
concentration and molecular structure of metabolites in a sample. The principle for 
NMR is that nuclei of elements or compounds have spin and all nuclei are electrically 
charged.  When the sample is placed in an NMR tube and subjected to an external 
magnetic field, the protons spin and align in one direction.  The radiofrequency (RF) 
electromagnetic radiation is applied that sends electromagnetic waves to the sample that 
excites the protons to move from the lower energy level (α-state) to the higher energy 
level (β-state) between a single energy gap.  When the RF is reduced, the protons relax 
back to the base level (relaxation) that emits energy generated as an NMR signal.  
Atoms with even mass number and even atomic number do not possess nuclear spin and 
become NMR invisible; whereas atoms with odd mass number have spin I and they 
behave like a magnet and will give NMR signal.  The nuclei when they are in magnetic 
field absorb and emit electromagnetic radiation.  The energy that drives the vibrating 
atoms in oscillation is referred to as resonance.  Therefore the frequency of resonance 
depends on the magnitude properties of the atoms as well as the strength of the 
magnetic field created.  Since distinct protons exist in different chemical environments, 
thus a different amount of energy is required to bring nuclei in different environment 
into resonance. This results in different protons generating different NMR signals.  The 
energy transfer generates some signals or peaks that are processed to produce NMR 
spectra to represent the amount of energy that brought the nuclei in the sample into 
resonance (reviewed in (Schanda and Ernst, 2016).    
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2.10 Statistical analysis. 
Statistical calculations were performed using GraphPad Prism version 5.01 (GraphPad 
software Inc. USA) and ‘R’ statistical software version (Rx64 3.2.5). To further 
evaluate the significance of these findings, One-way analysis of variance (ANOVA - 
Kruskal-Wallis test), and the t-test (Mann Whitney test and/or Wilcoxon signed rank 
test) were used to determine the differences among the means when comparing several 
groups or just two groups respectively.  A p.value of <0.05 was considered significant. 
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3 CHAPTER THREE 
 
3.1 Urinary metabolic profiling of HCV exposed uninfected injection drug users. 
3.2 Background. 
The liver serves as the main metabolic and biosynthetic organ (Mitra and Metcalf, 2009) 
and therefore infection by HCV may cause a range of metabolic changes that can be 
identified  not only in the liver itself, but also in blood and urine (Bundy, Davey and 
Viant, 2009; Nicholson et al., 2012).  A highly detailed metabolic profiling of body 
fluids using either nuclear magnetic resonance spectroscopy (NMR) or mass 
spectrometry (MS) techniques is an emerging scientific discipline and there remains 
considerable scope for improving the definition of the metabolic phenotype in liver 
disease  (Wishart et al., 2013).  
The urine is a sterile biofluid produced by the kidneys and useful for  metabolic 
profiling studies (Bujak et al., 2011) as it is the primary route for elimination of  water-
soluble waste products (Bouatra et al., 2013).  Urine has been recognised for centuries 
as an easily accessible human sample for the identification of certain disease-specific 
compounds  (Nicholson and Lindon, 2008; Echeverry, Hortin and Rai, 2010), but it is 
only recently that highly detailed chemical analysis has become possible using high-
field NMR spectroscopy or liquid chromatography mass spectrometry (LC/MS) (Law et 
al., 2008; Navarro-Muñoz et al., 2012).  Urinary metabolome identification may be 
further improved by performing a combination of these analytical methods (Yang et al., 
2008).  The urinary metabolites represent end products of both normal or pathological 
cellular process, and such metabolites are closely linked to the subject’s phenotype 
(Bouatra et al., 2013).  It is an advantage that urine sample collection is non-invasive 
and requires little, if any, subject  preparation (Zhang et al., 2012) and may therefore 
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provide real-time information about the disease state (Beckonert et al., 2007).  Urinary 
metabolic profiling studies can be affected by external confounding factors such as diet, 
lifestyle and medication (Lenz et al., 2003) and, importantly, may also reflect alterations 
in gut microbiota.  A number of statistical tools provide rapid and reliable analysis of 
complex NMR spectra that allow extraction of trends and patterns (Lindon et al., 2000).   
To date little is known about urinary metabolomic profiling in HCV infection.  The 
urinary NMR profiles able to discriminate cirrhosis and hepatocellular carcinoma (HCC)  
have been described in an African population (Shariff et al., 2010, 2011; Ladep et al., 
2014) and more recently in a UK population where multivariate analysis models (with a 
sensitivity and specificity of 53.6% and 96% respectively) reported reduced creatinine, 
citrate and hippurate and elevated carnitine that were comparable with the African 
studies (Shariff et al., 2016).   
I therefore hypothesise that there are host metabolic determinants involved in 
interrupting the HCV life cycle that could potentially confer resistance to HCV exposed 
uninfected cohort.  Therefore, determination of systemic metabolic alterations 
associated with HCV exposed but uninfected cases may provide information on factors 
that confer resistance to HCV infection.  The urine metabolic profiling studies in the EU 
cases may provide such insight.   
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3.3 Results. 
3.3.1 Demographics of the study subjects. 
Baseline demographics and risk behaviour characteristics for the recruited IDU cases 
are summarised in Table 3.1.  There were no significant differences in age or duration 
of injection use between IDU groups.   All subjects were Caucasian and the majority 
were male.  The median age for the healthy control group was 26.1 years and the age 
range was 21 – 39 years.   
Table 3.1 Demographics and injection history for study groups. 
Variable EU (n=38) SR (n=8) CHCV (n=9) 
Gender (Female) 9 3 1 
Gender (Male) 29 5 8 
Age, Range (years) 23 - 58 33 - 53 29 - 50 
Age, Average (years) 33.5 37.6 36.3 
Age, Median (years) 32 36 36 
Caucasian 38 8 9 
Duration of injection use, Range (years) 1-34  2-25  13-30  
Duration of injection use, Average (years) 11.7 13.1 17.5 
Currently injecting 34 6 7 
Sharing behaviour (n)    
Sharing around others 36 7 9 
Shared needles 31 7 9 
Shared syringes 30 7 8 
Shared other drug injecting paraphernalia 35 7 9 
Shared with someone known to have HCV 10 3 2 
Other risk factors:    
Had blood transfusion before 4 1 3 
Had tattoos 32 7 8 
Had body piercing 29 6 7 
Had acupuncture before 8 4 3 
Sex with HCV infected person 6 2 1 
Family member injects drugs 22 5 3 
Imprisoned before 28 6 7 
HCV testing results:    
HCV antibody testing Negative Positive Positive 
HCV RNA results Negative Negative Positive 
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3.3.2 Urinary NMR multivariate analysis. 
The total number of the EUs cases were 38 but 2 individuals (study identification 
numbers SW575 and SW584) did not give urine samples.  Ten urine samples from 
healthy volunteers were provided by the University College London.  Thus, a total of 63 
samples comprising the 36 EUs, 8 SRs, and 9 CHCV (all recruited in Plymouth) and 10 
healthy control (from UCL) samples were analysed for the urinary NMR metabolomics. 
Whilst urinary NMR data from all subjects showed good spectral resolution (linewidths 
of <1Hz) and quality, 21 of 63 HCV data sets (20 cases from Plymouth and one control 
from UCL) were excluded for various confounding factors (dominant signals from 
ethanol (5 EU, 1 SR, 3 CHCV); comparatively strong signals from taurine (3 EU); 
multiple peaks from mannitol (3 EU, 1 SR); resonances from 2-hydroxybutyrate (1 
CHCV); high levels of paracetamol metabolites (1EU); extremely high TMAO levels in 
a fish eater (1 healthy control), and unassigned peaks (1EU, 1 SR).  
The final cohort for multivariate NMR analysis therefore comprised 23 EU, 5 SR, 5 
CHCV, 9 controls.  The NMR spectra showed wide range of metabolites resonances 
observed in the spectra.  The principal component analysis was performed to assess the 
clustering and presence of outliers.    
 
 
 
 
Figure 3.1 below shows the clustering of study groups in a 3D format.   
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Figure 3.1: Urinary NMR class separation. 
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Figure 3.1 (A) shows a 3D factor scores plotted based on the 1H NMR spectra of urine 
obtained from the EUs, SRs, CHCV patients, and healthy control groups.  Factor 
analysis is a variable reduction method used for the identification of observed computed 
variables.  In this 3D plot, the factor analysis assumes that the covariation in the 
observed variables is due to the presence of one or more latent urinary metabolic 
variables (factors) that exert causal influence on these observed variables.  The factors 1, 
2, and 3 estimations are mathematically computed (done by the statistical software), 
presented in a 3D format and estimated by a linear combination of the observed 
variables (e.g. hidden metabolites). (B) shows the urinary NMR class separation ranked 
statistically by the KnowItAll Informatics System v9.0 (Bio-Rad, Philadelphia, PA) 
software. The higher the number in class separation the greater the possible difference 
between groups (e.g. the EUs vs SR class separation is 0.53).  The high difference was 
observed when the EUs were compared to the HCs followed by SRs and CHCV. (C) 
shows the number of factors scored in a 3 D format.  (D) shows an example of a 
chromatogram for factor 1 variables with creatinine peaks (3.03s  –  4.03s) as reference 
points. 
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3.3.3 The Urinary NMR spectra. 
The forty two NMR spectra were of good quality and were usable.  To measure the 
quality of the data, the line with NMR reference standard (TSP) (δ 0.00 ppm) was 
measured (0.5 – 1.0 Hz width).  The normal urine NMR spectra contain the following 
metabolites: the creatinine (3.05s – 4.06s), hippurate (3.98d, 7.55t, 7.64t, and 7.84d), 
creatinine (3.03s  –  4.03s), glycine (3.55s), trimethylamine N-oxide (TMAO) (3.27s), 
dimethylamine (2.72s),  citrate (2.55d and 2.7d), acetate (1.92s); all are endogenously 
synthesised.    
Figure 3.2: Urinary NMR spectrum. 
 
Figure 3.2 shows the urinary NMR spectrum for subject SW580.  Apart from the 
normal urine constituents observed in the NMR spectra, additional components were 
observed from the whole dataset such as; ethanol (1.2m and 3.7m), paracetamol 
metabolites (7.00 – 7.40m and 2.10 – 2.30t ppm), mannitol (3.60m –3.95 ppm), taurine 
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(3.40s – 3.44 ppm), 2-hydroxybutyrate (0.85s – 0.95 ppm), scyllo-inosotol (3.35 – 3.4 
ppm), and unassigned peaks (1.10 – 1.20s ppm and 1.15d ppm). The peak position(s) 
depends on the chemical structure of the metabolite.  The peak height relates to 
concentration of the metabolite.  The numbered peaks represent the matbolites on the 
NMR spectrum (e.g. creatinine fingerprint has two peaks on separate positions).  ppm = 
parts per million (in relation to the 1H chemical shift). The line with NMR reference 
standard (trimethylsilyl propanoic acid (TSP) was assigned δ 0.00 ppm for an internal 
chemical shift reference. s = singlet, d = duplet, t = triplet, m = multiplet. 
3.3.4 Urinary NMR confounding metabolites. 
Assignment of the candidate urinary metabolites was based on the web-accessible 
reference databases of authentic compounds such as Human Metabolome Data Base 
(HMDB)–http://hmdb.ca/ and urine metabolome database (UMDB) – 
http://www.urinemetabolome.ca.   
Out of 63 samples, 21 (33.3%) had possible confounding metabolites (appendix B); that 
were excluded from the analysis.  The following were the confounders: (dominant 
signals from ethanol (5 EU, 1 SR, and 3 CHCV); strong signals from taurine (3 EU); 
multiple peaks from mannitol (3 EU, 1 SR); resonances from 2-hydroxybutyrate (1 
CHCV); increased paracetamol metabolites (1 EU); one control data set from a healthy 
control (known fish eater) was excluded due to high TMAO; and unassigned peaks (1 
EU, and 1 SR).  The final study cohort for multivariate analysis therefore consisted of 
42 subjects (i.e. 23 exposed uninfected cases, 5 spontaneous resolvers, 5 chronic HCV 
cases, and 9 cases from individuals without history of HCV exposure or liver disease).  
The median age for healthy control samples was 26.1, whereas the mean was 24; and 
the age range was 21 – 39 years.   
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3.3.5 NMR metabolites annotation. 
Low citrate levels were observed in 5 out of 63 subjects (7.9%) and were all 
predominantly males (4 EU and 1 SR).  The most prominent peaks recorded in the 42 
samples were creatinine, hippurate, glycine, DMA, citrate, and TMAO.  Refer to Figure 
3.2 for citrate position and fingerprint on the NMR spectrum.   
 
3.3.6 Comparison of discriminating metabolites. 
To investigate the influence of discriminating metabolites on the data, the 
concentrations of creatinine, hippurate and TMAO were determined (Figure 3.3).  The 
concentrations of all the three discriminating urinary metabolites were high as compared 
to other urinary metabolites in the NMR spectra.  Creatinine levels were elevated in HC 
as well as in EU group.  The CHCV group had the least levels of creatinine and 
hippurate but slightly elevated TMAO levels.  
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Figure 3.3: Concentrations of discriminating metabolites. 
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Figure 3.3 shows the different absolute levels of selected metabolites among the four 
study groups.  Each blue block on the graph represents a sample. The differences in 
absolute hippurate and TMAO levels were not significant. 
3.3.7 One-way analysis of variance (ANOVA). 
I analysed the differences of urinary metabolites among EU, SR, CHCV and HC groups 
by comparing the creatinine, hippurate, and TMAO levels.  Bonferroni's Multiple 
Comparison Test was performed and statistical significance was accepted at p <0.05.  
The mean creatinine concentrations were significantly different between EU vs HC (95% 
confidence interval (CI) -0.04650 to -0.01589); SR vs HC (95% CI of difference -
0.06890 to -0.02158); and CHCV vs HC (95% CI of difference -0.06606 to -0.02214).    
The one-way anova t-test statistical differences were again observed for creatinine 
between EU vs HC (Wilcoxon signed rank test p.value < 0.0039) (Figure 3.4). 
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Figure 3.4: Comparison of hippurate, creatinine, and TMAO among EU, SR, CHCV & 
HC study groups. 
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Figure 3.4 shows the different mean concentrations of hippurate, creatinine and TMAO 
among different study groups as analysed by one-way ANOVA.  There was significant 
increase in creatinine levels observed between EU and HC (Wilcoxon signed rank test 
p.value < 0.0039), and HC vs CHCV (p.value < 0.001).  No differences were observed 
in hippurate and TMAO levels among the four cohorts.   
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3.4 Discussion. 
I studied differences in host metabolism by identification and quantification of urine 
metabolic biomarkers by panning strategy using 1H NMR spectroscopy in individuals 
with different outcomes from HCV exposure to seek metabolic correlates of resistance 
to HCV infection. This is the first report of urinary metabolomic profiling in exposed 
uninfected intravenous drug users and I have observed that the urinary NMR metabolic 
profiles have the potential to distinguish different study cohorts.  Multivariate statistical 
analysis identified hippurate, TMAO, and creatinine as the possible discriminatory 
metabolites.  Creatinine distinguished the EUs from the healthy control group. No 
differences were observed for hippurate and TMAO.  
In this study, different metabolites were identified in NMR spectra that were associated 
with either diet, or biological metabolism.  The urinary NMR data from all the subjects 
showed good spectral resolution (TSP linewidth of ≤ 1Hz) and were of high quality.  
However, 21 out of 63 data sets were excluded for a range of confounding factors.     
3.4.1 Confounding metabolites. 
Ethanol: The urinary NMR spectra revealed large peaks of ethanol (1.2m and 3.7m) in 
nine subjects (5 EU, 1 SR, and 3 CHCV).  This demonstrates that ethanol can be 
excreted from normal humans following consumption of alcohol as much as 50 units 
per week.  The few subjects who provided their dietary history, those who accepted 
drinking less than 18 units of alcohol per week did not show ethanol peaks on urine 
spectra.  Therefore all subjects with reported high ethanol levels were excluded from the 
analysis.  
Taurine is an amino acid synthesized endogenously in human adults, abundant in 
kidneys, brain, gallbladder, but largely dietary dependent (Cross, Major and Sinha, 2011) 
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especially consumption of food stuff derived from animal origin (Lissner et al., 2007).  
Despite taurine’s presence in animal produce, it is also an ingredient of some energy 
drinks.  Lack of adequate dietary history in this study makes it difficult to suggest the 
source of taurine in this data.  However, because it is strongly dietary related, it was 
excluded from the analysis.  Excessive alcohol consumption is also related to taurine 
loss in urine and other metabolic disorders; this is consistent with our data where high 
ethanol levels were recorded in this cohort. 
Mannitol is a sugar alcohol poorly absorbed by humans but its presence in urine is 
dietary related.  It is present in fruits such as apples, pineapples, asparagus, and carrots 
(Kern et al., 2003) and other foods such as eggs, meat, milk and fish.  In this data, 
mannitol could possibly be an adulterant in injecting drugs.  It is popularly known as 
‘baby laxative’ among IDUs when it is used in this manner.       
2-hydroxybutyrate:  Urinary excretion of 2-hydroxybutyrate is usually associated with 
high alcohol consumption as well as physical exercise.   2-hydroxybutyric acid is also 
associated with ketoacidosis and lactic acidosis.  Some studies reported increased 2-
hydroxybutyrate as a result of microbial degradation of dietary proteins (Li et al., 2008).  
In this study 2-hydroxybutyrate was high in two EU and CHCV male subjects that 
skewed the data.  This did not demonstrate any specific functional differences between 
the study groups; therefore 2-hydroxybutyrate was excluded from the analysis since 
there was no control mechanism for confounders. 
Paracetamol metabolites: PCA examination of the data set revealed some paracetamol 
peaks on urinary NMR spectra.  All the samples save healthy controls showed some 
trace signals of paracetamol metabolites.  High signals were observed in samples 
SW555, SW578, SW583 and SW586.  All the four subjects were HCV exposed 
uninfected.  Visual inspection of the urine spectra showed tiny peaks of paracetamol 
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that could not be identified as outliers by PCA analysis.  Therefore, those EU samples 
were distinct outliers that skewed the data, and were excluded from the analysis.  
Paracetamol was reported as one of the commonest drugs involved in self poisoning 
episodes in the United Kingdom (Buckley et al., 1995) which may suggest that the 
study participants might have used it as an analgesic.  Paracetamol NMR resonances 
constitute four metabolites (sulfate, glucuronide, cysteinyl, and N-acetyl-cysteinyl 
conjugates).  Glucuronides are the major paracetamol metabolites that are excreted in 
urine within 24 hours (Godejohann et al., 2004). 
Unassigned peaks:  Two data sets were excluded from the analysis due to unassigned 
peaks (1.10 – 1.20s ppm and 1.15d ppm).   
3.4.2 Discriminant metabolites on urinary NMR spectra. 
Hippurate, creatinine and TMAO were the discriminant metabolites on the spectra. 
Hippurate is a gut microbial co-metabolite of benzoic acid that is associated with diet 
and gut microbial activities.  Gut microbes act upon aromatic compounds and 
polyphenols, and hydrolyse hippurate to benzoic acid and subsequently conjugates with 
glycine in mammalian mitochondria (reviewed in (Lees et al., 2013)).  Benzoic acid, 
and consequently hippurate is produced from metabolism of dietary components that are 
transformed through microbial and mammalian co-metabolism (Clifford et al., 2000).  
Alterations in urinary hippurate levels have significantly been associated with gut 
microbial activities.  Studies have reported that animals that are free from intestinal 
microorganisms do not excrete hippurate; but following environmental exposure 
hippurate becomes a dominant metabolite 2 – 3 weeks post-exposure (Nicholls, 
Mortishire-Smith and Nicholson, 2003; Claus et al., 2008).  The role of gut microbiota 
has been investigated through administration of oral antibiotics in animals with an 
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established gut microbiota.  The findings suggest that antibiotic-induced suppression of 
gut microbiota reduce excretion of hippurate levels and its co-metabolites (Williams et 
al., 2002; Yap et al., 2008; Swann et al., 2011). 
Alterations in hippurate levels have also been described in HBV infection (Cox et al., 
2016) and as a urinary biomarker of Hepatocellular carcinoma where hippurate levels 
were significantly reduced in HCC subjects compared to healthy controls but was not 
significantly different compared to cirrhotic patients (Shariff et al., 2011).    
Creatinine levels were significantly increased in healthy controls compared to the three 
cohorts.  Creatinine levels were also significantly higher in the exposed uninfected 
group compared to SR and CHCV patients. There was no statistical difference between 
SR and CHCV groups.  Creatinine is formed through non-enzymatic breakdown of 
creatine in the muscle.  Creatine is involved in muscular energetic metabolism that 
results in phosphocreatine.  Creatinine excretion in the urine is largely dependent on the 
individual’s physical activities and muscle mass (Baxmann et al., 2008).  In this data, 
creatinine gave rise to two singlet peaks (3.03s and 4.03s ppm) in the ratio of 3:2 
according to their NCH3 and CH2 protons.  I therefore speculate that the increased 
creatinine levels among healthy controls could be attributed to possible behavioural 
changes or increased muscle mass among healthy volunteers compared to injection drug 
users in whom poor nutrition is common. Objective assessment of dietary patterns 
among free-living individuals is challenging and has some limitations since the obtained 
information relies on self-reported dietary history (Garcia-Perez et al., 2017).  Dietary 
misreporting prevalence was estimated at 30 – 80% (Rennie, Coward and Jebb, 2007; 
Poslusna et al., 2009) due to utilisation of assessment tools such as questionnaires, and 
dietary diaries  (Garcia-Perez et al., 2017).  In this study I did not monitor the dietary 
history and body mass index (BMI).  
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TMAO was one of the potential metabolite that could be used in urinary NMR 
metabolomics to distinguish study groups.  However, TMAO levels in EUs were not 
significantly different from the comparator groups.  TMAO is a small amine oxide 
derived from dietary choline and phosphatidylcholine (Tang et al., 2014; Kaysen et al., 
2015) through action of gut microbial activities.  Red meat, eggs and dairy products are 
potential sources of TMAO because they are rich in choline, lecithin, and carnitine.  
Intestinal microbes metabolise dietary choline and convert it to trimethylamine (TMA) 
and then TMAO by the liver catalysed by hepatic flavin monooxygenases 3 (FMO3) 
(Koeth et al., 2014).  TMAO was reported to serve as a substrate in metabolism of 
anaerobic marine microbiota; therefore studies have reported increased TMAO levels in 
animals that were colonised with TMA-producing bacteria  but not in animals that were 
colonised with bacteria that do not convert choline to TMA (Romano et al., 2015).  
Therefore this information suggests that TMAO levels are determined by the alteration 
of gut microbiota, hepatic FMO enzymes, and diet.   
Patients with advanced liver disease or  HCC have reduced TMAO levels compared to 
healthy controls (Shariff et al., 2011).  Increased TMAO levels suggest a competent 
liver function through conversion of choline to TMAO.  Therefore TMAO could be an 
important predictor of liver function through its ability to convert choline.  There is no 
published data available about the clinical relevance of TMAO perturbation in 
pathophysiology of liver diseases. Gut microbial activities also affect TMAO levels in 
such a way that reduced microbial activities could potentially reduce TMAO levels and 
vice-versa.   
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3.4.3  Additional NMR metabolites. 
Glycine fingerprints were also detected on NMR spectra from the majority of the 
majority of the samples.  Glycine is a small non-essential amino acid found in human 
proteins synthesized from serine.  Glycine is involved in several functions including 
protein synthesis; and it is an essential component of methylation reaction in cells 
(Ogawa et al., 1998).  Glycine was reported to be a bi-product of hippurate hydrolysis 
to benzoic acid by microbial flora which provides a useful association of this data to the 
involvement of gut microbial activities.  Glycine conjugation of benzoic acid is one of 
the important factors that contribute to hippurate production (Gregus et al., 1993).  In 
this study, urinary glycine levels were increased in some subjects but not significantly 
raised in EU subjects to offer meaningful clustering in principal component analysis.  
Therefore increased glycine production in some EU subjects may have contributed to 
high hippurate levels observed in this study as a result of glycine conjugation of 
benzoate in mitochondria.  This suggests the involvement of intestinal microbial flora in 
determination of urinary metabolites.     
Dimethylamine (DMA) peaks were also detected on NMR spectra.  DMA is an organic 
compound, a weak base that is involved in salt formation following reaction with acids.  
DMA endogenously inhibits nitric oxide synthase (NOS), an enzyme that catalyses the 
production of nitric acid.   DMA levels were not significantly high or low in the study 
population.  Therefore DMA levels could not be identified as a discriminant by PCA.  
However, DMA has exogenous sources related to diet and TMAO is one of the main 
sources that increase DMA urinary levels  (Tsikas et al., 2007) but in this study 
increased TMAO levels did not influence DMA since subjects who has high TMAO did 
not show increased DMA levels.   
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Citrate, a tricarboxylic acid, is a derivative of citric acid, a weak organic acid 
synthesised endogenously in mitochondria through the Krebs cycle (Krebs and Johnson, 
1980); and its metabolic fingerprints were observed in the spectrum.  A greater amount 
of citric acid is present in fruits such as lemon, orange, and vegetables.  Citrate can also 
be transported out of the mitochondria and into the cytoplasm, where it is broken down 
into acetyl-CoA for production of fatty acid.  Citrate levels were significantly reduced in 
all HCV exposed uninfected cohort, predominantly male subjects as opposed to other 
comparator groups.  Studies in HCC patients revealed significant reduction in citrate 
levels in HCC patients as compared to healthy controls, non-significant reduction 
among healthy controls as opposed to cirrhotic patients (Shariff et al., 2011).  Citrate is 
a known factor that inhibits renal stone formation, therefore reduced citrate levels in 
HCV uninfected cohort may be associated with other mechanisms that could be 
associated with risk of kidney stone formation.  The participants could have had other 
underlying pathological conditions that were not reported during participation of this 
study that implicated metabolites levels.   
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3.4.4  Study limitations. 
Despite the interesting findings there are a number of limitations to this study.  No 
standardised dietary history was taken and no dietary restrictions imposed before 
sample collection in this study; only 10 subjects submitted a dietary history for the 24 
hours before sample collection.  It is therefore possible that high levels of the possible 
discriminant urinary metabolites were dietary related rather than a marker of metabolic 
differences between the groups.  
A large part of the original dataset was excluded from the full analysis due to presence 
of confounding factors; consequently reducing the sample size. As a result, our 
conclusions are largely observational and it is possible that they significantly concealed 
the trends and meaningful association between the identified metabolites and any 
consequence of biological differences.   
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3.5 Conclusion. 
The urinary metabolic profiling have the potential to distinguish study groups.  This 
study identified creatinine as the main urinary metabolite that distinguished the EUs 
from the control groups.  There was no statistical difference observed for hippurate and 
TMAO metabolites.  The computed analysis in multivariate analysis observed that 
hippurate and TMAO were slightly elevated but the differences were statistically 
insignificant.  
The mechanism of resistance to HCV in exposed uninfected cases remains unclear, 
although a potential link between the gut microbiome and resistance to HCV infection 
using urine metabonomics approach may be of interest.  At present these findings are 
unverified but warrant further study in additional cases with a clear dietary history and 
BMI evaluation.  The study was limited by lack of dietary history and metabolic 
information.  The sample numbers were reduced due to confounders; therefore the 
findings are observational and descriptive.  Therefore this data paves the way for future 
studies in a bigger cohort to assess the link between gut microbial activities and 
resistance for HCV infection.   
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4 CHAPTER FOUR 
 
4.1 Determination of serum apolipoprotein profiles and lipidomics in exposed 
uninfected cases compared to other groups. 
4.2  Background.  
The HCV life cycle is reported to be associated with lipoprotein metabolic pathways.  
HCV utilises virally encoded envelope glycoproteins, and cellular protein 
apolipoprotein E (ApoE) (Jiang et al., 2012) and other apolipoproteins for attachment 
onto the host cellular receptors.  The apolipoproteins are present on the outer surface of 
lipoprotein particles and play an important role in lipoprotein metabolism as well as 
ensuring adhesion of HCV into cellular receptors.  The liver is the central platform for 
lipoprotein/apolipoprotein metabolism in the body.  The triglycerides, cholesterol, and 
proteins are the main constituents of lipoproteins which transport lipids around the body.  
The protein component of lipoproteins is used to emulsify lipid/fat molecules.   An 
essential stage in the HCV lifecycle is the formation of lipoviral particles that are 
associated with different lipoproteins (Dao Thi, Dreux and Cosset, 2011).  The 
formation of LVPs possibly obscures the virus from host immune response, which may 
in turn help the virus to gain entry into the host cell  (André et al., 2005).  Previous 
studies reported that reduced serum lipid levels in HCV infection are also associated 
with PEG-IFN treatment failure (Bassendine et al., 2013).  Since the ApoE is an 
important ligand for receptor mediated removal of triglyceride rich lipoproteins by the 
liver (Bassendine et al., 2013), the determination of their levels in EU cohort would 
strongly link the purported resistance that has been observed in this unique cohort of 
IDUs.  No published studies have reported the apolipoprotein profiles in HCV exposed 
uninfected cohort.  
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One of the strategies employed by HCV to escape immune surveillance and establish 
persistent infection is exploiting the lipid pathways.  The production of infectious HCV 
is dependent on the export of VLDL by the hepatocytes and the HCV replication cycle 
depends on host lipid pathways (Bassendine et al., 2011).  The HCV interacts with host 
lipid metabolism at all stages of the viral lifecycle - from attachment and entry into 
hepatocytes, to replication and assembly of new viral particles.  The circulating HCV is 
associated with lipoproteins as complex ‘lipoviral particles’ (LVP) (Piver, Roingeard 
and Pagès, 2010) which contain viral RNA, viral proteins, and host apolipoprotein 
constituents including apoB, apoE, apoA1, and apoC (Diaz et al., 2006).  Growing 
evidence suggests that the LVP lipid and apolipoprotein components facilitate viral 
attachment to host cells by binding to cellular lipoprotein receptors and that the 
exchangeable ApoE appears to be crucial for infectivity at the attachment step and at 
masking envelope glycoproteins from neutralising antibodies (Fauvelle et al., 2016).  
The HCV association with lipoproteins may also be one means by which circulating 
HCV can avoid immunoglobulin recognition and evade the host’s immune surveillance.  
Given this co-dependency on host lipid pathways, any mechanism that would disrupt 
the LVP formation would potentially reduce the viral infectivity and influence outcome 
following HCV exposure (Shawa, Sheridan, et al., 2017).   
I carried out apolipoprotein profiling to assess if there were significant differences in 
apolipoprotein profiles in HCV exposed uninfected cases as opposed to the comparator 
groups.  Therefore, I considered the whole lipidomics investigation to observe if there 
are lipid profiles distinct in EUs.    
Furthermore, LC-MS allows for a highly detailed and quantitative analysis of all the 
lipid constituents found in the serum; and allows distinguishing between them due to its 
high sensitivity and stability.  The analysis of serum lipid perturbations using this 
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allows us to interrogate and better understand the mechanisms associated with HCV 
resistance.  Either fasting or non-fasting blood samples are less important in this method 
in view of previous studies that did not show significant differences in lipids, 
lipoproteins and apolipoproteins profiling between non-fasting and fasting serum 
samples with the exception of triglycerides, which were higher in non-fasting state 
(Nordestgaard, 2009).  Therefore I performed serum lipidomics on non-fasting samples 
as described in the methods chapter (Chapter 2).  Given the importance of lipid 
pathways for all stages of the viral life cycle, we have investigated whether variation in 
the lipidome of apparently HCV-resistant individuals may be associated with the EU 
phenotype. 
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4.3 Results. 
In this Chapter I have taken two approaches investigating the association between 
perturbations in lipid metabolism and HCV resistance.  First, I have studied serum 
apolipoproteins, and secondly serum lipidomics profiling on non-fasting samples.   
The lipidome of 386 serum samples were analysed comprising 60 EU cases (collected 
in Plymouth), 36 SR (16 cases collected in Plymouth, whereas 20 additional cases were 
provided by HCVRUK), 159 CHCV patients (9 collected in Plymouth, the rest were 
from HCVRUK), 100 SVR samples from HCVRUK, and 31 healthy controls (all from 
Plymouth).  All samples were stored in John Bull research laboratory, and later 
transported to London on dry ice.  Refer to Chapter 2 for details of sample collection, 
processing, storage, transport and analysis.   
Serum apolipoprotein levels were measured by our collaborators at University of 
Newcastle.  I went to Imperial College London for training and performing lipidomics 
experiments using LC-MS.  There were no statistical apolipoprotein differences in EUs 
and the other groups.  Serum lipidomics findings were relevant and offered more 
meaningful relationships. 
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4.3.1 Study subjects for apolipoprotein profiling. 
Apolipoproteins A1, apoB, and apoE levels in a total of 61 non-fasting serum samples 
were studied.  They comprised 22 HCV exposed uninfected, 8 spontaneous resolvers, 
and 31 healthy controls.  No significant differences were observed in apolipoprotein 
levels among all study cohorts. 
Figure 4.1: Apolipoprotein levels in different cohorts. 
 
 
Figure 4.1 shows comparison of apolipoprotein levels in EU, SR, HC and chronic HCV 
patients.  There were no statistically significant differences observed in apolipoproteins 
A1, B and E between the four groups (Figure 4.1 A, B, and C).  Apo A1 Mann Whitney 
test: EU vs SR (p.value <0.38); EU vs CHCV (p.value <0.21); EU vs HC (p.value 
<0.81).  ApoB Mann Whitney test: EU vs SR (p.value <0.57); EU vs CHCV (p.value 
<0.45); EU vs HC (p.value <0.55).  ApoE Mann Whitney test: EU vs SR (p.value 
<0.67); EU vs CHCV (p.value <0.79); EU vs HC (p.value <0.52).   
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4.3.2 Study subjects for serum lipidomics. 
All the study participants were Caucasians and the mean ages for EUs, SRs, and CHCV 
groups were 32, 36, and 36.3 years respectively.  A total of 386 subjects were analysed 
comprising 60 EUs, 31 HC, 36 SRs, 100 SVRs, and 159 CHCV, utilising EU cases 
collected locally and additional SR, SVR, and CHCV samples from the HCV Research 
UK (HCVRUK) biobank as described in the methods section (Chapter 2).  UPLC-MS 
of all the serum samples were acquired and analysed using multivariate methods in 
order to determine the differences in lipid profiles in EUs versus different comparator 
groups.  Statistical estimations utilising XCMS package within the R statistical software 
and SIMCA were performed. 
Table 4.1: Demographics for the serum UPLC-MS lipidomics profiling. 
 
Characteristic EU 
(n=38) 
SR  
(n=28) 
SVR  
(n=100) 
CHCV  
(n=159) 
HCV Ab Negative Positive Positive Positive 
HCV RNA Negative Negative Negative Positive 
Age (Mean) 
(years) 
32 36 48+/-5 years 48+/-5 years 
Age range 
(years) 
23 - 58 33 - 53  43-53 43-53 
Gender 
(M/F) % 
76.3/23.7 62.5/37.5 70/30 70/30 
Cirrhosis (%) None None 25% compensated 
cirrhosis 
25% compensated 
cirrhosis 
Anti-viral 
treatment 
None None Peg-IFN/Ribavirin None 
Table 4.1shows the demographics of the cases studied for the UPLC-MS lipidomics.  
All the EU (38) and some SR (8), and 9 (CHCV) cases were recruited from Plymouth.  
Additional 20 SR , 100 SVR and 150 CHCV cases were provided by the HCVRUK. 
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4.3.3 Initial lipidomics PCA for all samples including quality controls (QCs) in 
both ESI+ and ESI- modes.  
The LC-MS lipidomics analysis generates a vast amount of data but its analysis is 
highly complex requiring use of a variety of statistical methods.  Some lipid classes may 
comprise more than 100 different species, their routine quantification represents a great 
challenge.  In this study, the approach used for data pre-processing, multivariate 
analysis, filtration and peak identification was performed using XCMS package within 
the R statistical software and SIMCA (details provided in the Methods chapter, Section 
2.9.2.4).  The serum lipidomics features for all the study groups were modelled together 
using the principal component analysis that aids visualisation of major sources of 
variations in the data.  Different high-tech models were explored which showed that 
serum contains a wealth of lipidomics information that provide deeper understanding of 
lipid species that distinguish the groups.  In this Chapter, data mining and multivariate 
data analysis has been presented with unsupervised PCA and supervised OPLS-DA.  A 
combination of S- and VIP plots generated from the OPLS-DA models were carried out 
that selected distinct lipid features as potential markers for distinguishing the EUs from 
the control groups. 
The PCA was created on the matrix of 386 variables comprising 60 EUs, 31 HC, 36 
SRs, 100 SVRs, and 159 CHCV collected from Plymouth and some were provided by 
the HCVRUK as previously described in Section 2.2.3.   Trends and patterns were 
observed in this PCA (encircled).  Further interrogation revealed that the clustered 
samples went through increased freeze-thawing cycles.  The QC samples clustered 
together defining the system suitability, analytical stability, and sample repeatability.     
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Figure 4.2: PCA for combined cohorts. 
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Figure 4.2 shows (A) shows the scores plots of principal components analysis (PCA) 
model generated from the ultra-performance liquid chromatography mass spectrometry 
(UPLC-MS) analysis of serum samples, and quality controls (QCs).  (A) and (B) show 
green and blue histograms that represent R2 and Q2 in both positive and negative 
electrospray ionisation modes (ESI+ and ESI-).  The R2 is a measure of fit, i.e. how well 
the model fits the data and Q2 indicates how well the model predicts new data.  A large 
R2 (close to 1) is a necessary condition for a good model, but it is not sufficient.  
Because Multivariate Analysis separates out useful information from the noise a low R2 
indicates a large amount of noise or irrelevant information in the data.  The Q2 indicates 
how well the model predicts new data, with a large Q2 (Q2 > 0.5) indicating good 
predictivity.  Both R2 and Q2 are established statistical data presentation methods used 
to confirm the validity of the models of the data.  (C) and (D) show PCA for all the 
samples in both ESI+ and ESI- (C and D respectively).  A dot represents one sample, 
and they are coloured according to different groups.  The tight grouping of the QCs, 
which are run at the same time with the samples, highlights the instrument stability and 
reliability of the assay. 
The X and Y axes are derived from the development of the PCA as orthogonal linear 
combinations of the factors exhibited in the dataset. The PCA are the linear 
combinations of the original variables. In this scores plot, the original factors were not 
assigned units since they were patients recognizable study numbers, therefore the PCA 
won't have a unit. Consequently, the units are the crude components scores.  The X and 
Y axes in a PCA plot correspond to a mathematical transformation the X-axis (PC1 – 
the ﬁrst principal component) and the second principal component (Y-axis) so that data 
can be displayed in two dimensions.  In this initial analysis there was a mixed group of 
outliers from healthy controls, EU and SR cases that underwent increased freeze-thaw 
cycles.   
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4.3.4 PCA for all samples after removing the old samples. 
This PCA plot provided good graphical overview of the entire data in multivariate 
analysis after exclusion of old samples.   The old samples undergoing multiple freeze-
thaw cycles comprised all healthy controls (31), 22 EUs, and 8 SRs.  The subsequent 
supervised models were prepared from this PCA.  
   
Figure 4.3: PCA model for all samples after excluding old samples. 
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Figure 4.3 shows the scores plots of the principal components analysis (PCA) model 
generated from the ultra-performance liquid chromatography mass spectrometry 
(UPLC-MS) analysis of serum samples after excluding old samples that had increased 
freeze-thaw cycles.  (A) and (B) show the PCA for all the samples in both ESI+ and 
ESI- respectively.  A dot represents one sample, and they are coloured according to 
different groups.   
The X and Y axes are derived from the development of the PCA as orthogonal linear 
combinations of the factors exhibited in the dataset. The PCA are the linear 
combinations of the original variables. In this scores plot, the original factors were not 
assigned units since they were patients recognizable study numbers, therefore the PCA 
won't have a unit. Consequently, the units are the crude components scores.  The X and 
Y axes in a PCA plot correspond to a mathematical transformation the X-axis (PC1 – 
the ﬁrst principal component) and the second principal component (Y-axis) so that data 
can be displayed in two dimensions. 
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4.3.5 Is the lipidome different between the EU and HCV susceptible cases? 
This model shows lipidomics analysis comparing lipid profiles in serum from HCV 
‘susceptible’ with HCV ‘resistant’ cases in order to observe if the HCV resistance is 
associated with a different lipidome than in those susceptible to HCV.  The multivariate 
analysis was performed from HCV susceptible cases, who were all HCV antibody 
positive and divided into 3 categories of 1) chronic infection (HCV RNA positive) 
[CHCV] 2) sustained viral responders to previous anti-viral treatment (HCV RNA 
negative), [SVR] or 3) spontaneous resolvers (HCV RNA negative) [SR]. The 
lipidomes of these groups was compared to HCV ‘resistant’ exposed uninfected cases.  
The PCA and OPLS-DA were performed on all data and showed that the HCV exposed 
uninfected cohort had very distinctly different lipidomics features from all the HCV 
‘susceptible’ groups including CHCV, SVR and SR in both positive and negative 
ionisation modes (Shawa, Sheridan, et al., 2017).  
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Figure 4.4: EUs vs HCV Ab+ groups. 
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Figure 4.4 shows multivariate analysis the principal component analysis (PCA) and 
orthogonal projections to latent structures discriminant analysis (OPLS-DA) for HCV 
‘resistant’ cases [n=38]) compared to HCV ‘susceptible’ (HCV antibody positive, 
[n=295]), including chronic HCV patients genotypes 1 or 3 (HCV RNA positive 
[n=159]), sustained virological responders (SVR) [n=100] and spontaneous resolvers 
[n=36] (Shawa, Sheridan, et al., 2017).   
 The scores plots (OPLS-DA) models (‘A’ and ‘B’ in both ESI+ and ESI- respectively) 
generated from the ultra-performance liquid chromatography mass spectrometry 
(UPLC-MS) analysis of serum samples.  A dot represents one sample, and they are 
coloured according to different groups.  The data was subjected to multivariate 
statistical analysis using SIMCA-P (version 14.1, Umetrics, Umeå, Sweden).  The 
statistical estimations utilising XCMS package within the R statistical software and 
SIMCA were performed using ANOVA of the cross-validated residuals (CV-ANOVA).  
The serum lipidomics features distinguished the EU from the HCV Ab+ groups in both 
ESI+ and ESI- (p.value <1.5 x10-024, and <2.5 x10-021 respectively). 
The X and Y axes are derived from the development of the PCA as orthogonal linear 
combinations of the factors exhibited in the dataset. The PCA are the linear 
combinations of the original variables. In this scores plot, the original factors were not 
assigned units since they were patients recognizable study numbers, therefore the PCA 
won't have a unit. Consequently, the units are the crude components scores.  The X and 
Y axes in a PCA plot correspond to a mathematical transformation the X-axis (PC1 – 
the ﬁrst principal component) and the second principal component (Y-axis) so that data 
can be displayed in two dimensions. 
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4.3.6 Analysis for EU vs CHCV group.  
The 38 EU cases were compared to 159 CHCV cases.  Figure 4.5 compares non-viremic 
EU cases (green dots) vs viremic (red dots) cases.  The lipidomics analysis showed clear 
segregation of the 2 groups with highly significant differences between EU cases and 
CHCV patients.  
 
Figure 4.5: EU compared to CHCV patients. 
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Figure 4.5 shows multivariate analysis the principal component analysis (PCA) and 
orthogonal projections to latent structures discriminant analysis (OPLS-DA) for the EU 
vs CHCV patients.   
The scores plots (OPLS-DA) models (‘A’ and ‘B’ in both ESI+ and ESI- respectively) 
generated from the ultra-performance liquid chromatography mass spectrometry 
(UPLC-MS) analysis of serum samples.  A dot represents one sample, and they are 
coloured according to different groups.  The data was subjected to multivariate 
statistical analysis using SIMCA-P (version 14.1, Umetrics, Umeå, Sweden).  The 
statistical estimations utilising XCMS package within the R statistical software and 
SIMCA were performed using ANOVA of the cross-validated residuals (CV-ANOVA).  
The serum lipidomics features distinguished the EU from the CHCV patients in both 
ESI+ and ESI- (p.value <2.1 x10-16, and <7.9 x10-31 respectively). 
The X and Y axes are derived from the development of the PCA as orthogonal linear 
combinations of the factors exhibited in the dataset. The PCA are the linear 
combinations of the original variables. In this scores plot, the original factors were not 
assigned units since they were patients recognizable study numbers, therefore the PCA 
won't have a unit. Consequently, the units are the crude components scores.  The X and 
Y axes in a PCA plot correspond to a mathematical transformation the X-axis (PC1 – 
the ﬁrst principal component) and the second principal component (Y-axis) so that data 
can be displayed in two dimensions. 
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4.3.7 Host’s susceptibility to HCV infection and the ability to resolve 
spontaneously (EU vs SR). 
The lipidomics multivariate analysis was also able to distinguish the two groups that 
were both aviremic (i.e. HCV RNA negative), the EUs who were both HCV antibody 
and HCV RNA negative and the SRs were HCV Ab positive and RNA negative.  The 
LC-MS serum lipidomics analysis clearly distinguished the EUs from the SRs (p-value 
<0.0005 and p-value <0.005 for both positive and negative ionisation modes 
respectively).  
Figure 4.6: The EU compared to the SRs. 
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Figure 4.6 shows multivariate analysis the principal component analysis (PCA) and 
orthogonal projections to latent structures discriminant analysis (OPLS-DA) for the EU 
vs the spontaneous resolvers (SRs).   
The scores plots (OPLS-DA) models (‘A’ and ‘B’ in both ESI+ and ESI- respectively) 
generated from the ultra-performance liquid chromatography mass spectrometry 
(UPLC-MS) analysis of serum samples.  A dot represents one sample, and they are 
coloured according to different groups.  The data was subjected to multivariate 
statistical analysis using SIMCA-P (version 14.1, Umetrics, Umeå, Sweden).  The 
statistical estimations utilising XCMS package within the R statistical software and 
SIMCA were performed using ANOVA of the cross-validated residuals (CV-ANOVA).  
The serum lipidomics features distinguished the EU from the SRs in both ESI+ and 
ESI- (p.value <0.004, and <0.005 respectively). 
The X and Y axes are derived from the development of the PCA as orthogonal linear 
combinations of the factors exhibited in the dataset. The PCA are the linear 
combinations of the original variables. In this scores plot, the original factors were not 
assigned units since they were patients recognizable study numbers, therefore the PCA 
won't have a unit. Consequently, the units are the crude components scores.  The X and 
Y axes in a PCA plot correspond to a mathematical transformation the X-axis (PC1 – 
the ﬁrst principal component) and the second principal component (Y-axis) so that data 
can be displayed in two dimensions. 
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4.3.8 Host’s susceptibility to HCV infection and the ability to resolve the infection 
following anti-HCV therapy.  
Figure 4.7 shows comparison of two aviraemic groups but one group were susceptible 
to HCV infection but cleared the infection following IFN-base therapy (SVRs).  This 
study has also revealed that the EUs have distinctly different lipid profiles from SVRs 
(p-value <0.0, and p-value <6.9 x 10-30 for positive and negative ionisation modes 
respectively).   
Figure 4.7: The EU compared to the sustained viral responders (SVRs). 
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Figure 4.7 shows multivariate analysis the principal component analysis (PCA) and 
orthogonal projections to latent structures discriminant analysis (OPLS-DA) for the EU 
vs the sustained viral responders (SVRs).   
The scores plots (OPLS-DA) models (‘A’ and ‘B’ in both ESI+ and ESI- respectively) 
generated from the ultra-performance liquid chromatography mass spectrometry 
(UPLC-MS) analysis of serum samples.  A dot represents one sample, and they are 
coloured according to different groups.  The data was subjected to multivariate 
statistical analysis using SIMCA-P (version 14.1, Umetrics, Umeå, Sweden).  The 
statistical estimations utilising XCMS package within the R statistical software and 
SIMCA were performed using ANOVA of the cross-validated residuals (CV-ANOVA).  
The serum lipidomics features distinguished the EU from the SVRs in both ESI+ and 
ESI- (p.value <0.00, and <6.9 x 10-30 respectively). 
The X and Y axes are derived from the development of the PCA as orthogonal linear 
combinations of the factors exhibited in the dataset. The PCA are the linear 
combinations of the original variables. In this scores plot, the original factors were not 
assigned units since they were patients recognizable study numbers, therefore the PCA 
won't have a unit. Consequently, the units are the crude components scores.  The X and 
Y axes in a PCA plot correspond to a mathematical transformation the X-axis (PC1 – 
the ﬁrst principal component) and the second principal component (Y-axis) so that data 
can be displayed in two dimensions. 
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4.3.9 Resolution of HCV infection by different mechanisms. 
The resolution of HCV infection separated both groups that were previously infected 
but cleared the infection by different mechanisms.  In order to evaluate whether HCV 
specific variation in the lipidome persists after HCV resolution following treatment or 
spontaneous resolution, a supervised model was created.  This OPLS-DA shows clear 
distinction in lipidomics species between the SRs and SVRs. 
Figure 4.8: Spontaneous resolvers compared to a group that received IFN-based therapy. 
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Figure 4.8 shows multivariate analysis the principal component analysis (PCA) and 
orthogonal projections to latent structures discriminant analysis (OPLS-DA) for two 
groups that were both susceptible to HCV infection but cleared the infection by 
different mechanisms, the spontaneous resolvers (SRs) vs the sustained viral responders 
(SVRs). 
The scores plots (OPLS-DA) models (‘A’ and ‘B’ in both ESI+ and ESI- respectively) 
generated from the ultra-performance liquid chromatography mass spectrometry 
(UPLC-MS) analysis of serum samples.  A dot represents one sample, and they are 
coloured according to different groups.  The data was subjected to multivariate 
statistical analysis using SIMCA-P (version 14.1, Umetrics, Umeå, Sweden).  The 
statistical estimations utilising XCMS package within the R statistical software and 
SIMCA were performed using ANOVA of the cross-validated residuals (CV-ANOVA).  
The serum lipidomics features distinguished the EU from the SVRs in both ESI+ and 
ESI- (p.value <0.001, and <0.0004 respectively). 
The X and Y axes are derived from the development of the PCA as orthogonal linear 
combinations of the factors exhibited in the dataset. The PCA are the linear 
combinations of the original variables. In this scores plot, the original factors were not 
assigned units since they were patients recognizable study numbers, therefore the PCA 
won't have a unit. Consequently, the units are the crude components scores.  The X and 
Y axes in a PCA plot correspond to a mathematical transformation the X-axis (PC1 – 
the ﬁrst principal component) and the second principal component (Y-axis) so that data 
can be displayed in two dimensions. 
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4.3.10 Host’s ability to clear the HCV infection, and establishment of chronic 
infection. 
The figure below describes an OPLS-DA model for two groups that were both 
susceptible to HCV infection.  The SRs were HCV Ab positive but HCV RNA negative; 
whereas CHCV cases were both HCV Ab and RNA positive.  The two groups displayed 
different lipid features as observed in this model.  The CHCV group did not receive any 
treatment at the time of the study. 
Figure 4.9: OPLS-DA models comparing SRs vs CHCV. 
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Figure 4.9 shows multivariate analysis the principal component analysis (PCA) and 
orthogonal projections to latent structures discriminant analysis (OPLS-DA) for the 
spontaneous resolvers (SRs) vs the chronic HCV (CHCV) patients. 
The scores plots (OPLS-DA) models (‘A’ and ‘B’ in both ESI+ and ESI- respectively) 
generated from the ultra-performance liquid chromatography mass spectrometry 
(UPLC-MS) analysis of serum samples.  A dot represents one sample, and they are 
coloured according to different groups.  The data was subjected to multivariate 
statistical analysis using SIMCA-P (version 14.1, Umetrics, Umeå, Sweden).  The 
statistical estimations utilising XCMS package within the R statistical software and 
SIMCA were performed using ANOVA of the cross-validated residuals (CV-ANOVA).  
The serum lipidomics features distinguished the EU from the SVRs in both ESI+ and 
ESI- (p.value <1.9 x 10-14, and <1.1 x 10-6 respectively). 
The X and Y axes are derived from the development of the PCA as orthogonal linear 
combinations of the factors exhibited in the dataset. The PCA are the linear 
combinations of the original variables. In this scores plot, the original factors were not 
assigned units since they were patients recognizable study numbers, therefore the PCA 
won't have a unit. Consequently, the units are the crude components scores.  The X and 
Y axes in a PCA plot correspond to a mathematical transformation the X-axis (PC1 – 
the ﬁrst principal component) and the second principal component (Y-axis) so that data 
can be displayed in two dimensions.  
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4.3.11 The viral effect on lipidome (CHCV vs SVR). 
A serum lipidomics was analysed to assess the viral effect on the lipidome by 
comparing two separate HCV susceptible groups i.e. the chronic HCV (CHCV) patients 
and the sustained viral responders (SVRs).  The 150 CHCV cases were treatment naïve 
and comprised 50% HCV genotype 1 and 50% HCV genotype 3 with 25% compensated 
cirrhosis.  The SVRs achieved a sustained response following PEG-IFN and RBV based 
therapy.  Further 100 HCV RNA negative sera post SVR was provided by the 
HCVRUK consisting of 50 HCV genotype 1 and 50 HCV genotype 3 SVRs also with 
25% compensated cirrhosis.  All samples were provided by the HCVRUK biobank in 
Glasgow.  This was utilized to evaluate whether HCV specific variation in the lipidome 
persists after sustained viral response, or resolvers.  The serum lipidomics showed that 
there are some differences in lipid features between the CHCV patients and SVR serum 
lipidomics post treatment.   
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Figure 4.10: The CHCV compared to SVRs. 
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Figure 4.10 shows multivariate analysis the principal component analysis (PCA) and 
orthogonal projections to latent structures discriminant analysis (OPLS-DA) for the 
CHCV patients compared to the SVRs. 
The scores plots (OPLS-DA) models (‘A’ and ‘B’ in both ESI+ and ESI- respectively) 
generated from the ultra-performance liquid chromatography mass spectrometry 
(UPLC-MS) analysis of serum samples.  A dot represents one sample, and they are 
coloured according to different groups.  The data was subjected to multivariate 
statistical analysis using SIMCA-P (version 14.1, Umetrics, Umeå, Sweden).  The 
statistical estimations utilising XCMS package within the R statistical software and 
SIMCA were performed using ANOVA of the cross-validated residuals (CV-ANOVA).  
The serum lipidomics features distinguished the CHCV from the SVRs in both ESI+ 
and ESI- (p.value <6.4 x 10-016, and <4.4 x 10-006 respectively). 
The X and Y axes are derived from the development of the PCA as orthogonal linear 
combinations of the factors exhibited in the dataset. The PCA are the linear 
combinations of the original variables. In this scores plot, the original factors were not 
assigned units since they were patients recognizable study numbers, therefore the PCA 
won't have a unit. Consequently, the units are the crude components scores.  The X and 
Y axes in a PCA plot correspond to a mathematical transformation the X-axis (PC1 – 
the ﬁrst principal component) and the second principal component (Y-axis) so that data 
can be displayed in two dimensions. 
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4.3.12 Exposed uninfected compared to health controls. 
The trends observed in the unsupervised PCA for all cohorts showed clustering of all 
samples that were subjected to increased freeze-thawing cycles.  22 EU and 31 health 
control samples were analysed separately.  This OPLS-DA model shows clear 
separation of the EUs from the healthy controls.    
Figure 4.11: The EUs compared to healthy controls. 
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Figure 4.11 shows multivariate analysis the principal component analysis (PCA) and 
orthogonal projections to latent structures discriminant analysis (OPLS-DA) for the EU 
vs healthy control (HC) group.  All these samples were collected in Plymouth but 
underwent an increased free-thaw cycles.  In this model the EUs are clearly distinctly 
different from the HCs. 
The scores plots (OPLS-DA) models (‘A’ and ‘B’ in both ESI+ and ESI- respectively) 
generated from the ultra-performance liquid chromatography mass spectrometry 
(UPLC-MS) analysis of serum samples.  A dot represents one sample, and they are 
coloured according to different groups.  The data was subjected to multivariate 
statistical analysis using SIMCA-P (version 14.1, Umetrics, Umeå, Sweden).  The 
statistical estimations utilising XCMS package within the R statistical software and 
SIMCA were performed using ANOVA of the cross-validated residuals (CV-ANOVA).  
The serum lipidomics features distinguished the EU from the SVRs in both ESI+ and 
ESI- (p.value < 3.2 x 10-5, and < 3.2 x 10-5 respectively). 
The X and Y axes are derived from the development of the PCA as orthogonal linear 
combinations of the factors exhibited in the dataset. The PCA are the linear 
combinations of the original variables. In this scores plot, the original factors were not 
assigned units since they were patients recognizable study numbers, therefore the PCA 
won't have a unit. Consequently, the units are the crude components scores.  The X and 
Y axes in a PCA plot correspond to a mathematical transformation the X-axis (PC1 – 
the ﬁrst principal component) and the second principal component (Y-axis) so that data 
can be displayed in two dimensions.  
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4.3.13 ELISpot positive EUs vs ELISpot negative vs CHCV. 
One potential criticism of the exposed uninfected cohort is that in the absence of 
serological evidence of infection, the presumed exposure and evidence of resistance to 
infection with HCV is determined by history alone.  The presence of HCV-specific T 
cell responses does provide confirmation of HCV exposure but is found in only around 
half of the EU cases.  This comparison was to see if there are any differences in 
lipidome between the EU cases with HCV-specific T cell responses from those without. 
The demonstration of HCV specific T cell responses using an IFN-gamma ELISpot is 
described in Chapter 5.  No differences were seen between the EU with or without T 
cell responses.  This suggests that the EU cohort as defined by injection history is 
uniform and that the lack of T cell responses is not likely to indicate lack of exposure as 
described in Chapter 5.      
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Figure 4.12: The IFN-γ positive versus IFN-γ negative EUs. 
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Figure 4.12 shows multivariate analysis the principal component analysis (PCA) and 
orthogonal projections to latent structures discriminant analysis (OPLS-DA) for EU 
cases that were categorised as ELISpot positive or negative. 
The scores plots (OPLS-DA) models (‘A’ and ‘B’ in both ESI+ and ESI- respectively) 
generated from the ultra-performance liquid chromatography mass spectrometry 
(UPLC-MS) analysis of serum samples.  A dot represents one sample, and they are 
coloured according to different groups.  The data was subjected to multivariate 
statistical analysis using SIMCA-P (version 14.1, Umetrics, Umeå, Sweden).  The 
statistical estimations utilising XCMS package within the R statistical software and 
SIMCA were performed using ANOVA of the cross-validated residuals (CV-ANOVA).  
The serum lipidomics features distinguished the EU from the SVRs in both ESI+ and 
ESI- (p.value < 0.97, and < 0.1 respectively). 
The X and Y axes are derived from the development of the PCA as orthogonal linear 
combinations of the factors exhibited in the dataset. The PCA are the linear 
combinations of the original variables. In this scores plot, the original factors were not 
assigned units since they were patients recognizable study numbers, therefore the PCA 
won't have a unit. Consequently, the units are the crude components scores.  The X and 
Y axes in a PCA plot correspond to a mathematical transformation the X-axis (PC1 – 
the ﬁrst principal component) and the second principal component (Y-axis) so that data 
can be displayed in two dimensions.  
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4.3.14 Sample collection centres. 
Figure 4.13 shows a PCA for all samples collected at different centres. There was no 
difference observed in lipidomics features between samples collected in Plymouth and 
those obtained from the biobank.  
Figure 4.13: Plymouth samples compared to HCVRUK biobank samples. 
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Figure 4.13 shows multivariate analysis the principal component analysis (PCA) and 
orthogonal projections to latent structures discriminant analysis (OPLS-DA) for samples 
collected in Plymouth vs HCVRUK biobank samples. 
The scores plots (OPLS-DA) models (‘A’ and ‘B’ in both ESI+ and ESI- respectively) 
generated from the ultra-performance liquid chromatography mass spectrometry 
(UPLC-MS) analysis of serum samples.  A dot represents one sample, and they are 
coloured according to different groups.   
The X and Y axes are derived from the development of the PCA as orthogonal linear 
combinations of the factors exhibited in the dataset. The PCA are the linear 
combinations of the original variables. In this scores plot, the original factors were not 
assigned units since they were patients recognizable study numbers, therefore the PCA 
won't have a unit. Consequently, the units are the crude components scores.  The X and 
Y axes in a PCA plot correspond to a mathematical transformation the X-axis (PC1 – 
the ﬁrst principal component) and the second principal component (Y-axis) so that data 
can be displayed in two dimensions.  
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4.3.15 Preliminary assignment of lipid species in lipidomics profiling. 
Assignment of lipid profiling features that distinguish the EU cohort from other classes 
revealed phosphatidylcholines and triglycerides were significantly elevated in EUs 
compared to CHCV patients.  The discriminant compounds (not annotated) between the 
EUs and the SVRs had very low retention times, eluting very early in the 
chromatographic domain along with the solvent front.  Therefore, such polar 
compounds were not easily annotated using the online databases and were classified as 
unknowns.  
Table 4.2 Assigned lipid compounds. 
 
 Lipid species 
assigned 
Ions Formula Mass rt ppm 
error 
EU vs 
CHCV 
PC(32:1) M+H C40H78NO8P 184.0742 5.57 5 
PC(34:1) M+H C42H82NO8P 759.5778 7.29 3 
PC(34:2) M+H C42H80NO8P 184.0742 5.90 3 
PC(36:1) M+H C44H86NO8P 787.6091 9.63 4 
PC(36:4)  M+H C44H80NO8P 782.573 5.65 4 
PC(36:5)  M+H C44H78NO8P 779.5465 4.75 5 
PC(38:4)  M+H C46H84NO8P 809.5935 7.45 4 
PC(38:5) M+H C46H82NO8P 808.59 5.73 6 
PC(38:6)  M+H C46H80NO8P 805.5622 5.26 4 
TG(52:2) M+NH4 C55H102O6 858.7676 15.71 4 
TG(52:3) M+NH4 C55H100O6 874.789 15.46 3 
TG(52:4) M+NH4 C55H98O6 854.7363 15.19 5 
TG(56:5) M+NH4 C59H104O6 908.7833 15.65 5 
 
EU vs SR 
TG(40:0) M+NH4 C43H82O6 694.6111 14.37 2 
TG(42:1) M+NH4 C45H84O6 720.6268 14.39 3 
TG(44:2) M+NH4 C47H86O6 746.6424 14.44 3 
TG(42:0) M+NH4 C45H86O6 722.6424 14.75 3 
TG(46:4) M+NH4 C49H86O6 770.6424 14.76 4 
TG(44:1) M+NH4 C47H88O6 748.6581 14.77 5 
TG(46:2) M+NH4 C49H90O6 774.6737 14.80 4 
TG(46:1) M+NH4 C49H92O6 776.6894 15.10 4 
TG(48:1) M+NH4 C51H94O6 802.705 15.12 5 
TG(48:1) M+NH4 C51H96O6 804.7207 15.41 5 
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4.4 Discussion.  
Growing evidence suggests that lipids and lipid interactions are crucial to HCV 
infectivity.  I have interrogated this in two ways; first, I have investigated the 
apolipoprotein levels (apoA1, apoB and apoE) in EUs compared to controls.  Secondly, 
I have studied serum lipidomics profiling using LC-MS platform which allowed several 
lipid features that distinguished the EUs from the comparator groups.  The use of LC-
MS lipidomics approach substantially allowed assignment and annotation of lipid 
moieties relevant to EU phenotype.   
This work has demonstrated that whilst serum concentrations of Apolipoprotein A1, B 
and E are similar across cohorts, the EU group are distinctly different in their lipidome 
from the HC, SR, and CHCV groups as discussed in Section 4.4.2.   
4.4.1 Serum apolipoprotein analysis. 
There were no significant differences in serum apolipoproteins A1, B and E 
concentrations observed among all the cohorts.  This suggests that differences are not 
important in conferring resistance to HCV infection.  Other explanations include 
problems related to analysis of samples that were subjected to repeated freeze-thaw 
cycles, or the variability from analysing non-fasting serum.  It would be necessary to 
conduct similar investigations in fasting samples and postprandial samples since 
different factors would affect postprandial lipaemia. 
HCV entry in hepatocytes is a complex process involving the apolipoproteins especially 
apoE that mediates the LVP attachment to cellular HSPG receptor thereby playing a 
significant role in HCV infectivity.  HCV replication takes place on lipid droplets with 
co-localization of core protein and non-structural NS5A to the lipid droplet.  Co-
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dependency of HCV assembly on VLDL secretion is demonstrated by silencing of 
VLDL synthesis components apolipoprotein B (apoB), apoE, and microsomal 
triglyceride transfer protein, all of which inhibit HCV production in Huh 7 cells.  Thus, 
HCV replication and assembly is dependent on host VLDL pathways (Shawa, Sheridan, 
et al., 2017).  Exposure to HCV alone did not show any significant changes in 
apolipoprotein levels as observed in EU samples compared to comparator groups.   
4.4.2 Lipidomics investigations. 
The lipidomics profiling demonstrated that the HCV resistant EU phenotype was clearly 
distinct from HCV susceptible individuals, even those who clear viremia, either 
spontaneously or following antiviral therapy.  The HCV-lipid interaction is an essential 
feature of the virus lifecycle with the early formation of lipoviral particles a key step to 
establish infection in susceptible individuals.  The demonstration of clearly distinct lipid 
profiles in cases apparently resistant to HCV infection provides further support that 
lipid pathways are crucial for early and persistent HCV infection (Shawa, Sheridan, et 
al., 2017).   
Further interrogation of the EUs compared to CHCV patients revealed marked 
differences between the two cohorts.  The obtained OPLS-DA plot distinguished the 
EUs from the CHCV.  The findings suggest that there are distinct lipid profiles in 
exposed uninfected individuals that are different from infected patients.  Such lipid 
species could potentially confer resistance for HCV infection in EU population.  Some 
EUs may exhibit similar lipid profiles with CHCV as observed in the OPLS-DA model 
where EU overlap with CHCV patients, but this could be due to small EU sample size.  
This observation suggests that there is presence or absence of lipid species that could be 
responsible for preventing the establishment of HCV infection in EU cohort.  It is not 
clear at this stage whether the observed lipidomics differences between the EUs and the 
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CHCV patients could be due to the presence of the liver disease (rather than a specific 
EU phenotype).  However, other OPLS-DA models comparing the EUs with HCV 
infected groups (HCV antibody positive) in this thesis also showed that the EUs are 
clearly distinct from the HCV infected cohorts (Figure 4.4). 
This data shows that there is a difference between HCV susceptibility and resistance 
which determines the outcome of HCV exposure.  This lipidomics data has revealed 
fundamental differences between the exposed uninfected cases and those that were 
susceptible to HCV infection.  Additionally, the virus – lipid interaction as expected is 
important and that the different lipid profiles are associated with very different 
outcomes.  Identification of the precise lipid moieties that distinguish the susceptible 
from resistant phenotypes is the next step in finding out an explanation of this key 
interaction.   
Likewise, an OPLS-DA model was created to explore the host’s ability to clear the 
infection (i.e. EUs vs SRs).  The aim was to investigate how the host’s lipid-viral 
interaction affects host’s susceptibility to HCV infection.  A number of research groups 
have investigated the ~ 20% that are able to clear HCV spontaneously (Baden, 
Rockstroh and Buti, 2014).  Despite both cohorts being aviremic, the SRs were 
susceptible to HCV infection but they spontaneously cleared the infection.  The EUs 
were observed to be clearly different from the SRs.  This represents variations in lipid 
profiles among HCV RNA negative populations.   Several lines of evidence indicate 
that the host’s cellular immune response to multiple HCV epitopes is vital in controlling 
early HCV infection.  Successful early immune responses may lead to spontaneous 
resolution.  Conversely, ineffective early cell-mediated response may lead to 
development of chronic HCV infection (Bowen and Walker, 2005).  These lipidomics 
findings open another chapter that may provide useful insights into the existence of the 
213 
 
EU phenotype which is distinct from the SRs.  Our immunological investigations also 
support the existence of the EUs as described in the subsequent paragraphs of this 
chapter.  These findings strongly indicate that the EUs are a distinct group different 
from all the comparator groups; and the differences are very statistically significant.  
Therefore this data has helped to provide further insights into the existence of EUs, and 
rest any debate whether the EUs is a genuine group of PWIDs or are similar to SRs.   
Another OPLS-DA model was created in order to observe if the HCV resistance is 
associated with a different lipidome than in those susceptible to HCV but resolved the 
infection following IFN-based treatment (i.e. EUs vs SVRs).  The clear lipid lipidomics 
separation observed in this model suggests that there are lipid pathways that are 
involved in offering protection for HCV infection.  The HCV sustained viral response is 
defined as aviremia 24 weeks following completion of antiviral therapy (Lindsay, 2002; 
Ghany et al., 2009).   In this case, SVR was achieved after interferon-based treatment, 
and the subjects tested HCV RNA negative but anti-HCV antibody positive.   
Discriminant compounds (not annotated) between the EUs and the SVRs had very low 
retention times, eluting very early in the chromatographic domain along with the solvent 
front.  Therefore such polar compounds were not easily annotated using the online 
databases and were classified as unknowns.  The effects of therapy on perturbations of 
lipid metabolites have not been investigated yet, but it is clear that antiviral therapy 
changes the host lipidome.   
The host’s ability to resolve HCV infection either spontaneously or following antiviral 
therapy is dependent on a complex set of interactions between the virus and the host that 
ultimately changes the lipidome.  In addition, two different groups who were both 
susceptible to HCV infection were also investigated in this study.  These two cohorts 
achieved viral resolution by different mechanisms.  The OPLS-DA plot distinguished 
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the SRs from the SVR group.  The separation between the two HCV susceptible groups 
indicated presence of different lipid profiles even after viral clearance.   The lipidomics 
separation confirms that there are different mechanisms involved in host’s ability to 
resolve infection spontaneously and after interferon-based therapy.  Variables that affect 
virus/host lipid interactions that predict clinical outcomes are different between the two 
cohorts.  I suggest further investigation of lipid profiling between spontaneous resolvers 
and CHCV patients that failed to respond to treatment in order to establish the 
differences in their lipidomic classes.   
The OPLS-DA model for SR vs CHCV was explored and it indicated the host’s ability 
to clear HCV infection.  This model was aimed at investigating the lipid factors that 
enable the host to resolve HCV infection spontaneously compared to absence of similar 
lipidomics compounds that lead to development of chronic infection.   Again the SRs 
were observed to be different from the CHCV patients.   
The OPLS-DA model for CHCV vs SVR was also explored.  There were some lipid 
profile differences observed between the CHCV and SVR groups.  This suggests that 
variations in serum lipidomics features that specifically related to HCV, change after 
HCV clearance following treatment.  It is unclear if similar differences would be 
observed if the SVRs achieved sustained response post DAAs therapy.    
I have analysed the lipidomics to assess the HCV exposure between the EUs that 
secreted IFN-γ and those that did not.  One of the traditional criticisms of the EU group 
is that you cannot confirm exposure.  The surrogate for exposure has been the presence 
of T cell responses as detected by ELISpot assay.  The similar lipidomics profiles seen 
in this study in both ELISpot positive and negative EU cases suggests that the EU 
population is similar and that the presence or absence of T cell responses does not 
confirm or exclude evidence of HCV exposure.   
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The LC-MS technique using PCA has a high degree of reliability and reproducibility in 
both ionisation modes. 
The effect of storage time and freeze-thaw cycles was observed when the PCA model 
was created for all the samples.  This suggests that increased freeze-thaw cycles affect 
lipid stability and potential viability in MS analysis.  Therefore lipidomics studies 
utilising samples of increased freezing cycles must be interpreted with great care; where 
possible such samples should be avoided.  Freeze thaw cycles clearly showed great 
impact on lipid profiles.  Previous studies showed that some lipid metabolites were 
reduced by freeze-thawing (Ishikawa et al., 2014).  Interestingly, when all old samples 
were analysed separately they still clearly showed the EU lipidome to be different from 
healthy volunteers.  
Furthermore, there were no variations observed in samples collected in Plymouth and 
those obtained for the HCVRUK biobank based on OPLS-DA model in Section 4.3.14 .  
This confirmed that the Plymouth samples met the required standard and were 
comparable to the biobank samples.  Therefore the findings in this study were not 
influenced by differences between centres. 
4.4.3 Annotation of lipid species that distinguish the EUs from the other groups.  
Lipidomics profiling has shown clear difference between the EUs and the control 
groups.  It is essential to identify where these differences lie in the spectrum.  I have 
assigned lipid species focussing on the highest ranked species (top 10) that discriminate 
the EUs from the other cohorts; prioritized based on their VIP values.  Assignment of 
lipid species is a complicated process; but candidate lipidomics moieties were carefully 
annotated utilising their m/z values as described is Section 2.9.2.7. 
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ESI-MS is a robust sensitive tool that has reliably been used in clinical and biomedical 
research to study small (femto-molar) quantities of lipids of various polarities that are 
hardly detectable by other conventional methods.  The preliminary assignment of lipid 
species in this lipidomics study identified phosphatidylcholine (PC) and triglycerides 
(TG) as the main lipidomics classes among the top 10 compounds highly expressed 
among EUs.   
A classic OPLS-DA comparison of EUs versus CHCV group, the EUs showed 
significant increase in PCs and TGs as opposed to the CHCV patients.  Similarly, TGs 
were also the main lipid class identified that distinguished the EUs from the SRs.  The 
TGs were increased in SRs which supports the evidence that lipid metabolism plays a 
crucial role in HCV infectivity.    
The findings of elevated PC and TGs in EUs versus CHCV OPLS-DA model reinforces 
the evidence that HCV infection relies on host-viral lipids interactions at all stages of its 
life cycle (i.e lipid metabolism affects host susceptibility to HCV infection or vice 
versa).  The elevated levels of lipoproteins in the circulation could suggest a defect in 
their clearance mechanisms through the liver which is consistent with our data because 
of the expression of high PCs in EUs.  Our data further shows that HCV utilises lipid 
metabolism at each stage of its life cycle in that we observed different lipid   
compounds that separated the EUs from those that were susceptible to HCV.   
Furthermore, the following TGs: TG(52:4), TG(52:3), TG(52:2), and TG(56:5) were 
assigned in EUs as opposed to CHCV patients but their acyl side chains were not fully 
characterised.  All TG compounds were detected in positive ionisation mode and the 
dominant ions were [M+NH4]
+ adducts, their related dimers and isotopes were observed 
as well.  Due to the lack of hydroxyl groups in the fatty acid chain, TGs cannot ionise 
properly and are not detected in negative mode.  The following TGs: TG(40:0), 
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TG(42:0), TG(42:1), TG(44:1), TG(44:2), TG(46:1), TG(46:2), TG(46:4) and TG(48:1) 
were also high in SRs as opposed to EUs.  In separate studies, HCV infection was 
reported to be associated with decreased plasma TG levels (Marzouk et al., 2007) and 
this supports the evidence that HCV infection is associated with lipid metabolism.  
Previous studies have reported low TGs levels in HCV chronic cases as opposed to SRs 
(Dai et al., 2008) which is consistent with our data in that TG levels were low in CHCV 
group as opposed to SRs.   
The TGs are neutral lipids secreted by the liver and intestines in association with 
lipoproteins such as VLDL and chylomicrons.  The TGs secreted as VLDL and 
chylomicrons are derived from lipid droplets (Wiggins and Gibbons, 1992).  To link 
TGs and PCs, the PC biosynthesis was reported to be associated with TG secretion, 
therefore any interference in PCs secretory pathway directly influences changes in TGs 
synthesis (Moessinger et al., 2014).  Inhibition of PCs secretory pathway leads to 
potential increase in TGs formation (Jackowski, Wang and Baburina, 2000).  Therefore, 
the role of TGs in confirming resistance to HCV infection is of interest. 
4.4.4 Phosphatidylcholine synthesis. 
The PC is the major phospholipid component of lipoproteins (Skipski et al., 1967) 
responsible for lipoprotein assembly and excretion.  Three pathways have been 
described for PC synthesis namely: 1. The CDP-choline pathway, 2. The 
phosphatidylethanolamine N-methyltransferase (PEMT) pathway and 3. The Land 
Cycle.  
The PC de-novo synthesis via CDP-choline also known as Kennedy pathway is the 
major pathway occurring in all nucleated cells (Kennedy and Weiss, 1956).  Three 
enzymatic steps are involved in catalysis of choline to PC.  Firstly, choline obtained 
218 
 
from a dietary source is phosphorylated by choline kinase using adenosine triphosphate 
(ATP) to produce phosphocholine.  Secondly, this follows a reaction between 
phosphocholine and CTP catalysed by CTP:phosphocholine cytidylyltransferase (CT) 
for production of CDP-choline.  The third enzyme in this pathway is CDP-choline:1,2-
diacylglycerol cholinephosphotransferase that converts CDP-choline to form PC (Vance 
and Vance, 2004; Cole, Vance and Vance, 2012; Vance, 2015).  This reaction occurs at 
the surface of the endoplasmic reticulum (ER). 
The second pathway for PC synthesis is PEMT pathway.  PC is endogenously 
synthesised primarily in the liver through this second pathway where 20 – 40% of total 
hepatic PC is synthesised (Sundler and Akesson, 1975; Noga, Zhao and Vance, 2002; 
Da Costa et al., 2011) and consists of ~70% of total phospholipids of VLDL (Ågren, 
Kurvinen and Kuksis, 2005).  PEMT is active in the ER where three repeated 
methylation reactions that convert phosphatidylethanolamine (PE) to PC occur.  The PE 
is methylated by PEMT for the production of PC through 
phosphatidylmonomethylethanolamine (PMME) and 
phosphatidyldimethylethanolamine (PDME) intermediates (Shields et al., 2003; Hartz 
and Schalinske, 2006; Jacobs et al., 2010).  PC(38:6) and PC(40:6) fragments are 
products of PEMT hepatic pathway that may influence the biosynthesis of PC (DeLong 
et al., 1999).  In this study, PC(38:6), PC(38:5), PC(36:4), PC(36:5), PC(34:2),and 
PC(34:1) were highly expressed in EU subjects which may indicate a possible 
perturbation linking the viral-lipid interaction in the liver; resulting in protection from 
establishment of HCV infection.  The PC (40:6) was not annotated in this study.   
Thirdly, PC is also synthesised through the Lands cycle (Jacobs et al., 2010).  In the 
Lands cycle PC is synthesised through the activity of phospholipase A2 (PLA2), an 
enzyme that removes fatty acids at the sn-2 position for PC resulting in the production 
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of lysophosphatidylcholine (LPC) (Moessinger et al., 2014).  When fatty acids are 
added (re-acylation) on PC’s sn-2 position, resulting in formation of PC (Moessinger et 
al., 2014) that is catalysed by lysophosphatidylcholine acyltransferases (LPCATs) 
(Lands, 1958) present in the ER.  Two important subgroups of LPCATs (LPCAT1 and 
LPCAT2) were found to be expressed on the surface of lipid droplets (LDs); and were 
essential for the production of PC.  The LDs are metabolic cellular organelles that 
regulate storage and trafficking of neutral lipids (Liu et al., 2004).  The LDs consist of 
neutral lipids core of triglycerides, and PC as a lipid monolayer (Tauchi-Sato et al., 
2002; Walther and Farese, 2009).  HCV replication takes place on double membrane 
vesicles of LDs with co-localization of structural core protein and non-structural NS5A 
(Masaki et al., 2008). 
Studies have reported that decreased PC concentration was reported to impair hepatic 
secretion of VLDL (Rusiñol, Verkade and Vance, 1993).  It was also reported that PC 
expression on the surface of VLDL is involved in viral-host cell receptor interaction that 
consequently affects the rate of lipoprotein removal from the circulation (Fielding and 
Fielding, 2008).  Therefore, one additional possible explanation for the increased PC 
expression in EUs is the altered interation between the LVPs and the host cellular 
receptors.  No previous lipidomics studies were performed in the EU cohort.   
 
4.4.5 PC regulation. 
When there is adequate supply of choline through the diet, approximately 30% of PC is 
synthesised in the liver through the first and second pathways described above.  Choline 
supply is essential for regulation of PC synthesis through the CDP-choline pathway.  
When choline supply is limited to ensure PC synthesis, PEMT pathway maintains PC 
220 
 
supply in the liver.  It is clear that sustainability of CDP-choline pathway is dependent 
on choline and CTP that are the rate limiting factors.  On the contrary, PC production 
via PEMT pathway increases when choline supply is limited for PC production via 
CDP-choline pathway.  Other factors that regulate PC production are the Lands cycle 
enzymes (LPCAT1 and LPCAT2) that affect the PC content in LDs (Moessinger et al., 
2014).  
 
4.4.6 Possible pathway involved in EUs resistance. 
The above explored evidence suggests that the increased PCs production in EUs may 
occur via the PEMT pathway or the Lands cycle pathway.  Increased PCs levels in the 
circulation suggest perturbations in PCs clearance from the circulation through 
mechanisms that remain unclear.  It is clear that regulation of PEMT pathway maintains 
normal lipid metabolism.   Another possible explanation could be the interruption of the 
viral-host interaction at the host cellular receptors that prevents successful initiation of 
the viral life cycle.  Again, I speculate that high serum PC concentration could be due to 
blocked clearance through the hepatocytes.  PC is highly expressed in the lipoproteins 
whose clearance from the circulation is affected by the integrity of host cellular 
receptors.  This is in agreement with the earlier possibility about perturbations in host 
cellular receptors.  The PC is highly expressed in lipoproteins whose clearance from the 
circulation is affected by integrity of host cellular receptors.  It is necessary to determine 
the lipoprotein class that expresses high PC level.  It is not clear which host receptors 
that could be involved; but HSPG seems a possible candidate based on its reported 
interaction with apoE during attachment stage. 
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On the whole, I explored the lipidomic alterations that could be association with HCV 
resistance.  The serum lipidomics profiling findings reveal that the EUs have unique 
profiles that are different from SR, SVR and CHCV groups.  Serum PCs and TGs were 
found to be significantly elevated in EUs compared to CHCV patients.  Assignment of 
potential lipid classes provided biological evidence that discriminated the EUs from 
other comparator groups.  The non-targeted LC-MS ‘omics’ approach employed in this 
study has limitations such as lack of direct biomarker identification.  Despite the 
limitations, this work demonstrates the utility of serum lipidomics profiling for 
identification of lipid moieties that are associated with physiological processes and 
disease.  However, lipidomics profiling and not targeted lipid identification was the 
major objective of this study, justifying this approach.  This data also refines the 
available knowledge about the HCV life cycle involving host lipid metabolism as well 
as re-affirming the existence of the EU phenotype among PWIDs.  Therefore 
understanding mechanisms in which HCV disrupts metabolic pathways for viral 
replication provides an essential area for development of vaccine and therapeutic agents. 
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4.5 Conclusion.  
Investigation of serum lipidomics utilising UPLC-MS system has identified perturbed 
lipid pathways that may be associated with resistance for HCV infection.  The study 
cohorts were matched by demographics and clinical characteristics in order to control 
confounding factors that may influence the data interpretation.   
The primary aim of this study was to identify lipid profiles that may be highly 
associated with HCV resistance.  This thesis has clearly shown the difference between 
the EUs and the comparator groups.  The preliminary efforts to identify the discriminant 
lipids point toward PC and TG.  The next efforts should focus specifically on these 
compounds and others to look for biologically plausible mechanisms that can be 
associated with resistance to HCV infection.   
The results point very strongly to the profound influence on HCV susceptibility by the 
lipidome.  This reinforces how important the host lipid-virus interaction is; therefore, 
this observation calls for further study.  I have preliminary identified PC and TG as 
being important but precisely how these perturb host lipid-virus interaction remains to 
be determined.   
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5 CHAPTER FIVE 
 
5.1 HCV-specific T cell responses in exposed uninfected cohort compared to 
healthy volunteers and spontaneous resolvers. 
5.2 Background. 
There is published evidence including our group’s previous work (Thurairajah et al., 
2008), suggesting that the HCV exposed uninfected cases demonstrate specific immune 
responses without detectable anti-HCV antibodies and HCV-RNA (Kamal et al., 2004); 
and such cellular immune responses may result in the clearance of infection (Zeremski 
et al., 2009).  Our previous studies reported 50% of HCV-specific T helper cell 
responses in exposed but uninfected individuals (Thurairajah et al., 2008).  The 
frequency of HCV virus-specific T cell responses are usually low that makes it difficult 
to control viraemia and to design in vitro detection experiments. 
The purpose of this chapter was to verify the proportion of HCV exposure among 
exposed uninfected IDUs as previously reported by our group.  There is an on-going 
debate as to whether the EU phenotype exists or they are the same as spontaneous 
resolvers.  The lipidomics investigations identified unique lipid moieties that suggest 
that the EU cohort is distinctly different from the comparator groups.   
The exposure to HCV was assessed for production of IFN-γ utilising ELISpot assay.  
Detection of ELISpot positivity among the EU cases will confirm that the lipidomics 
investigations were performed on a truly exposed cohort; and consequently confirm that 
a good proportion of EU cases demonstrate T cell immune responses.   The principal 
technique employed to identify immune responses was ELISpot assay in order to 
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determine the frequency of cytokine secreting T cells; and details of this assay has been 
described in Chapter 2. 
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5.3 Results. 
5.3.1 Demographics of EU and SR subjects. 
Due to limited number of cryopreserved peripheral blood mononuclear cells (PBMCs), 
twenty-two EU subjects were studied for T cell immune response to determine the 
exposure to HCV.   All the EU cases had persistently tested negative for anti-HCV 
antibodies and HCV RNA using standard diagnostic methods reviewed in Section 1.7.1 
and described in Section 2.2.2.  All the EU cases reported current drug injection and 
sharing either needles or other paraphernalia.  The 22 EU cases, 16/22 (72.7%) were 
males, whereas 6/22 (22.3%) females.  Eight cases that spontaneously cleared HCV 
infection were analysed for the purpose of this study; of these five subjects were males 
(62.5%).  Demographics of all cases recruited for the purpose of this thesis are detailed 
in Table 3.1.  The mean duration of injection drug use was 11.7 years but ranged from 1 
to 34 years.  All the participants had reported a minimum of 1 – 3 injecting episodes per 
day and they had admitted currently sharing needles or other injecting equipment. 
5.3.2 High HCV-specific T cell response to HCV peptides in EUs compared to 
control group. 
The frequency of IFN-γ T cell immune responses determined by ELISpot assay 
indicated that 41% of EU cases showed sufficient HCV specific T cell responses to at 
least one HCV peptide as shown in Figure 5.1 below.  ELISpot positivity was 
determined by calculating the mean plus 2 standard deviation of IFN-γ response 
produced by the healthy volunteers.  The figure below summarises the number spot 
forming units per million cells of EU cases that gave a positive IFN-γ response to at 
least one pool of HCV peptides. 
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Figure 5.1: Proportion of IFN-γ ELISpot positives. 
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Figure 5.1 shows the percentage and the fraction of subjects studied that gave the IFN-γ 
ELISpot response.  Only one healthy volunteer was ELISpot positive to HCV NS5B 
peptides.  The EUs exhibited high IFN-γ response as opposed to the health volunteers 
and seven out of eight SR subjects were ELISpot positive to different HCV peptides. 
Key: EU = exposed uninfected; SR = spontaneous resolvers. 
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5.3.3 IFN-γ responses for specific HCV peptides for EUs compared to healthy 
volunteers. 
Individual HCV peptides were considered to ascertain the production of IFN-γ in EU 
cohort compared to the healthy volunteers.  The spot forming units (SFU) per million 
cells were counted in response to HCV Core, NS3, NS5A, and NS5B peptides.  The EU 
showed high IFN-γ response as compared to healthy volunteers but the differences did 
not reach the desired statistical difference (p.value >0.05) for all the HCV peptides 
between the two cohorts.  The p.values were as follows: Core =0.4070; NS3 =0.5638; 
NS5A =0.3223; NS5B =0.6877 using Mann Whitney test to compare the two groups. 
Wilcoxon signed rank test was also used to compare the two groups but there was no 
statistical difference observed with p.value >0.05 for all comparisons. 
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Figure 5.2: Cross sectional IFN-γ response to specific HCV peptides. 
 
Figure 5.2 shows a cross sectional IFN-γ response for HCV peptides for EUs compared 
to control group.  The production of IFN-γ by PBMC stimulated with HCV Core, NS3, 
NS5A, and NS5B peptides was measured in healthy volunteers (HV; n =11) and the 
exposed uninfected cases (EU; n = 22).  The IFN-γ production was expressed as the 
number of spot forming units (SFU) per million cells.  Each dot represents the mean 
SFU per well for one subject.  All statistical estimations were evaluated by the Mann-
Whitney U test but the differences were insignificant (p>0.05).  Key: HV = healthy 
volunteers; EU = exposed uninfected; ns = not significant. 
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5.3.4 EUs exhibit high IFN-γ response to HCV NS5A peptides. 
The strength of IFN-γ  response for each HCV peptides was assessed for the EU cohort.  
High IFN-γ response was elicited by NS5A (31.8%), followed by NS5B (18.2%), NS3 
(18.2%), and Core (13.6%) respectively.  
Figure 5.3: The strength of IFN-γ response for each HCV peptide for EU cohort. 
 
Figure 5.3 shows the IFN-γ response for EU cohort to each HCV peptide.  The 
production of IFN-γ by PBMC stimulated with HCV Core, NS3, NS5A, and NS5B 
peptides was measured in healthy volunteers (HV; n =11) and the exposed uninfected 
cases (EU; n = 22).  The EUs showed high IFN-γ responses to the HCV NS5A, NS3, 
NS5B and Core peptides respectively. No significant statistical differences were 
observed. 
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5.3.5 EUs demonstrated multi-specific IFN-γ responses to HCV peptides 
compared to healthy volunteers. 
The EU subjects demonstrated multi-specific IFN-γ responses to HCV peptides.  All EU 
ELISpot positive subjects showed IFN-γ to at least a single pool of HCV peptides 
(Figure 5.4A) whereas, the healthy volunteers, only one case (HV22) gave an IFN-γ 
response to HCV NS5B peptides. 
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Figure 5.4: IFN-γ response for individual EU subjects to HCV peptides. 
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Figure 5.4 shows multi-specific responses for IFN-γ production for EUs vs HVs.  The 
magnitude of the HCV-specific IFN-γ response to different HCV peptides (Core, NS3, 
NS5A, and NS5B) in exposed uninfected subjects compared to healthy control group.  
The exposed uninfected subjects demonstrated multi-specific IFN-γ responses to HCV 
peptides as compared to healthy volunteers.  Each bar on the graph represent the IFN-γ 
response for an individual sample expressed as the spot forming unit (SFU).  Key: SW 
= South West; HV = healthy volunteer.  
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5.3.6 SRs elicit stronger IFN-γ production compared to EU subjects. 
In order to validate the CEFT peptide pool as an effective recall antigen (positive 
control) in ELISpot assay, eight samples (62.5% males) from spontaneous resolvers 
were analysed.  Out of the eight cases, seven were ELISpot positive for at least one 
HCV peptide as shown in Figure 5.5 below.    The strength of IFN- γ production for EU 
cohort was also compared to the spontaneous resolvers.  The SRs elicited strong IFN- γ 
response to all the HCV peptides.  Only one subject (SW560) was ELISpot negative. 
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Figure 5.5: ELISpot results for SR cases. 
 
 
Figure 5.5 shows a proportion of positive the IFN-γ ELISpot responses to the HCV-
specific peptides (Core, NS3, NS5A, and NS5B) for the spontaneous resolvers (SRs).  
ELISpot responses expressed as spot forming units (SFU) per million cells (peripheral 
blood mononuclear cells).  All samples gave the IFN-γ response to atleast a single pool 
of HCV peptides.  Each bar on the graph represent the IFN-γ response for an individual 
sample expressed as the spot forming unit (SFU).  Key: SW = South West; SR = 
Spontaneous resolver; SFU = Spot forming unit. 
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5.3.7 The strength of IFN-γ response in EU cohort is different from comparator 
groups. 
The strength of all IFN-γ responses was assessed by calculating the sum of SFU for all 
4 HCV peptides in each subject and compared between study groups.  Overall, the EUs 
elicited strong IFN-γ responses followed by the SR, and healthy volunteers (median 
186.7; 149.2; 14.17 SFU) respectively with a significant p.value <0.0231estimated by 
Kruskal-Wallis test.   
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Figure 5.6: Strength of pooled IFN-γ responses. 
 
Figure 5.6 shows the strength of the sum of IFN-γ responses for 4 HCV peptides (Core, 
NS3, NS5A, and NS5B) for EUs compared to the SRs and healthy volunteers (p.value 
<0.0231, Kruskal-Wallis test (ANOVA).  The EUs elicited significant IFN-γ responses 
when compared to the spontaneous respolvers (p.value >0.23 estimated by Kruskal-
Wallis test).  There was no difference in IFN-γ responses when compared to the healthy 
volunteers.  Box and whisker plots show the median, upper and lower quartiles, as well 
as the ranges of the IFN-γ responses.  Key: HV = healthy volunteer; EU = exposed 
uninfected; SR = spontaneous resolver. 
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5.3.8 Two separate phenotypes of EU the population exist. 
The existence of the EU phenotype was confirmed by the production of HCV-specific T 
cell responses.  The nine subjects out of the 22 were ELISpot positive whose 
demographics are summarised in Table 3.1.     
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Figure 5.7: ELISpot positives vs ELISpot negatives. 
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Figure 5.7 shows IFN-γ responses for individual subjects that separated the EU cohort 
between the IFN-γ ELISpot positive and the IFN-γ ELISpot negative phenotypes.  The 
positive IFN-γ responses were determined based on the mean + 2SD of the healthy 
volunteers.  The positive IFN-γ ELISpot responses were detected in nine EU cases 
(Figure 5.7 A), whereas thirteen EU cases (Figure 5.7 B) were IFN-γ ELISpot negative.  
The bars in the graphs represent an individual IFN-γ ELISpot responses for each sample 
expressed as spot forming units (SFU) per million cells.    
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5.4 Discussion. 
The HCV-specific T cell responses were analysed in this study comparing the exposed 
uninfected cohort to the healthy volunteers in order to establish the previous exposure to 
HCV.   
A total of thirty-eight samples from exposed uninfected cases were recruited, but only 
twenty-two EU subjects were studied for T cell immune response to determine the 
exposure to HCV since the extracted PBMCs were also used for other investigations.  
The findings in this chapter help to redefine the exposed uninfected cohort.  Nearly half 
of the studied EU subjects demonstrate HCV-specific T cell responses secreting IFN-γ 
to at least one pool of HCV peptides.  Our group (Thurairajah et al., 2008) and others 
(Mizukoshi et al., 2008) previously reported the presence of HCV-specific adaptive 
immune responses detected by IFN-γ ELISpot assay, among individuals who remained 
uninfected despite repeated exposure to HCV risk factors.  Consistent with these 
findings, this data showed that IFN-γ production was prominent in EU subjects as 
opposed to the healthy volunteers; however, the differences were not significant enough 
between the two groups.  IFN-γ responses for EUs were significantly different when 
compared to subjects who achieved spontaneous resolution to HCV infection. 
In addition, all the 4 HCV peptide pools of Core, NS3, NS5A, and NS5B elicited IFN-γ 
ELISpot response where NS5A showed dominant immune responses among EU 
subjects.  However, there was no significant difference observed in IFN-γ cross-
sectional to the 4 HCV peptides.  This data shows that the studied EU subjects were 
indeed exposed to HCV; further supporting evidence obtained through risk assessment 
questionnaire during case identification and recruitment process.   
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IFN-γ production was further assessed among SRs after PBMC stimulation with the 
HCV peptides utilised in similar experiment for the EU cohort.  The SRs elicited strong 
IFN- γ response to all the HCV peptide pools; whereas the EU subjects exhibited a 
weaker response comparatively.  This data suggests that the EU phenotype is distinct 
from the spontaneous resolvers.  All recruited subjects had high frequency rate of 
injecting and sharing needles which represents a high risk group that had multiple 
exposures to HCV for a mean duration of 11.7 years (refer to Table 3.1).  The highest 
incidence of HCV infection was reported to occur during the first 2 years following 
initial injection drug use; and the possibility of getting infected rises with increased 
duration (Lorvick et al., 2001).  Therefore, this data supports the notion that HVC-
specific T cell immune response could be used to describe HCV exposure in EU cohort.  
One SR subject (SW560) was a low CEFT responder; and did not give IFN-γ response 
to HCV peptides as well.  
Evidence suggests that Th-1 cell responses are essential in spontaneous or treatment-
related resolution of HCV infection.  Some researchers suggested that T cell mediated 
immune response may offer protection in an event of re-exposure (Osburn et al., 2010).  
Furthermore, cross-sectional studies have previously reported that HCV-specific T cell 
responses are primed and maintained in individuals upon repeated exposure to low viral 
doses; which may offer protection against development of HCV infection (Freeman et 
al., 2004; Zeremski et al., 2009).  In this data, eligible study participants were identified 
and adequate information was obtained in relation to their risks of exposure that 
included duration.  For this reason, and consistent with these findings, the studied 
participants were indeed exposed despite remaining uninfected.  The IFN-γ responses 
dispute the possibility of the development of humoral responses as suggested by other 
researchers (Cramp et al., 2000; Takaki et al., 2000) who reported that the EU 
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phenotype may have resolved an acute infection in the past and had lost HCV-specific 
antibodies.       
Equally important, IFN-γ responses have categorised the EU phenotype into two 
separate groups of individuals who are either ELISpot positive or negative.  This data 
suggests that within the exposed but uninfected cohort, there are some individuals who 
do not elicit IFN-γ T cell responses.  It will be interesting to further interrogate the 
immunological and genetic characteristics of these two categories of the EU population. 
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5.5 Conclusion. 
I have demonstrated that HCV-specific T cell immune responses can reliably be utilised 
as an immunological marker of low dose HCV exposure.  Determination of the high 
probability of HCV exposure based on T cell responses coupled by robust risk 
assessment questionnaire, and laboratory assays for detection of HCV antibodies and 
viraemia may aid description of the EU cohort.   
The HCV-specific T cell responses were observed among EU subjects.  Such T cell 
responses were associated with injecting habits that are high risk factors for HCV 
exposure.  The findings suggest that the study subjects were truly exposed to HCV; 
further confirming the existence of the EU phenotype among some PWIDs.  Though the 
EU cohort exhibited IFN-γ responses, but the strength of the T cell responses were 
weaker as compared to the spontaneous resolvers.  The findings in this Chapter are 
consistent with our previous work; where more than half of the EU cases were expected 
to give demonstrable HCV specific ELISpot responses as previously reported by our 
group (Thurairajah et al., 2008).  
It is still unclear whether these T cell immune responses represent protective immunity 
or the involvement of the early innate immune responses.  The role of the innate 
immunity will be addressed in the next chapter of this thesis (Chapter 6). 
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6 CHAPTER SIX 
 
6.1 Upregulated innate immune responses in an HCV exposed uninfected cohort. 
6.2 Background. 
The findings presented in Chapter 5 of this thesis showed that nearly half of the studied 
EU subjects demonstrate HCV-specific T cell responses secreting IFN-γ to at least one 
pool of HCV peptides.  Such T cell responses were not strong enough and I propose that 
the innate immune responses may be important.  
The type I IFNs is a key mediator of the innate immune response to viral infection by 
directly inhibiting viral replication, preventing viral attachment to host cellular receptors, 
as well as indirectly stimulating innate and adaptive responses (Stetson and Medzhitov, 
2006).  The direct antiviral activity for type I IFNs is exerted by preventing viral 
transcription, translation, and cleavage of RNA (Haller, Stertz and Kochs, 2007) and at 
the same time promoting an anti-viral state in surrounding uninfected cells (Yokota, 
Okabayashi and Fujii, 2010).   
The type I IFNs is a family of cytokines secreted by virally infected cells, and have 
diverse effects on both the innate and adaptive immune responses that promote host 
defence against viral infections.  All the type I IFNs bind to specific IFN-α/β cellular 
receptor (IFNAR) complex that consists of IFNAR1 and IFNAR2.  IFN-α, IFN-β, - 
IFN-ε, IFN-kappa (IFN-ĸ) and  IFN-omega (IFN-ω), have been described as members 
of human type I IFNs (Sun, Rajsbaum and Yi, 2015).  Both the type I IFNs (IFN-α/β) 
play an important role in activation of NK cell cytotoxicity, and upregulation of MHC-I 
on host cells and costimulatory molecules on APC (Biron et al., 1999; Vivier et al., 
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2008) to facilitate  antigen specific T cell responses (Curtsinger et al., 2005; Kolumam 
et al., 2005).  Different cell types have the potential to secrete type I IFNs.   
The type I and II IFN subsets have different signal transduction receptor complexes to 
type III IFNs, but they activate similar intracellular signalling pathway that induce an 
antiviral immune response.  The type III IFNs (IFN-λ) and their subsets IL-29, IL-28A, 
and IL-28B induce their immune response through a receptor complex distinct from the 
type I IFNs (Kotenko et al., 2003; Siren et al., 2005).  The antiviral activity of IFN-λs in 
vivo is poorly described, but has been demonstrated in-vitro to be induced by ssRNA 
viruses.   
All the IFNs are produced in response to viral recognition by cellular receptors and 
modulate the host immune responses.  The virus infected cells have the potential to 
release viral particles that can infect the neighbouring cells.  Therefore, the infected 
cells send IFN warning signals to the nearby cells to help them prepare against a 
potential virus infection.  In response to IFNs, the cells secrete protein kinase RNA-
activated (PKR) to facilitate shut-off of general translation, induction of apoptosis and 
inhibition of virus replication (Park and Rehermann, 2014). 
In this study, I investigated the expression of a panel of cytokines secreted by PBMCs 
in response to overnight stimulation with low infective doses of Influenza A virus H3N2 
strain or with synthetic model ligands of RNA viruses such as Polyinosinic-
polycytidylic acid (PolyIC):Lyovec complex (RIG-I/MDA-5 ligand), and R848 
(Resiquimod, TLR7/8 ligand).  The data presented in Chapter 5 of this thesis, and 
previous work of our research group has reported low level T cell and humoral 
responses to HCV, but it remains unclear if these can prevent infection and recent 
evidence points to an important role for innate immune responses in determining the 
outcome of  HCV exposure (Shawa, Felmlee, et al., 2017).  
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In this chapter I have looked for differences in innate immune response to low level 
RNA viral exposure (influenza) and to stimulation with RIG-I and TLR7/8 ligands in 
exposed uninfected cases compared to healthy controls and some spontaneous resolvers 
of HCV infection.  38 EU, 8 SRs, and 11 healthy controls cases all collected from 
Plymouth were analysed for IFN-α ELISA, and the multiplex cytokine bead array.  The 
EU and healthy control cases only were analysed for a panel of cytokines in response to 
the lower dose of Influenza A virus used to mimic the likely low level exposure of EU 
cases to HCV.   For details refer to the methodology section (Chapter 2). 
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6.3 Results. 
The data of this chapter will be presented in two categories.  Firstly, the IFN-α ELISA, 
and secondly the luminex multiplex bead array.  There were no commercial microbeads 
for IFN-α available to be included on the multiplex panel, hence the utilisation of 
ELISA technique.  The Luminex multiplex assay was preferred as it provides a more 
comprehensive representation of the immune responses unlike measuring individual 
cytokines which is prone to inter-assay variabilities.   
6.3.1 EUs demonstrate stronger IFN-α responses to TLR, RLR ligands and 
Influenza A virus than healthy controls and spontaneous resolvers. 
This data shows that the EUs demonstrate a stronger IFN-α responses to TLR, RLR 
ligands and Influenza A virus than healthy controls and spontaneous resolvers.   
Both R848 and Influenza virus induced a strong IFN-α response as opposed to 
PolyIC:Lyovec complex.  There were IFN-α signals detected in unstimulated cells for 
some EU subjects as compared to healthy volunteers (p.value < 0.0013).  There was 
insignificant difference in IFN-α response between healthy volunteers and EUs 
following PolyIC:Lyovec complex and R848 stimulations (p.value < 0.23, and < 0.56 
respectively).  Little differences were also observed in SR group that were stimulated 
with PolyIC:Lyovec complex and R848.  The SRs were stimulated with the Influenza 
virus low dose only and they showed good response, whereas the EU and healthy 
controls were stimulated with the lower dose of Influenza virus.  I observed no 
significant difference for IFN-α production in EU subjects in response to 
PolyIC:Lyovec complex stimulation, and the unstimulated cells.  I observed an increase 
in IFN-α production in SRs in response to cell stimulation with R848, and low dose 
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influenza exposure.  No IFN-α production was observed in response to PolyIC:Lyovec 
complex.   
 
Figure 6.1: IFN-α responses for EUs, healthy controls and the SRs. 
 
 
Figure 6.1 shows IFN-α production for the healthy volunteers (n=11), the EUs (n=38), 
and the spontaneous resolvers (n=8) in response to PolyIC:Lyovec complex, R848, and 
low doses of Influenza A virus measured by ELISA assay.  Due to limited number of 
peripheral blood mononuclear cells (PBMCs), only one dose of Influenza A virus was 
used to assess IFN-α production in SRs.  The dot plots and the error bars represent the 
mean and the standard error of the mean.  The EUs demonstrated a strong IFN-α 
production in response to the lower dose of Influenza A virus but no difference was 
observed other stimulants. 
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6.3.2 EUs demonstrate stronger IFN-α responses to low doses of Influenza A 
virus compared to healthy volunteers. 
A significant high level of IFN-α was observed in EUs compared to healthy controls 
following stimulation with two different low doses of Influenza A virus (p.value 
<0.0005).  The increased IFN-α response was sustained in EUs as a result of PBMC 
stimulation with a low dose of Influenza A virus (p.value <0.002).  Some high IFN-α 
secretors with low Influenza doses are coloured blue in both graphs.  The blue coloured 
dots were samples SW565 SW568, SW552, SW559, and SW557.  
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Figure 6.2: IFN-α response for EUs vs healthy controls stimulated with Influenza virus.  
 
 
 
Figure 6.2 shows a separate presentation for IFN-α production in response to two doses 
of Influenza A virus (9.68 x 103 PFU – lower dose, and 29.04 x 103 PFU – low dose).  
The IFN-α production in the EUs (n=37) measured by ELISA assay was compared to 
the healthy volunteers (n=11).  The EUs showed a significant increased IFN-α 
production in response to the low doses of Influenza A virus as compared to the healthy 
volunteers (p<0.001, and p<0.002 for lower and low doses respectively estimated by 
Wilcoxon signed rank test).  The plots and the error bars represent the mean and the 
standard error of the mean.   The blue coloured dots represent the high IFN-α secretors 
(same individuals) in both cohorts.  Key: HV = healthy volunteer.  EU = exposed 
uninfected. 
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6.3.3 EUs demonstrate stronger IFN-α responses to Influenza A virus than SRs. 
As described above, again the EUs show significant stronger IFN-α production than the 
SRs when stimulated with a low dose of Influenza virus.  This data is presented 
separately for a good graphical presentation of the separation between EUs and SRs. 
 
Figure 6.3: The EUs secrete high IFN-α than SRs. 
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Figure 6.3 shows IFN-α production in response to the low dose (29.04 x 103 PFU) of 
Influenza A virus.  The IFN-α production in the EUs (n=37) measured by ELISA assay 
was compared to the SRs (n=8).  The EUs showed a significant increased IFN-α 
production in response to the low dose of Influenza A virus as compared to the 
spontaneous resolvers (p<0.0156 estimated by Wilcoxon signed rank test).  The plots 
and the error bars represent the mean and the standard error of the mean.  Key: EU = 
exposed uninfected, SR = spontaneous resolver. 
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6.3.4 EU cohort produce high IFN-α with lower doses of Influenza A virus. 
In order to establish the strength of IFN-α production following exposure to lower doses 
of the virus, 3 EU samples (SW601, SW603, and SW606) were stimulated with 
different doses of Influenza A virus.  0.9x103 PFU was the lowest dose tested; and there 
was no significant difference observed in IFN-α level secreted by the other seven doses 
as indicated in Figure 6.4 below. 
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Figure 6.4: Dose dependent IFN-α secretion for EU cohort. 
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Figure 6.4 shows IFN-α production for 3 exposed uninfected samples (SW601, SW603, 
and SW606) only that had more PBMCs, stimulated with 7 different possible low doses 
of Influenza A virus (0.9x103PFU, 1.94x103PFU, 2.9x103PFU, 3.87x103PFU, 
4.84x103PFU, 9.68x103PFU, and 29x103PFU).  The ANOVA (Kruskal-Wallis test) or 
Wilcoxon signed rank test analysis did not show significant differences between doses. 
Key: PFU = Plaque forming unit. 
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6.3.5 EUs secrete higher levels of cytokines than the healthy volunteers in 
response to influenza virus. 
In this next part of the study I analysed secretion of six different cytokines in response 
to Influenza A virus using a Luminex 6-plex magnetic bead-based assay in supernatants 
of stimulated PBMCs.  I selected a Luminex quantitative assay that allowed detection of 
IFN-γ, IL-6, IL-10, IL-27, IL-28A, and TNF-α.  These cytokines were carefully selected 
to demonstrate the main type of the immune system that is activated following cell 
stimulation with ligands for ssRNA virus.  I studied the capacity of stimulated PBMCs 
to secrete different cytokines in response to exposure to low doses of Influenza A virus.  
IFN-γ, IL-10, and IL-27 production was significantly higher in EUs than healthy 
controls whereas IL-6, IL-28A, and TNF-α production was similar.  The Wilcoxon 
signed rank test was performed on each comparison.  The EU subjects that were 
identified as high IFN-α secretors with low Influenza dose above are coloured blue in 
this graph.  Those values that clustered together on x-axis close to zero are hardly 
visible. 
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Figure 6.5: Cytokine production for EUs compared to healthy controls.  
 
Figure 6.5 shows scatter plots for cytokine levels for EU cohort in comparison to 
healthy volunteers using Luminex magnetic bead-based assay.  The EUs showed 
significant increased production of IFN-γ (fig. 6.5A p.value <0.0322), IL-10 (fig. 6.5C 
p.value <0.0391), and IL-27 (fig. 6.5D p.value <0.0124) compared to the healthy 
volunteers whereas IL-6 (fig. 6.5B), IL-28A (fig. 6.5E) and TNF-α (fig. 6.5F) 
production was similar estimated by Wilcoxon signed rank test.  The plots and the error 
bars represent the mean and the standard error of the mean.  Key: EU = exposed 
uninfected, HV = healthy volunteer. 
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6.3.6 ELISpot positive vs ELISpot negative characteristics. 
IFN-γ ELISpot assay used for the screening of immune responses to Influenza A virus 
were grouped into ELISpot positive and negative subsets (Chapter 5).  To further 
characterise the EU cohort using the multiplex Luminex assay, the ELISpot positive 
subgroup secreted slightly high levels of IFN-γ, IL-6, IL-10, IL-27, and TNF-α 
cytokines than the ELISpot negative subgroup.  The IL-6, IL-10, IL-27, and TNF-α 
cytokines expression was significantly different, and increased in ELISpot positive 
subgroup than in the ELISpot negative subgroup (p.values <0.03; <0.03; 0.06; and 
<0.08 respectively).  The ELISA assay showed slightly elevated IFN-α levels in the 
ELISpot negative subgroup, but the difference was not significant enough (p.value 
=1.0). 
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Figure 6.6: Cytokine secretion between ELISpot positive and ELISpot negative EU 
groups.  
 
 
Figure 6.6 shows the comparison of cytokine secretion between ELISpot positive and 
negative groups.  The ELISpot positives showed significant increased IL-6, IL-10, IL-
27, and TNF-α production as compared to the ELISpot negative group.  The box and 
whisker plots show the median, upper and lower quartiles, as well as the ranges of the 
cytokine productions.   
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6.4 Discussion. 
The cytokines play an essential role in the mediation and regulation of immune and 
inflammatory responses to viral infection.  
I have demonstrated significantly increased secretion of IFN-α, IFN-γ, IL-10, and IL-27 
in EUs compared to healthy controls in response to Influenza A virus RNA.  The 
differences in IFN-α production are especially striking and indicates a strong innate 
immune response.  The EUs showed high IFN-α secretion in unstimulated cells which is 
consistent with the role of type I IFNs in mediating an early innate immune response 
that is able to prevent establishment of HCV infection.   
In this study, the cytokine panel was carefully selected to demonstrate the main type of 
the immune system that is activated following cell stimulation with ligands for ssRNA 
virus.  These results show that both IFN-α and IFN-γ are secreted by human PBMCs 
after stimulation with the lower dose of Influenza A virus.  The IFN-α is reported to be 
produced by pDCs consistent with reports suggesting the role of pDCs in secretion of 
IFN-α  and other cytokines (Hao, Kim and Braciale, 2008) whereas IFN-γ is produced 
by T cells, monocytes, and NK cells.  Therefore, it is necessary to determine the cell 
type that secretes increased IFN-α in the EUs.  The IFN-α was the principal cytokines 
that was strongly produced in EUs compared to the comparator groups.  The high IFN-α 
production in the EUs is indicative of an initiation of a primary cell defence against 
establishment of HCV infection or others.   
A complex set of interactions between the host’s ability to induce an effective antiviral 
immune response and the viral mechanisms to oppose them, determines the outcome of 
exposure to HCV.  The low levels of IFN-α secretion were also observed following cell 
stimulation with PolyIC:Lyovec complex (a RIG-I/MDA-5 ligand) in both the EU 
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cohort and healthy volunteers, suggesting that cytosolic PRRs are not involved in 
mediating the upregulated immune response found in the EU cohort.   In contrast, R848 
which activates cells via TLR7/8 induced some IFN-α production suggesting activation 
of an innate immune response. 
The type 1 IFNs were discovered to have an antiviral activity against Influenza virus 
(Lindenmann, 1982).  Th1 cells are characterised by the production of IFN-γ, IL-2, 
TNF-α and other cytokines; whereas Th2 cells secrete IL-5, IL-10, IL-13 and other 
cytokines (Lauer, 2013).  Therefore, if early HCV-specific T helper cells do not produce 
sufficient cytokines, the possibility of development of CHCV is high.  Loss of CD4 T 
helper cells function directly affects the proliferation of HCV-specific CD8 T cells 
(Wedemeyer et al., 2002).  Th2 cytokines are important in the inhibition of cytokines 
derived from Th1cell that consequently downregulates the Th1 immune responses by 
inhibiting APC capacity as well as promoting B cell proliferation. 
I would like to speculate that individuals with more coordinated protective factors such 
as an upregulated innate immune response, perturbed lipid metabolism, and early 
recruitment of T cell response have a greater possibility of remaining uninfected despite 
repeated exposure to HCV. 
It is interesting to note that IFN-α production was upregulated in the SR individuals 
than in healthy controls, but not with the same magnitude as the EUs.  This data 
confirms that the SRs are different to the healthy control group, as well as the exposed 
uninfected cases.  Therefore, this data shows that the SRs may not have enough, a 
strong innate immune response to prevent establishment of HCV infection, hence the 
need for an adaptive response. 
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I attempted to explore the dose response to lower levels of viral RNA to mirror what 
happens in vivo with IDUs following exposure to low levels of viral particles but the 
study was hampered by the limited number of cells. Therefore, due to the limited 
number of cryopreserved cells, 9.68x103 PFU of Influenza A virus was the lower 
number of viral particles tested to determine cytokines secretion for EU cohort in this 
study.  Three EU subjects (SW601, SW603, and SW606) who had more cryopreserved 
cells were stimulated with additional lowest viral doses.  These three cases studied were 
selected for convenience since they had more cells than others.  None of these three 
cases were high IFN-α secretors.   The high IFN-α levels produced by the three samples 
suggest induction of the innate immune response due to exposure to low HCV viral 
particles since PWIDs are thought to be exposed to varying amounts of viral particles.  
It is not clear if there was any cross-reactivity as a result of exposure to other viral 
proteins.  I used Influenza A virus in this work to mimic HCV since they are both 
ssRNA viruses.   
One of the cytokines that was highly secreted by the EUs was IL-6 which is a pleotropic 
cytokine released by a number of human cells such as monocytes, DCs, and epithelial 
cells.  The IL-6 has multiple roles that include activation of the innate immune response 
during an acute phase of HCV exposure (Bode et al., 2012).  The IL-6 level was 
increased in EU cohort compared to healthy volunteers.  The increased IL-6 levels may 
be a result of activation of the innate immune cells including DCs and macrophages.   
IL-10 was also investigated in order to determine the production of type II cytokines.   
The IL-10 is an anti-inflammatory cytokine that activates B cells for antibody 
production and also downregulates the development of Th1 response (Couper, Blount 
and Riley, 2008; Darrah et al., 2010).  The IL-10 was high in EUs compared to the 
healthy controls but not as high as IFN-α.  The IL-10 is essential in offering a good 
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balance between pro- and anti-inflammatory responses.  I therefore speculate that the 
high production of IL-10 in EU cohort may suggest that the host immune system had 
recognised the viral particles resulting in pro-inflammatory stimulus, hence the 
increased pro-inflammatory cytokines.  These IL-10 levels would be considered low 
levels when interpreted in relation to high IFN-α production.  Other researchers reported 
that IL-27 and IL-6 induced T helper cells to secrete IL-10 (Stumhofer et al., 2007).   
Another member of the IL6/IL-12 family of cytokines (IL-27) was also tested in this 
project.  The EU cohort showed significant higher IL-27 secretion in response to 
Influenza virus stimulation than the healthy volunteers.  The IL-27 is secreted by APCs 
and is important in activating antiviral Th1 cells (Siebler et al., 2008) (Hunter and 
Kastelein, 2012).  Similarly, increased IL-27 levels in EU subjects suggest the presence 
of an early induction of pro-inflammatory cytokines as discussed above in this section.  
Consistent with this data, the IL-27 possibly induces T cell proliferation through 
activation of the IL-10 which is another anti-inflammatory cytokine.  Available 
evidence suggests that IL-27 induces T cell secretion of the IL-10 (Stumhofer et al., 
2007).  The IL-27 has both pro- and anti-inflammatory properties that aid in bridging 
both innate and adaptive immune responses (Hunter and Kastelein, 2012).  In addition 
to the immune regulatory functions, IL-27 was reported to inhibit HCV replication 
(Frank et al., 2010) signifying its role in mediating a pro-inflammatory response.  
Genome wide association studies described the role of SNPs near IL-28B gene are 
associated with response to chronic HCV genotype 1 response.   IL-28A was not 
identified in the cases studied.    
On the other hand, those individuals who exhibit immunological evidence of exposure 
employ multifaceted approach including the involvement of the innate and adaptive 
responses to prevent HCV infection.  While ELISpot responses suggesting HCV 
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exposure was detected, there was a weak correlation of high IFN-γ secreting subjects 
and IFN-α secretion offering protection from establishment of the infection.  The fact 
that the presence of an adaptive immune T cell response has demonstrated that ELISpot 
did not correlate with the production of IFN-α, gives further credibility that the innate 
immune response is a key part in protective immunity against HCV infection.      
This data suggests that low viral dose elicits an early innate immune response but such a 
response is not strong enough.  It is not known whether early T cell activation observed 
in this study was as a result of Influenza viral particles or presence of an immune 
response already primed by exposure to HCV particles.  This data concurs with 
previous studies that have shown clearance of low levels of HCV viraemia in the 
absence of seroconversion can occur without demonstrable adaptive immune responses 
(Post et al., 2004; Meyer et al., 2007).  Increased injection episodes, and long duration 
were the main factors that delineated the EU cases into ELISpot positive and negative 
categories. 
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6.5 Conclusion. 
The EUs demonstrate stronger IFN-α responses to Influenza A virus than healthy 
controls or spontaneous resolvers.   In this study, I have demonstrated that the exposed 
uninfected cohort elicit HCV-specific immune responses through induction of type I 
IFNs, and recruitment of adaptive responses.  The increased IFN-α production in 
response to low dose of Influenza virus indicates an enhanced induction of early anti-
viral innate cytokine responses in EU subjects.  I suggest that following exposure to low 
doses of HCV an enhanced innate immune response may contribute to the resistance to 
clinical HCV disease seen in our EU cohort.  Since this study was performed using 
Influenza RNA, it would be ideal to conduct similar experiments using HCV RNA.   
The possible immunological mechanisms that protect the EUs are yet to be fully 
described but it is possible that these responses are a consequence of exposure to low 
doses of HCV.  This thesis confirms that these virus specific immune responses 
represent a footprint of exposure to HCV.  I therefore hypothesis that the upregulated 
innate immune responses are a possible mechanism for HCV resistance in concert with 
the adaptive T cell and B cell responses.  Further studies involving multiple cytokines 
and increasing the samples sizes for both the EU cohort and the comparator groups 
should be considered.   
In conclusion, this data has shown that the EUs produce high levels of cytokines in 
response to Influenza virus, but we would like to know if they can produce similar 
levels with HCV. 
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7 CHAPTER SEVEN 
 
7.1 General discussion. 
This study has provided a number of new insights into potential mechanisms of 
resistance to HCV infection in PWIDs.  I have studied urine metabolic biomarkers to 
seek profiles able to distinguish individuals who inject drugs who develop chronic HCV 
infection from those who resolve it spontaneously and those who appear to be resistant 
to HCV and remain uninfected despite their long history of injection drug use.  The 
findings of this investigation revealed altered urinary metabolic profiles in EU subjects 
weakly indicative of altered gut microbial metabolism.  However, I observed that 
detection of urinary metabolic signatures was prone to variability from dietary and 
possibly lifestyle factors resulting in the exclusion of outliers from the analysis.   These 
findings that potentially link the microbiome to viral resistance are novel, but require 
confirmation in a larger cohort where careful account is taken of dietary and lifestyle 
influences.    
The serum metabolome (complete set of metabolites) contains diverse classes of 
compounds including lipids among others.  The lipidome is a general term used to refer 
to complete set of lipid classes and their subclasses, including small lipid signalling 
molecules.  The lipidomics spectra were acquired from a large data set of 386 serum 
samples comprising 60 EU, 36 SR, 100 SVR, 31 HC, and 159 CHCV.  Analysis was 
performed using an ACQUITY UPLC system in both positive and negative electrospray 
ionisation modes (ESI+ and ESI-).  A composite quality control sample prepared by 
combination of equal aliquots of all samples and injected at regular intervals (i.e. one 
QC injection after every 9 samples) throughout the run determined the system’s stability 
and offered reliable results.  In this study, UPLC-MS lipidomics profiling identified 
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very highly significant differences in lipid profiles between EU and all other groups 
with a number of lipid moieties found to be highly expressed in EU cohort compared to 
chronic HCV patients.  Of note, the serum lipidomics analysis identified 
phosphatidylcholine (PC- the building block of the family of lipids) as one of the 
discriminant lipid class that was highly expressed among the EUs compared to the 
CHCV patients.   
I also measured the HCV-specific T cell responses whose magnitude was determined by 
IFN-γ secretion upon recognition of HCV-peptides using ELISpot assay.  As expected 
from previous work by our research group (Thurairajah et al., 2008), approximately 50% 
of the EU cases had demonstrable T cell responses to HCV peptides using ELISpot.  
However, the ELISpot positive and negative cases could not be distinguished on the 
basis of their self-reported injection behaviour and importantly did not differ in their 
lipidomics profile or in their innate immune response to stimulation with a low dose of 
single stranded RNA virus (Influenza).  The fact that all EU cases, regardless of HCV-
specific T cell reactivity, have similar lipid profiling and innate immune responses 
provides further evidence to support the fact that we have identified a true cohort of 
HCV exposed but uninfected cases and that the HCV-specific T cell response on its 
own is unlikely to confer protection.  In this thesis I have demonstrated that exposure to 
low doses of ssRNA virus induces a much greater IFN- α response in EU cohort than in 
healthy controls and spontaneous resolvers.  We know that the outcome of HCV 
infection is determined by series of complex host – viral interactions and that effective 
innate and adaptive immune responses are crucial in controlling HCV infection (Sun, 
Rajsbaum and Yi, 2015).    
This thesis has also shown increased production of pro-inflammatory innate cytokines 
such as IFN-α, IL-6, and TNF- α in EU cohort as opposed to healthy volunteers 
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suggesting a potential role of the innate immune response in offering protection to 
PWIDs exposed to HCV but remain uninfected.  The TLR dependent pathway (Iwasaki 
and Medzhitov, 2004; Kawai and Akira, 2009, 2011; Yokota, Okabayashi and Fujii, 
2010; Kumar, Kawai and Akira, 2011), and the cytosolic pathway (Yoneyama et al., 
2004; Kato et al., 2006; Park and Rehermann, 2014) are the two well described 
pathways that detect the HCV viral genome to limit development of CHCV infection.  It 
would be informative to measure additional cytokines such as IL-12 which is an 
important pro-inflammatory cytokine that is secreted as a result of IFN-γ stimulation 
(Vignali and Kuchroo, 2012) to support the IFN-α, IL-6, IL-10, IL-27 and other 
cytokines reported in this thesis.   Other researchers already reported the polymorphism 
of IL-12 and KIR:HLA genes as important factors associated with resistance.  This 
thesis provides further evidence for the role played by the innate immune response in 
providing some protection from HCV infection following low dose exposure. 
The hypotheses of this thesis were: firstly, that there are host metabolic determinants 
involved in interrupting the HCV life cycle; and secondly, that there is involvement of 
host innate immunological responses that could potentially confer resistance to HCV 
exposed uninfected cohort.  Based on the cases studied in this thesis, both hypotheses 
were upheld.  Therefore, I speculate that there are concerted host mechanisms involving 
the innate immune response, which consequently recruit an adaptive response, and 
perturbed host lipid – viral interactions together effectively offering protection for HCV 
infection.  The exact putative mechanisms involved in this complex interplay that offer 
potential resistance for the HCV exposed uninfected cohort remain unclear and require 
further interrogation.  The disruption of formation of LVPs in the vascular compartment, 
interrupted LVP attachment to host cellular receptors, the activated innate and weaker 
adaptive responses, all work in concert to offer protection to HCV infection.  In general, 
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this work has provided a benchmark for further studies to describe how the innate 
responses and lipid – viral interactions are related. 
7.2 Limitations of the study. 
There were some inevitable limitations in this thesis as described below: 
The major limitation of this work was the sample size for EU subjects and the 
comparator groups which resulted in reduced power for detection of significant 
differences that define the EU phenotype in comparison to the CHCV, SR, and control 
population.  The PWIDs represent a transient subgroup within the HCV high risk 
population who are difficult to reach; therefore, restricted recruitment of study 
participant that include imposing dietary restrictions to enable sufficient recording of 
demographic data becomes difficult.   
The multivariate analysis results from urinary NMR were less impressive than UPLC-
MS.  Lack of dietary and BMI data, 19 cases that were excluded from the analysis, 
made it difficult for the urinary NMR study to be other than observational.  Larger 
studies are needed to tease out any significant urinary metabolic fingerprint differences 
between the EUs and other comparator groups.   
The UPLC-MS protocols were labour intensive that involved many steps.  Assignment 
of candidate lipid biomarkers involves complex steps that require adequate time to 
complete all the extracted features.  Furthermore, identification of final biomarkers was 
difficult owing to the need for further fragmentation experiments, technical training, and 
external validation.  
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7.3 Recommendations for future work. 
The research that has been undertaken for this thesis has generated very useful 
information and opens new important avenues on which further research would be 
greatly beneficial.  Several gaps were identified and highlighted in the Introduction 
Chapter.  Whilst this thesis has addressed some of them, others still remain to be 
considered.  There are a number of potential areas for further research that have been 
highlighted by findings of this thesis.  These include further recruitment of the EU study 
participants, healthy controls and other comparator groups in order to increase the 
sample size, and extrapolate the findings of this thesis to a larger population. 
The identification and recruitment of the EU individuals is more challenging which 
makes longitudinal follow up even more challenging.  Therefore, I propose engaging 
the nurses who work in needle exchange centres to assist in future case identification 
and recruitment process, they can combine this with their routine duties since they 
already work with PWIDs.  This will obviously be an additional responsibility on top of 
their already busy schedule, therefore such decisions have to be made in liaison with the 
relevant authorities.  More healthy volunteers have to be recruited to offer meaningful 
comparison and improve the statistical power of the research findings.  Despite the 
challenges of recruiting the EUs, if possible, a longitudinal follow up on the EU cases is 
important to assess their serostatus changes and confirm that their resistance to HCV 
continues and they remain exposed but uninfected, as opposed to exposed and infected.  
The existence of the ELISpot positive and negative subsets within the EU phenotype is 
of great interest.  Future studies might, for example, look at the specific phenotypic, 
immunological, and genetic characteristics that describe these two subsets of PWIDs.  
This would help to confirm, and possibly to quantify the magnitude of any changes in 
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relation to cytokines productions and demographics characteristics of EUs that can 
emerge during case identification process.    
There are also several areas for further development, such as developing an in vitro 
HCV replicon system to be used to stimulate PBMCs and monitor secretion of wide 
range of cytokines.  This would give a better impression of the HCV doses that 
stimulate an effective innate immune response, and allow comparison of findings from 
our approach using low dose Influenza.   
The discriminant features identified using lipidomics that separate the EUs from the 
other cohorts reported in this thesis need to be confirmed, and could then potentially be 
validated by performing the knock-in or knockdown experiments such as siRNA or 
CRISPR Cas 9 in HCV model systems.  Further insights into alterations in PC and TG 
metabolism could be gained by detailed lipoprotein fractionation and interrogation of 
lipoprotein compositions, to assess whether this disrupts HCV-lipoprotein interactions.  
Other as yet unidentified factors may also play a role in resistance to HCV infection 
following low dose exposure.  Additional numbers of EU cases will be needed for any 
meaningful genome wide association study, but with collaboration with other groups 
this may be possible.    
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7.4 Conclusions. 
The study of a unique subgroup of PWIDs who remain uninfected despite long and 
repeated exposure to HCV, has unravelled novel findings that suggest a perturbation of 
host lipid-viral interactions, and activated innate immune response that works in concert 
with adaptive responses to protect from HCV infection.  This phenomenon has never 
been described before.   
This thesis has demonstrated the role of the activated innate immune response as a 
potential key factor for HCV resistance.  The human innate immune response plays a 
crucial role in providing immediate defence against invading pathogens.  Putative 
mechanisms of HCV resistance in HCV-lipid interactions are postulated that demand 
further investigations to enhance understanding of resistance and immunity to HCV 
infection.  Resistance to HCV infection depends on a complex balance between 
upregulation of pro-inflammatory immune response and host – viral lipid interactions. 
This work further suggests that there is no single mechanism that monopolises the 
putative mechanisms of resistance.  There is a combination of multifaceted factors 
involved in the HCV resistance.  However, the exact nature and sequence of how the 
innate and adaptive responses, and lipid metabolism work to affect the HCV resistance 
phenotype remains unclear and requires further elucidation. 
Therefore, elucidation of the mechanisms that confer resistance for HCV infection 
remains important in understanding why some individuals who are subjected to high 
risk behaviours for HCV transmission get infected whereas others do not. 
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9 Appendices  
9.1 Appendix A 
9.1.1 Consent form. 
 
PATIENT CONSENT FORM 
SOUTHWEST STUDY OF PATIENTS WITH HCV INFECTION 
 
Why are some people susceptible to hepatitis C and not others? 
A study of innate and immunological mechanisms of protection  
 The patient should complete the whole of this sheet himself/herself 
(Please 
circle one) 
1. 
Have you read the patient information sheet? 
(Please take a copy home with you to keep)  
YES/NO 
2. Have you had an opportunity to discuss this study and ask any 
questions? 
YES/NO 
3. Have you had satisfactory answers to all of your questions? YES/NO 
4. Have you received enough information about the study? YES/NO 
5. 
Who has given you an explanation about the study? 
Dr /Mr/Ms  ……………………………………………………… 
 
6. 
Do you understand that you are free to withdraw from the study: 
 At any time? 
 Without having to give reason? 
 Without affecting your future medical care? 
YES/NO 
7. Do you agree to your GP being informed? YES/NO 
8. Have you had sufficient time to come to your decision? YES/NO 
9. 
Do you agree to have some of your blood and/or urine kept and 
used to study genetic/immune factors; changes in the lipidome 
during HCV infection  
YES/NO 
11 Do you agree to take part in this study? YES/NO 
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Participant 
Name (BLOCK 
LETTERS) ……………………………………………………………………………….. 
Address: ………………………………………………………………………………….. 
D.O.B: ……………………………………………………………………………………. 
Hospital/NHS Number.…………………………………………………………………... 
 
Signed……………………………………………………………………………………. 
 
Date……………………………………………………………………………………… 
 
INVESTIGATOR 
I have explained the study to the above participant and he/she has indicated his/her 
willingness to take part. 
 
Signed…………………………………………………………………………………… 
 
Date……………………………………………………………………………………… 
 
Name (BLOCK LETTERS) ……………………………………………………………. 
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9.1.2 Questionnaire (version 4/2015). 
Why are some people susceptible to hepatitis C and not others? 
A study of innate and immunological mechanisms of protection. 
Questionnaire 
Date:    Trial No: 
Initials:   Date of Birth:   Age: 
1. How old were you when you first used drugs IV?.......................................... 
 
2. Did anyone else teach/ help you with your first injection?  YES/NO 
 
3. Roughly how old was the person who injected for you?................................ 
 
4. How long were you being injected before you could to do it yourself?......... 
 
5. How many years have you been/were you injecting drugs? ………………. 
 
6. At the most, how often were you injecting during that time? 
Less than once a month  □  About once a month   □ 
2 – 3 times a month   □  About once a week   □ 
2 – 3 times a week   □  Most days    □ 
1 – 3 times a day   □  4 – 6 times a day   □ 
More than 6 times a day  □ 
 
7. Which drug(s) did you mainly inject? 
Heroin    □ 
Crack    □  
Cocaine   □ 
Amphetamines (speed) □ 
Other……………………………………………………………………….. 
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8. Do you still use drugs IV?      YES/NO 
 
If not, when did you stop?  …………………………………………………. 
If yes, how often do you inject at the moment? 
Less than once a month □  About once a month  □ 
2 – 3 times a month  □  About once a week  □ 
2 – 3 times a week  □  Most days   □ 
1 – 3 times a day  □  4 – 6 times a day  □ 
More than 6 times a day □ 
9. Are you on a maintenance script?     YES/NO
    
10. Which drugs have you injected in the last 3 months? 
Heroin    □ 
Crack    □ 
Cocaine   □ 
Amphetamines (speed) □ 
Other……………………………………………………………………… 
11. Do/have you ever injected with others around?   YES/NO 
 
If yes, roughly how often do you inject around others? 
Every time  □  
About half the time □ 
Most times  □ 
Rarely   □ 
12. Where is the most common place you inject with others? 
Home     □ 
Friend’s house   □ 
Shooting gallery/ Sorter house □ 
Outside/ Public areas   □ 
Other place    □ 
Please specify……………………………………………………………… 
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13. Have you ever shared a needle (pin) with anyone else (using  
it either before OR after them)?     YES/NO 
If yes, roughly how many times?  
Once   □   Rarely  □ 
About half the time □   Most times □ 
Every time  □ 
If yes, when was the last time? …………………………………………….. 
14. Have you ever shared a syringe (barrel) with anyone else  
(using it either before OR after them)?    YES/NO 
If yes, roughly how many times?  
Once   □   Rarely   □ 
About half the time □   Most times □ 
Every time  □ 
If yes, when was the last time? …………………………………………….. 
15. Have you ever shared a spoon/ water container/ filter with  
anyone else (using it either before OR after them)?    YES/NO 
If yes, roughly how many times?  
Once   □   Rarely   □ 
About half the time □   Most times □ 
Every time  □ 
If yes, when was the last time? ……………………………………………… 
16. Have you ever shared ANY injecting items with someone you  
KNOW has hepatitis C (using it before OR after them)?  YES/NO 
If yes, what did you share? …………………………………………………. 
If yes, roughly how many times have you shared with someone you know has 
hepatitis C?  
Once   □   2 – 10 times  □ 
More than 10 times □   Every time □ 
When was the last time?................................................................................. 
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17. Have you ever snorted drugs?     YES/NO 
If yes, did you share the straw/banknote etc with anyone else (using it either 
before OR after them)?       YES/NO 
Have you ever shared a crack pipe with anyone else (using it before OR after 
them)?         YES/NO 
18. Have you ever shared a crack pipe with anyone else 
(using it before OR after them)?     YES/NO 
19. Have you ever received a blood transfusion or blood products?  
       YES/NO/DON’T KNOW 
If yes, in which year/years? ………………………………………………… 
20. Do you have tattoos?       YES/NO 
If yes, how many? ………………………………………………………….. 
If yes, where did you get these done? 
Professional parlour  □  Friend did it  □  
Did it yourself   □  In Prison  □  
Other (please state) ….................................................................................... 
21. Have you ever had any part of your body pierced?   YES/NO 
If yes, how many? …………………………………………………………. 
If yes, where did you get this done? 
Professional parlour  □  Friend did it  □  
Did it yourself   □  In Prison  □  
Other (please state) ….................................................................................... 
22. Have you ever had acupuncture?     YES/NO 
If yes, where? ……………………………………………………………… 
23. Do you know if anyone you’ve ever had sex with has/had  
hepatitis C?      YES/NO/DON’T KNOW 
If yes, did you use a condom?      YES/NO 
24. Does anyone else that you live with inject drugs?   YES/NO 
25. Have you ever been in Prison?     YES/NO 
 
 
Thank you. 
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9.1.3 Patient information sheet. 
Study Title 
 
Why are some people susceptible to hepatitis C and not others. 
What is the purpose of the study? 
Hepatitis C virus (HCV) currently infects 200,000 to 400,000 people in the United 
Kingdom. Many people have become infected through injection drug use and up to 75% 
of people who have injected drugs for 6 months or more will have hepatitis C virus 
infection. However, some people who have injected drugs for years or shared injecting 
equipment with people known to have hepatitis C do not become infected and test 
negative for both antibody and virus. It is these people we are interested in for this 
study. We wish to understand what can make some people resistant to infection with 
hepatitis C virus.  
The aim of this project is to identify immunological and / or inherited factors 
responsible for protection from HCV infection. There is still a large gap in our 
understanding of how this may happen, but information gained from this study has the 
potential to be of great importance in the development of new treatments and possibly 
design of a vaccine.  
Why have I been chosen? 
You have been potentially exposed to hepatitis C through injection drug use, however 
your results show no sign of hepatitis C virus infection. It may be that your immune 
system has protected you against hepatitis C virus, or it may be that you have inherited 
some factor that makes you resistant to this infection.  
We wish to study your blood and urine to analyse immune, metabolic and genetic 
factors that may have protected you.  
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Who is organising the study? 
Professor Matthew Cramp, Consultant Hepatologist and Honorary Senior Lecturer in 
Medicine is running this research project with the help of NHS Research and 
Development money at Derriford Hospital, Plymouth. The research will take place at 
Derriford Hospital, Plymouth University Peninsula Schools of Medicine and Dentistry 
in collaboration with other research units in London and Glasgow.  
What will happen to me if I take part? 
 
If you agree to take part in our study  
 We will ask you to fill in a questionnaire detailing your injection drug usage to 
assess the duration and degree of your exposure to hepatitis C virus infection.   
 We will ask your permission to take about 40 mls of your blood (two 
tablespoonfulls) and a small volume of your urine. We may ask you to provide 
blood samples in the morning before your breakfast (fasting) another specimen 
after we have provided you with some food.   
 Your blood will be tested for hepatitis C once again and will be used to study 
immune responses and genetic factors and lipid profile that may have protected 
you from infection. 
 With your permission, we will store some of your blood and urine samples for 
testing in the future when additional genetic factors likely to influence 
susceptibility to hepatitis C have been identified.  
 We may ask you to return at specific time intervals in the future for further 
blood tests.  
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Are there any disadvantages in taking part in this study? 
 
There may be some soreness and bruising after having the blood sample taken. 
We will be testing you on several occasions for any evidence of hepatitis C virus 
infection and it is possible that you will be found to have hepatitis C virus infection by 
highly sensitive modern tests. If this is the case then you will be informed of the result 
and you will be referred to our hepatitis clinic for further information and assessment.   
 
What are the possible benefits of taking part? 
There are no direct benefits to you from participating in this study. However, 
information learnt from you may help towards our understanding of this disease and 
will be a step closer towards developing a vaccine for hepatitis C.   
Is my doctor being paid for including me in the study? 
 
No.         
 
Are there any restrictions on what I might eat or do? 
 
No.  
 
What if something goes wrong? 
If taking part in this study harms you, there are no special compensation arrangements. 
If you are harmed due to someone's negligence, then you may have grounds for legal 
action. Regardless of this, if you have any cause to complain about any aspect of the 
way you have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms are available to you. 
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Confidentiality – who will know I am taking part in the study? 
The information will be shared with doctors and nurses involved in the study only. The 
questionnaire you fill in will be identified by a number only and will be kept securely. 
 GP Notification 
With your permission your GP will be informed that you are taking part in this study.  
 
What will happen to the results of the study? 
 
The results of this study will be presented during national and international specialist 
meetings. Results will be published in national and international peer review journals. 
No information identifying you as an individual will be published or presented.  
 
Contact for further information. 
 
If you have any problems, concerns, complaints or other questions about this study you 
should contact Professor. Matthew Cramp on 01752 432722.  Alternatively, you may 
contact the Patients Services, Derriford Hospital on 01752 439884.  
 
Thank you for taking time to consider entering this study. 
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9.1.4 HCV study flier/poster. 
RESEARCH  
   
 
Have you tested negative for 
 
Hepatitis C? 
 
Perhaps you would be interested in being involved in a study?  
 
If you are actively injecting intravenous drugs and have shared pins, barrels or 
other works we need your help. 
 
The Hepatology Research group, based at the Medical School in Derriford Hospital, has 
been carrying out research on people who are at risk from getting hepatitis C, but have 
not become infected. We are trying to determine if these people are protected from 
Hepatitis C which may help future work on a vaccine. 
 
Participation simply involves filling in a questionnaire on your drug use habits and 
having some blood and urine samples taken.  
 
There is a payment of £10 for participation 
 
Please call or text the Hepatology Research Group on 07980 143385 for further 
information. 
 
 
Approved by National Research Ethics Service REC 1703 
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9.2 Appendix B: Urinary NMR confounding metabolites. 
IoH 
code 
NMR date 
UCL 
code 
SW Status  Gender Mannitol Ethanol Paracetamol Taurine Others Dietary sheet 
1 01/03/2016 AR-1 SW552 EU F     ↑       
2 01/03/2016 AR-2 SW553 EU M   ↑↑ ↑       
3 01/03/2016 AR-3 SW554 Chronic M     ↑       
4 01/03/2016 AR-4 SW555 EU M     ↑↑       
5 01/03/2016 AR-5 SW556 Chronic M   ↑↑         
6 01/03/2016 AR-6 SW557 EU M     ↑   to be assigned   
7 01/03/2016 AR-7 SW558 EU F   ↑ ↑       
8 01/03/2016 AR-8 SW559 EU M     ↑       
9 01/03/2016 AR-9 SW560 SR F     ↑       
10 01/03/2016 AR-10 SW561 Chronic F     ↑       
11 01/03/2016 AR-11 SW562 SR F     ↑    d 1.15ppm   
12 01/03/2016 AR-12 SW563 EU M ↑↑   ↑       
13 01/03/2016 AR-13 SW564 EU F             
14 01/03/2016 AR-14 SW565 EU M     ↑       
15 01/03/2016 AR-15 SW566 EU M     ↑   to be assigned   
16 01/03/2016 AR-16 SW567 EU F       ↑↑     
17 01/03/2016 AR-17 SW568 EU M         2-hydroxybutryate   
18 01/03/2016 AR-18 SW569 Chronic M     ↑       
19 01/03/2016 AR-19 SW570 SR M     ↑       
20 01/03/2016 AR-20 SW571 EU M       ↑     
21 01/03/2016 AR-21 SW572 Chronic M   ↑↑ ↑       
22 01/03/2016 AR-22 SW573 EU M   ↑↑ ↑   low citrate   
23 01/03/2016 AR-23 SW574 EU F     ↑       
24 01/03/2016 AR-24 SW576 SR F     ↑       
25 01/03/2016 AR-25 SW577 EU M             
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26 01/03/2016 AR-26 SW578 EU M     ↑↑       
27 01/03/2016 AR-27 SW580 Chronic M         2-hydroxybutryate   
28 01/03/2016 AR-28 SW581 EU M ↑           
29 01/03/2016 AR-29 SW582 Chronic M     ↑       
1 02/03/2016 AR-30 SW583 EU M ↑   ↑↑   no citrate, d 1.15ppm   
2 02/03/2016 AR-31 SW585 EU M   ↑↑     scyllo-inositol   
3 02/03/2016 AR-32 SW586 EU M   ↑ ↑↑ ↑↑     
4 02/03/2016 AR-33 SW587 SR M ↑   ↑       
5 02/03/2016 AR-34 SW588 EU F             
6 02/03/2016 AR-35 SW589 EU F     ↑ ↑     
7 02/03/2016 AR-36 SW590 EU M     ↑       
8 02/03/2016 AR-37 SW591 EU F   
  ↑   
?s 3.15ppm, s 
3.30ppm    
9 02/03/2016 AR-38 SW592 EU M   ↑↑ ↑   scyllo-inositol   
10 02/03/2016 AR-39 SW593 SR M ↑↑ ↑ ↑   low citrate   
11 02/03/2016 AR-40 SW594 Chronic M     ↑       
12 02/03/2016 AR-41 SW595 EU M     ↑       
13 02/03/2016 AR-42 SW596 EU M ↑↑ ↑ ↑   low citrate   
14 02/03/2016 AR-43 SW597 EU M     ↑     BMI 21.4, Alc 1.5u/w 
15 02/03/2016 AR-44 SW598 EU M     ↑     BMI n/a, Alc 8u/w & 2u 24h 
16 02/03/2016 AR-45 SW599 EU M     ↑     BMI 30.0, Alc n/a, meat 
17 02/03/2016 AR-46 SW600 EU M     ↑     BMI 20.7, Alc n/a 
18 02/03/2016 AR-47 SW601 EU F   ↑↑ ↑   scyllo-inositol BMI 20.4, Alc 50u/w 
19 02/03/2016 AR-48 SW602 SR M   ↑↑ ↑   scyllo-inositol BMI 21.8, Alc cider  
20 02/03/2016 AR-49 SW603 EU M     ↑   low citrate BMI 24.7, Alc 18u/w 
21 02/03/2016 AR-50 SW604 Chronic M     ↑     BMI 33.0, Alc 9u 24h 
22 02/03/2016 AR-51 SW605 EU M     ↑ ↑↑   BMI n/a, Alc 2 bottles 24h 
23 02/03/2016 AR-52 SW606 EU M     ↑     BMI 19.4, Alc n/a 
24 02/03/2016 AR-53 SW607 SR M   
  ↑ ↑   
BMI 24.9, Alc 2u/w, 
methadone  
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9.3 Appendix C: Trainings and courses related to this thesis. 
9.3.1 BASL Basic Science Retreat 2017. 
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9.3.2 Research Governance Training: Good Clinical Practice. 
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9.3.3 BASL Annual Meeting 2016. 
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9.3.4 Human Tissues Training. 
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9.3.5 General Teaching Associates (GTA) course. 
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9.3.6 An Introduction of Immunology Certificate. 
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9.3.7 Metabolic Phenotyping training at Imperial College London. 
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9.4 Appendix D: Peer-reviewed publications and conference abstracts.  
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